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Abstract 
Introduction 
Appetite is often impaired in patients with gastrointestinal inflammation. Up to 75% of 
hospitalised Crohn’s disease (CD) patients are malnourished. Recent animal research 
has suggested that immune mediated upregulation of enteroendocrine cell (EEC) 
activity plays a mechanistic role in the appetite and feeding disturbance observed 
during gut inflammation. The role of EEC in producing factors regulating satiety and 
intestinal growth is well recognised but work on their use as therapeutic targets or 
agents in inflammatory bowel disease (IBD) is still in its infancy. EEC peptide dynamics 
are further controlled through dipeptidyl peptidase (DP4) protease metabolism but no 
data are yet available on its expression in IBD. My aim is to understand the roles of 
EEC in appetite control and the maintenance of gut mucosal integrity in intestinal 
inflammation. 
 
Methodology  
Patients with CD and healthy controls were studied. Symptoms were assessed using 
visual analogue scores (VAS). Gut hormone responses to a test meal were studied 
using a multiplex-ELISA technique, and correlated to symptoms. At the tissue level, 
EEC markers and transcription factors were quantified using immunohistochemistry, 
quantitative polymerase chain reaction (qPCR) and western blotting techniques. The 
same techniques were used to study DP4 expression. The effects of glucagon-like 
peptide-2 (GLP-2) on a gut model of the epithelial barrier were studied by measuring 
the transepithelial electrical resistance (TEER) across GLP-2 exposed Caco-2 cell 
monolayers after cytokine exposure. Tight junction protein expression in naïve and 
GLP-2 exposed cells was quantified by western blotting.  
 
Main Results 
CD patients with active inflammation displayed a significant reduction in appetite. At 
the tissue level, GLP-1 and chromogranin A (CgA) were significantly upregulated. At 
the mRNA level significant increased expression was noted for CgA, glucagon-like 
peptide-1 (GLP-1), ubiquitination factor 4a and neurogenin 3. At the plasma level, total 
polypeptide YY (PYY) was increased. A significant correlation was seen between 
postprandial PYY responses and symptoms of nausea and bloating. Ghrelin, was 3-fold 
higher in the CD group compared to controls, and showed a reversed postprandial 
response with a significant correlation with the CD activity index (CDAI). Protein DP4 
expression was significantly decreased at the tissue and plasma level in CD. GLP-2 
increased tight junction protein expression in Caco-2 cells and maintained stable TEER 
and tight junction protein expression after cytokine exposure. 
 
Conclusions 
The data presented are compatible with a potential role of EEC in appetite 
dysregulation in intestinal inflammation. An enhanced EEC response to food intake may 
directly affect appetite in such patients through increased gut-brain signalling. These 
may present tractable therapeutic targets. The decrease in mucosal DP4 expression in 
CD may make bioactive GLP-2 more available in the affected gut, hence improving gut 
mucosal integrity in intestinal inflammation. This pilot work has shown that GLP-2 has 
a role in maintaining gut mucosal integrity in intestinal inflammation through a positive 
effect on tight junction protein expression. 
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1.1 Aim and chapter structure  
 
 
This chapter is mainly divided into two complementary parts. The first set of sections 
give details on the human enteroendocrine system. The relationship between this 
system and appetite control is described both in health and disease. The alterations of 
the brain-gut-enteroendocrine cell circuitry are detailed in intestinal inflammation both 
in murine models and human diseases of intestinal inflammation such as inflammatory 
bowel disease (IBD).  
Finally, a Caco-2 cell monolayer has been used as a model of gut mucosal integrity. 
This model has been used to study the roles of the enteroendocrine peptide glucagon-
like peptide 2 (GLP-2) in maintaining gut mucosal integrity in intestinal inflammation. In 
this section, the Caco-2 cells are described in more detail and the cytokine-induced 
pathophysiological changes noted in tight junction proteins are discussed.  
 
1.2 The Enteroendocrine system 
 
The enteroendocrine system is the largest endocrine organ in the human body and is 
made up of enteroendocrine cells (EEC), effectively ~1% of the cells lining the intestinal 
mucosa [1]. In contrast to other endocrine systems, EEC are dispersed throughout the 
gastrointestinal system. In response to food intake they secrete different amine and 
peptide hormones, which regulate a variety of regulatory and homeostatic functions in 
the gastrointestinal tract such as postprandial secretion and motility. Different EEC 
secrete a variety of gastrointestinal peptides but co-secretion is widely observed. At 
least 15 subtypes of EEC have been described, with each peptide/amine having a 
specific function and secreted by cells in specific anatomical location in the 
gastrointestinal tract as seen in figure 1 and table 1. 
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Figure 1. Anatomical location of key gastrointestinal hormone secretion sites. 
 
It has become clear that the key function of EEC is to act as sensors of luminal 
contents, particularly nutrients. EEC ‘open’ to the lumen thereby function as 
transepithelial signal transduction conduits, with apical physiochemical signals resulting 
in basolateral exocytosis of biological mediators (figure 2). These act either in a 
classical endocrine fashion or by a paracrine effect on proximate cells, notably vagal 
afferent fibres (figure 3). Their diffuse distribution is thus functionally appropriate, the 
EEC network forming an intimate first-line component of the brain-gut axis. 
The localisation of nutrient receptors on EEC gives credence to such a role. Rodent 
gut and EEC cell lines have been shown to express G-protein coupled ‘taste’ receptors 
(T1R2, T1R3 and T2R) with short chain fatty acid receptors (40, 41, 43, 120) being 
ascribed as well [2-8]. Co-expression of the taste bud G-protein alpha-gustducin 
further supports the ‘taste’ analogy. 
 
Upper small intestine: 
CCK, GIP 
 
Ileum and colon: 
GLP-1 & - 2, PYY, 
5-HT  
Stomach:  
LEPTIN, 
GHRELIN, 
GASTRIN 
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Enteroendocrine 
hormone 
Related Function 
Cholecystokinin (CCK) Secretion secondary to lipid and protein ingestion. Delays gastric 
emptying, stimulates biliary contraction and pancreatic secretions, 
facilitates secretin-induced water and bicarbonate secretion in the 
exocrine pancreas. 
Glucagon-like peptide 1 
(GLP-1) 
Secretion secondary to lipid and carbohydrate ingestion. It delays gastric 
emptying and inhibits proximal intestinal motility. Has an incretin effect. 
GLP-2 An intestinotrophic hormone. Pivotal in maintaining gut mucosal 
integrity. 
Glucose-dependent 
Insulinotropic Polypeptide 
(GIP) 
Incretin hormone secreted from the proximally located K cells.  
Gastrin Released by the G cells in the stomach, duodenum and pancreas after 
peptide stimulation in the lumen. It stimulates gastric acid secretion by 
the parietal cells in the stomach and aids in gastric motility.  
Oxyntomodulin Decreases food intake and increases energy expenditure. 
Polypeptide YY (PYY) Pancreatic polypeptide family includes PYY, NPY, PP. Secreted from L 
cells (like GLP-1 and oxyntomodulin) secondary to calorie ingestion 
lipids>carbohydrate>protein. It decreases meal size and stimulates 
weight loss.  
Pancreatic polypeptide 
(PP) 
PP is produced in specialized islet cells under vagal control. It influences 
biliary and exocrine pancreatic function, gastric acid secretion, and GI 
motility. 
Serotonin (5-HT) A biogenic amine. Secreted from the enterochromaffin cells and 
increases intestinal motility and secretions. 
Ghrelin Ghrelin is produced primarily by the stomach and proximal small 
intestine; functions and is regulated oppositely to satiation peptides. It 
powerfully increases food intake in diverse species. 
Leptin An adipokine that plays a key role in regulating energy intake and 
expenditure, through alterations in appetite and metabolism.  
Table 1. Enteroendocrine hormone functions. PP=Pancreatic hormone, NPY=Neuropeptide Y. 
 
 
Figure 2. Electromagnetic resonance image of an enteroendocrine cell, showing its polarised 
structure with villi on the apical side and vesicles with stored enteroendocrine peptides and 
amines in the basolateral side ready for exocytosis. From Junqueira’s Basic Histology, a text 
and atlas, p. 307 [9]. 
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Real time polymerase chain reaction (RT-PCR) transcripts for T2R1 (bitter), ORIGI 
(class 2 olfactory), trace amine G-protein coupled receptors and transporters for 
glutamine, glucose and bile salts have been identified in fluorescence activated cell 
sorted (FACS) human enterochromaffin cells [10]. It remains to be determined 
whether, as seems likely, this very broad sensory functionality functions physiologically 
in the healthy human gut, and no research has addressed this emergent area in 
inflammatory gut disease. Data are now emerging from sorted primary EEC from 
mouse models of L- and K-cells, with array data supporting the concept that nutrient 
sensing receptors are expressed. 
It is interesting to speculate whether intraluminal drugs may activate EEC sensors on 
account of ‘tastant’ properties of the drugs, perhaps leading to gastrointestinal (GI) or 
anorexigenic side effects, or indeed be purposefully designed to activate these 
pathways. G protein coupled (GPR)119 agonists in trials have so far been very 
encouraging. PSN 821 (a GPR119 agonist) has been shown to lower glucose 
excursions by about 30% in response to a test meal in normal subjects [11]. In a 
second clinical study performed on patients with impaired glucose tolerance, MBX-
2982 (another agonist) was shown to improve insulin release in response to a graded 
glucose infusion and enhance glucose control after a test meal challenge [12]. 
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Figure 3. A simplified diagram of the EEC-brain-gut axis highlighting both the endocrine and 
paracrine pathways involved in the brainstem stimulation. 
 
 
 
1.3 EEC differentiation 
 
Unlike other endocrine systems, there is rapid cell turnover in the EEC population. 
EEC, together with Goblet and Paneth cells constitute the three secretory cell types in 
the small intestine lineages, whilst ~90% of the healthy epithelium is lined by absorptive 
columnar enterocytes. It is now clear that all lineages share a common crypt stem cell 
origin. The epithelial factors directing normal subsequent lineage commitments are 
becoming increasingly well understood. Broadly, a hair enhancer of split-1 (Hes-1) 
directed population follows the absorptive pathway, whilst the secretory lineages are 
directed by Math-1, with EEC progenitor differentiation further regulated by 
neurogenin 3 (ngn-3) [13]. EEC have a lifespan of 4-6 days.  
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Specific signalling pathways play a central role in the development and proliferation of 
EEC in both the gut and pancreas, in a mechanism involving lateral inhibition [14]. This 
cell-cell interaction allows a differentiating cell to inhibit neighbouring cells from doing 
the same and is mediated by the transmembrane receptor Notch, and by Delta, its 
transmembrane ligand. The transcription factor ngn3 is at the apex of this pathway.  
Stimulation of neurogenic differentiation (NeuroD) induces cellular expression and 
differentiation. Both ngn-3 and NeuroD are part of the basic helix-loop-helix (bHLH) 
transcription factor family, again involved in both gut and pancreatic endocrine cell 
differentiation. Transmembrane Delta-mediated Notch activation leads to 
downregulation of their cellular expression via Hes-1 stimulation [13, 15]. 
 
Figure 4. The differentiation mechanism involving lateral inhibition. A differentiating cell inhibits 
its neighbouring cells from having the same fate trough Delta/NOTCH signalling pathway. 
From Skipper, Nature Genetics, 2000 [15]. 
 
Appropriately, deletion of Hes-1 induces enhanced EEC proliferation and increased 
expression of these Notch transcription factors (Ngn3, NeuroD and Delta-1) [16].  
Disruption of Notch/Delta signalling causes accelerated pancreatic enteroendocrine 
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cells differentiation [17]. NeuroD signalling is required specifically for the 
differentiation of the secretin and CCK-expressing cell [18], whereas the remaining 
EEC lineages develop normally in the absence of NeuroD  [19]. NeuroD deficiency 
also results in diminished α and β cells in the pancreas. 
Math1 is another bHLH transcription factor and sits downstream of the Notch 
signalling pathway as shown in figure 5. Deletion of Math-1 leads to a depletion of all 3 
secretory cell lineages (Goblet cells, Paneth cells and enteroendocine cells) but leaves 
enterocytes unaffected [20]. 
The Notch1 signalling pathway seems to be conserved in neuroendocrine tumours. 
NeuroD1, NOTCH receptors, Delta ligand 1 and Hes-1 related NOTCH factors are 
all normally expressed in neuroendocrine tumours. Achaete-scute complex homolog-
like 1 (ASCL1), which induces terminal EEC differentiation and is inhibited by Hes-1 
through lateral inhibition is over-expressed in the majority of the GI carcinoid tumours 
examined. Mechanistic activation of the NOTCH signalling pathway in BON cells led to 
growth arrest as evidenced by a decreased expression of chromogranin A (CgA), 
synapthophysin, ASCL-1 and serotonin expression in these cells [21, 22]. This data 
shows that targeting this pathway could be a viable therapeutic option for 
neuroendocrine tumous.   
Growth factor independent 1 (Gfi1), a transcriptional repressor, has also been shown 
to play a primary role in deciding intestinal stem cell fate. Work using genetic 
modification of Gfi1 in mice has shown that low Gfi1 expression downregulates 
goblet/paneth cell differentiation but facilitates EEC differentiation. This transcription 
factor functions downstream of Math-1, Cdx and β-catenin but upstream of ngn-3 
hence highlighting its role in primary cell fate [23]. 
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The system is likely to be more complex than this, since experiments utilising ngn3 null 
mice have provided evidence for the existence of both ngn3 -/- dependent and 
independent lineages in the gut [24-26]. It has been proposed that ngn3 is needed for 
the initial proliferation of all endocrine cells in the gut, but subsequently required only 
for terminal differentiation of a restricted subset, notably gastric A, D and G cells, but 
not enterochromaffin-like cell [27] [27] or ghrelin cells, nor the more ubiquitous 
serotonergic enterochromaffin (EC) cells. Thus ngn3 deficiency provides a smaller pool 
of precursors from which EEC can differentiate. In addition, ngn3 deletion results in 
total absence of all four pancreatic endocrine cell types. Considerably more work is 
required to clarify this, particularly in humans.  
NKx2.2, a homedomain transcription factor has also been recently shown to be 
important in EEC differentiation [28].  Determining the expression of this transcription 
factor can be clinically useful to differentiate between GI and broncopulmonary 
carcinoid tumours. A short case series has described that none of the 
bronchopulmonary carcinoid tumours studied expressed this transcription factor; 
while this is a commonly expressed transcription factor in carcinoid tumours of GI 
origin [29].  
Sex determining region Y (SOX) transcription factors have also been highlighted in the 
enteroendocrine transcription factor pathway. Recent experimental work using 
SOX9EGFP transgenic mice have ascribed a dose dependent capacity for this 
transcription factor to modulate stem cell to EEC differentiation. Leucine-rich repeat-
containing G-protein coupled receptor 5 (Lgr5) expressing stem cells located at the 
bottom of the crypt do not express SOX9, while end-differentiated cells express high 
levels of SOX9, CgA, substance-P and low levels of ngn3 indicating that SOX9 is 
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expressed in post-mitotic cells [30]. Thus high levels of SOX9 inhibit proliferation but 
low levels support it. 
Finally, the winged helix transcription factors, forkhead transcription factor A (Foxa) 1 
and 2 have been studied using Foxa 1/2 knockout mice. Immunohistochemical work 
has revealed that the small bowel epithelia of these mice lack GLP-1 and 2 expressing 
cells while having reduced numbers of PYY expressing L and somatostatin D cells. 
Further work using quantitative polymerase chain reaction techniques have shown a 
down regulation in isl-1 and pax-6 expression hence highlighting the role of these 
transcription factors in EEC differentiation [31].  
The current understanding of how these multiple factors operate is summarised in 
figure 5. 
 
Figure 5. Transcription factors involved in stem cell to EEC differentiation. A Math-1 
dependent pathway leads to a secretory lineage, with ngn-3 specifying an enteroendocrine 
fate. Hes-1 dependent differentiation leads to an absorptive fate. 
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1.4 Enteroendocrine cells and appetite control 
 
Satiation, the process by which a meal is terminated is a composite and complex result 
of multiple interacting biological, psychological and social factors.  In response to a 
meal, short term satiety has 2 main gastrointestinal components under normal 
circumstances: mechanical gastric distension and EEC peptide hormone secretion. Both 
of these are mediated via vagal afferent stimulation. The hindbrain is the principal 
inputting site for short-acting satiation signals which are transmitted vagally, with 
signals such as CCK relayed to the nucleus of the solitary tract [32-34]. CCK and other 
peptides may also act in a classical hormonal manner, probably via the area postrema, 
which is sited outside the blood-brain barrier [35, 36]. Short term appetite control, is 
mediated by gut hormones such as GLP-1 and CCK, and best assessed experimentally 
by visual analogue scores. Long term food intake control is mediated by the effects of 
other factors such as leptin (most of which is derived from adipose tissue rather than 
the gut), adiponectin and ghrelin [37]. The parabrachial nucleus with its central 
connections to the hypothalamus has been suggested as a possible locus for 
convergence of short and long acting food control signalling. Its connections with the 
arcuate nucleus (containing leptin receptors and neuropeptide Y/agouti-related peptide 
containing cells) and the nucleus of the solitary tract (containing both leptin and CCK 
recpetors) make it an ideal location [38] (see figure 6). 
CCK is an appetite regulatory peptide that plays a primary role in proximal intestinal 
signalling through cholecystokinin receptor type 1 (CCK1R) stimulation [39]. It is 
secreted from the I cells in the duodenum and jejunum after luminal stimulation with 
fatty acids and proteins [40]. Fatty acids (FA) need to be of at least 12 carbon chain 
length to stimulate CCK release and they do this through intracellular mobilisation of 
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calcium ion (Ca2+) stores as evidenced by work on the cell line STC-1 [41]. CCK 
causes a delay in gastric emptying hence potentiating the role of simple gastric 
distension as a satiety signal. Apart from fatty acids, simple fat stimulation can induce 
CCK dependent satiety as well [42, 43]. 
 
Figure 6. A simplified version of the EEC-gut-brain circuitry. GLP-1 is used as ‘distal’ hormone 
and CCK as a ‘proximal’ hormone in this diagram. Postprandial stimulation of the nucleus of 
tractus solitarius through the EEC peptides GLP-1 and CCK induces a state of satiety. The 
interaction with leptin is highlighted. This adipokine plays a bigger role in long term food 
control.  From Cummings, Journal of Clinical Investigation, 2007 [44].  
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CCK has predominantly a role in short term food control as work on CCKR1 
knockout (KO) rats show. These rats feature increased meal size and consequent but 
inconsistent obesity probably secondary to concomitant neuropeptide Y over 
expression [45, 46]. More recent work showed such CCKR1 KO rats consume fewer 
but larger meals with such lack of meal size regulation more evident on a high fat diet 
[47]. Similar observations have been noted in human studies using loxiglumide a 
CCKR1 inhibitor. Such patients showed only a modest increase in calorie intake [48]. 
The concomitant action of CCK and leptin seems to have a more pronounced role in 
weight control. Repeated daily intraventricular injections of leptin and intraperitoneal 
administration of CCK in mice resulted in minimal hypophagia but a considerable loss 
of weight ascribing a new combined role to leptin and CCK. This combination might 
induce weight loss through an effect on metabolic rate, thermogenesis and nutrient 
absorption and storage [38]. 
Gastrin-induced CCKR2 receptor stimulation appears to increase the susceptibility of 
normal gastric epithelial cells in vivo to undergo apoptosis. This response is both gastrin 
and CCKR2 dependent. Tissue from humans with both Helicobacter pylori infection 
and hypergastrinemia, showed evidence of increased apoptosis. These results suggest 
that hypergastrinemia may increase the susceptibility of gastric epithelial stem cells to 
undergo apoptosis [49].  
Gastrin and CCKR2 link up once again to induce proliferation in Barrett’s metaplasia. 
This observation may be clinically relevant in patients with gastrooesophageal reflux 
disease treated with proton pump inhibitor therapy. The hypergastranaemia observed 
in these patients might accelerate the CCKR2 dependent proliferation of Barrett’s 
metaplasia [50].  
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Progastrin, a nonamidated and incompletely processed product of the gastrin gene has 
been shown to induce colonic proliferation and promote colorectal cancer in mice in a 
CCKR2 dependent mechanism. CCKR2 is expressed in the colonic crypts and 
upregulated in transgenic mice that overexpress progastrin. Inhibition of CCKR2 in 
these mice reduced the proliferative effect of gastrin and induced epithelial apoptosis. 
CCKR2 may thus be a future target in colorectal cancer treatment [51]. These 
observations in apoptosis and tumourogenesis highlight the multifunctionality of the 
CCK pathway.  
Two important EEC products of the preproglucagon gene are GLP-1 and 
oxyntomodulin. These gut hormones play a role in distal intestinal satiety signalling, and 
are secreted by L cells in the distal ileum and colon secondary to ingested fats and 
carbohydrates. GLP-1 release (and indeed ghrelin suppression) is dependent on the 
length of small bowel exposed as opposed to the other proximally secreted hormones, 
CCK and GIP [52]. 
The mechanism(s) by which GLP-1 suppresses food intake are poorly defined, although 
it is likely to act by directly stimulating regions of the brain associated with feeding 
[53].  GLP-1 can enter the central nervous system (CNS) via the subfornical organ and 
area postrema, areas which lack a typical blood-brain barrier, and the gene for GLP-1 
receptor (GLP-1R) is expressed in the brain [54].  In rats, the expression of the GLP-
1R is concentrated in the hypothalamus, thalamus and basal nuclei [55], whereas in 
humans, the gene is more widely expressed, and has been reported in the whole brain, 
i.e. the frontal, parietal, temporal and occipital cortices, the basal ganglia and the 
hypothalamus [54].  A role for GLP-1 in the central regulation of appetite and energy 
intake is supported by the observation that intracerebroventricular (i.c.v.) 
administration of GLP-1 inhibits feeding in fasted rats, and this effect is blocked 
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following i.c.v. injection of the specific GLP-1-receptor antagonist, exendin (9-39) [53].  
Furthermore, rats, receiving i.c.v. GLP-1 injection, expressed c-fos, a marker of 
neuronal activation, in the paraventricular nucleus of the hypothalamus and central 
nucleus of the amygdala, and this effect was reversed following prior administration of 
exendin (9-39). Both regions of the brain are of primary importance in the regulation 
of feeding.   
The role of peptide induced GLP-1 secretion has up to now not been well studied. L 
cells in the jejunum and ileum respond more effectively to protein stimulation than the 
same cells in the duodenum albeit these are very few in number. Ileal L cells produce 
higher and more long lasting GLP-1 secretion. GLP-1 secretion triggered by duodenal 
nutrients occurs in an indirect fashion and is dependent on vagally mediated ileal 
hormone secretion [56].  
When GLP-1 is injected peripherally, it elicits satiety in normal weight and obese 
subjects through stimulation of GLP-1R. GLP-1 enhances insulin secretion as well, this 
enteroinsular (incretin) effect contributing further to energy homeostasis [57] [58]. 
An anorectic effect of PYY has been shown in animal and human studies [59-61]. The 
precise sites of action of PYY3-36 remain uncertain. Complex electrophysiological, 
intra-arcuate administration and NPY2R antagonist studies suggest that PYY3-36 acts 
directly in the hypothalamic circuits that regulate energy homeostasis, but additional 
work has indicated that the brainstem and vagal inputs might play a role [62-67].  
PYY null mice, were selectively resistant to the satiating and weight-reducing effects of 
protein and develop marked obesity that is reversed by exogenous PYY treatment 
[68]. Interestingly, PYY secretion is reported to be attenuated in obesity [69] and 
conversely increased in anorexia nervosa [70]. Although intravenous infusions of 
biologically active PYY3-36 reduce food intake in humans, supraphysiological levels 
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induced nausea [60]. These observations therefore add credence to the possibility that 
unrecognised EEC dysfunction may be present in unexplained nausea or appetite 
disturbance.  
Ghrelin, a GI orexigenic peptide, secreted by gastric endocrine cells, conversely 
increases food intake in humans and animals. It has a role in both short and long term 
food control, and genomic deletion of the murine peptide or its receptor protects 
against weight gain on a high fat diet [59, 71, 72]. 
GIP is a 42-amino acid peptide hormones released from the K cells in the duodenum 
and jejunum. It has an incretin role in addition to aiding triglyceride clearance from the 
circulation. Genomic and pharmacological modulation of GIP activity has been shown 
to reverse and protect against obesity as well as glucose intolerance. In addition mice 
vaccinated with a virus like particle-bound GIP showed decreased fat accumulation and 
weight loss without developing signs of glucose intolerance, hence making this a 
promising treatment for obesity in the future [73]. 
Further indirect evidence that EEC and their products are biologically central to food 
intake, weight regulation and energy homeostasis in humans comes from bariatric 
surgery studies. Human subjects with severe obesity are increasingly treated thus to 
promote weight loss, initially simplistically considered to reflect either decreased 
gastric volume or small intestinal surface area. Increased plasma levels of PYY and GLP-
1 in Roux-en-Y gastric bypass patients have been reported and can be modelled in 
jejunointestinal bypass rats [74]. Altered gut anatomy, innervation or motility are likely 
to play a role in the aetiology of these hormonal changes. An increased exposure of 
the distal gut to partially undigested food is associated with decreased release of 
proximally secreted hormones and increased secretion of distally secreted anorectic 
hormones such as PYY, oxyntomodulin and GLP-1 [74, 75]. As well as mechanical and 
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satiety effects, the role of the enteroinsular axis and consequent beneficial effects on 
metabolism are therefore likely to be of mechanistic importance in the impact of 
bariatric surgery.  An increase in GLP-1 has been attributed to the sudden 
amelioration of diabetes control in post-operative patients therefore preceding weight 
loss and peripheral resensitisation to insulin [74, 76]. Hypoglycaemic episodes in 
patients post Roux-en-Y gastric bypass surgery have also been attributed to GLP-1 
hypersecretion, stimulating beta cells [77]. Clearly much remains to be explained here, 
and may ultimately lead to non-surgical strategies to reproduce these beneficial effects.  
These physiological and allied observations therefore place EEC and their targets, 
especially the vagus, centrally in the frame for emergent research into the mechanisms 
of abnormal appetite and satiety observed in gastrointestinal disorders, including 
Crohn’s disease (CD). 
1.5 EEC in intestinal inflammation 
 
1.5.1 Animal models of intestinal inflammation 
 
There is a close relationship between the enteroendocrine and immune systems. 
Intestinal inflammation is associated with increased intestinal secretions and altered 
motility, and a parallel decrease in food intake with consequent nutritional imbalances 
and weight loss [78-80]. Early evidence that EEC function was abnormal in GI infection 
came from veterinary studies. Food intake in lambs infected with the parasite 
Trichostrongylus colubriformis was increased by the administration of a specific CCK 
antagonist loxiglumide [81]. Increased plasma CCK has also been observed in swine 
infections with Ascaris suum [82]. 
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Genetically modified mice have proven to be a useful model of intestinal inflammation 
as data on IL-2 -/- mice have shown. This is relevant to EEC. Most IL-2 -/- mice die 
within 5-9 months of birth. The survivors tend to develop colonic inflammation 
characterised by a Th1 response. Histological examination of these colon samples have 
identified decreased expression of PYY cells and decreased tissue levels of PYY, 
substance P and vasoactive inhibitory peptide (VIP) as compared to healthy IL-2 +/- and 
IL-2 +/+ mice [83]. 
Recent work has sought to study intestinal inflammation mechanistically, using 
experimental models of parasitisation. Enteritis can be induced in rodents by the 
nematode Trichinella spiralis and colitis by Trichuris muris. These offer a more biologically 
meaningful approach than the more established chemical methods, such as 2,4,6 
trinitrobenzene sulfonic acid (TNBS) and in dextran sodium sulphate (DSS). They will 
be discussed separately. 
1.5.1.1 Parasitic models of intestinal inflammation 
 
T. spiralis was recently shown to induce CCK and serotonin (5-HT) hyperplasia and 
hypersecretion in mice, coinciding with the peak severity of enteritis, at about day 9 
post-infection [84]. Food intake was reduced by about half at this time point, and was 
significantly improved by the administration of the same CCKR1 antagonist, 
loxiglumide. It was also shown that immunocompetence was essential, as experimental 
work in mice with severe combined immunodeficiency (SCID) has shown with the 
CD4 T-lymphocyte population identified as the key effector cell, inducing secretory 
cell hyperplasia via an interIeukin 4 (IL-4) receptor alpha subunit-dependent 
mechanism. The parasite was not the primary driver of the EEC response, since in 
animals undergoing CD4 immunoneutralisation, the nematodes remain in the lumen, 
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yet EEC hyperplasia, hypophagia and weight loss fail to occur. Therefore it is the 
immunological response to this vector that drives the EEC plasticity observed, and this 
model of the immuno-enteroendocrine axis is therefore likely to have broader 
applicability to other forms of GI infection and inflammation. It offers an excellent 
platform to explore the biological role of EEC in innate immunity, in crosstalk with 
other immune cell types, and in the mechanisms linking gut inflammation to abnormal 
feeding behaviour [84].   
Subsequently, it has been demonstrated that T.muris-induced colitis drives colonic EC 
proliferation by very similar mechanisms. However, this was advanced by the discovery 
that adoptive transfer of CD4+ cells from immunocompetent infected mice to SCID 
mice induced EC hyperplasia in the recipient [85]. This was also more marked in Th2-
predominant responders and dependent upon (signal transducer and activator of 
transcription) STAT-6. Therefore, might ongoing immune responses perpetuate EEC 
hyperplasia if unregulated or in susceptible genotypes? Might this apply in chronic 
human intestinal inflammation? 
However, CD is, simplistically, a Th1 mediated disease while ulcerative colitis (UC) is 
Th2 mediated. Work with BALB/c mice (generating a Th2 response and resistant to 
infection) and AKR mice (Th1 response/susceptible to infection) has shed further light 
on the growing relationship between the immune system and EEC [86]. BALB/c mice 
infected with Trichuris muris, expressed an increase in IL-4 and IL-13 leading to 
activation of STAT-6. Intestinal mucosal samples showed an increased expression of 
EC with an associated increase in 5-HT content when compared to AKR mice. BALB/c 
mice (generating a Th2 response) show a faster worm expulsion than the AKR mice. 
These data show that in immune BALB mice, a STAT-6 mediated increase in EC and 5-
HT is associated with increased worm expulsion. Alternatively, in AKR mice (or 
 55 
STAT6 -/- mice), the STAT-4/IL-12 mediated increase in mucosal EC and 5-HT did not 
feature. In fact, worms were still being expelled at day 15. Hence, in mice susceptible 
to this nematode infection, the Th1 response predisposes to a chronic nematode 
infection [87]. These data once more show the close association between gut mucosal 
immunity and EEC.  
In a more translational study, the Th2 response associated with a nematode (Trichinella 
spiralis) infection was shifted to a Th1 response through IL-12 overexpression. Such an 
immune shift resulted in altered gut physiology through increased intergeron gamma 
(IFNγ) (a TH1 cytokine) and decreased IL-4 and IL-13 expression. This featured 
decreased intestinal muscular contractility and attenuated goblet cell hyperplasia, which 
permitted worm survival in the intestine [88]. 
Changes in EEC have been demonstrated in Citrobacter rodentium infected mice [89]. 
Decreased expression of 5-HT and somatostatin positive cells associated with a 
decreased serotonin transporter (SERT) expression and an enhanced stimulated 5-HT 
release at day 10 was shown. Similarly, in this study, the altered EEC expression is 
regulated through the host’s acquired immune response as these changes were 
maximal at day 10 when the immune reaction secondary to the infection is at its peak. 
Levels returned to normal at day 30. In addition, in immunoparetic SCID mice 
following Citrobacter rodentium infection the changes described above were not 
apparent.  
The role of T-cells in EEC proliferation is further supported by studies in T cell 
receptor α -/- mice, which express reduced cytokines (IL-2, IL-10, tissue growth factor 
beta (TGF-β)) and display decreased CCK, 5-HT and neurotensin cell numbers, whilst 
developing an UC-like phenotype [90]. 
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1.5.1.2  Chemical Models of intestinal inflammation 
 
TNBS-induced ileitis in mice causes an increase in 5HT-immunoreactive EEC, a 
decrease in SERT and an increase in 5-HT release [91]. Neurotensin cells and 
somatostatin cell number also changed, but the mucosal content of other gut peptides 
was not significantly altered.  Recent data from the same group have shown that the 
hyperproliferation of EC seen in ileitis is probably not due to proliferation of these 
terminally differentiated cells, although they still do possess a limited capability to 
proliferate. The associated goblet cell hyperplasia in these inflamed areas, in addition to 
a specific percentage increase in this Math-1 dependent lineage, makes one postulate 
that the increase in EEC is due to cellular hyperplasia initiated at the stem cell level 
[92]. 
The data from TNBS induced colitis in guinea pigs are very similar [93]. Mucosal 
samples from inflamed gut show an increase in 5HT EC, although this held true only if 
the number of 5HT +ve cells were counted per number of crypt gland, mucosal 
surface area or colonic length. These changes were again associated with a decrease in 
SERT expression and an increase in stimulated 5HT secretion. The effects of 5-HT on 
the colon include enhanced colonic motility and secretion, hence in this study colonic 
propulsion was measured in inflamed and control samples using fluoxetine (a specific 
SERT inhibitor) and SDZ-205-557 (a 5HT3 and 5HT4 receptor antagonist). Decreased 
colonic propulsion after using fluoxetine at high concentration and an inability of SDZ-
205-557 to inhibit colonic propulsion in the inflamed samples both suggest a 
serotonergic insensitivity in inflamed samples due to high 5-HT availability. 
Theoretically, the data may offer an in vitro explanation to proximal constipation in 
patients with distal colitis. 
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Changes in EEC and neuronal signalling also happen at sites distant from active 
inflammation [94]. Distal colonic mucosal samples in guinea pigs with TNBS-induced 
ileitis have shown an increase in 5-HT and GLP-2 immunoreactive EEC. This was 
associated with an increase in colonic prostaglandin E2 content, stimulated 5-HT 
release and altered enteric neurophysiology with an elevated basal short circuit 
current signifying elevated sodium re-absorption. This is probably a compensatory 
mechanism for the loss of absorptive power in the distal ileum. The data once again 
illustrate the “hard wiring” that may exist between intestinal inflammation, 
enteroendocrine cells, gut immunity and physiology. 
Similar results have been noted in DSS induced colitis in rats. An intense inflammatory 
reaction with an enhanced mast cell density is seen in the distal colon with 
enterochromaffin cell hyperplasia and increased serotonin expression more typically 
found in the proximal colon [95]. Such changes in the numbers of 5-HT containing cells 
with consequential increased 5-HT expression would give a physiological explanation 
to the symptoms in colitis as 5-HT is important in intestinal motility, blood supply and 
mucosal secretion. 
1.5.2 Human intestinal inflammation  
 
Early reports associating human intestinal inflammation to alterations in EEC 
postprandial response have been described. In patients with tropical sprue an increase 
in postprandial motilin, enteroglucagon and PYY has been noted [96, 97]. In more 
recent reports in patients with Giardia lamblia enteritis a similar trend has been 
observed. Giardia lamblia enteritis is a human infection affecting the proximal small 
bowel. In recent work, an association between proximal small bowel inflammation and 
an exaggerated plasma CCK response has been noted. The elevated postprandial CCK 
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response to a standardised test meal in this group of patients coincided with loss of 
appetite and other gut related symptoms. Pharmacological treatment of this enteritis 
was associated with normalisation of fasted and postprandial CCK levels and patient 
symptoms [98].  
Limited work has been conducted on patients with inflammatory bowel disease. The 
data are however sparse and contradictory, highlighting the need for the work in this 
thesis. 
1.5.2.1 Crohn’s disease – a background 
 
CD is an IBD of yet an unknown aetiology. Once developed, it is a lifelong disease 
arising from an interaction between genetic and environmental factors, but observed 
(or diagnosed) predominantly in developed countries of the world. It is typically 
characterised with transmural granulomatous inflammation and can have a potentially 
pan-enteric localisation.  
Nutritional imbalance in patients with CD is a real entity. Up to 75% of hospitalised 
CD patients are malnourished and as many as 50% are in negative nitrogen balance. In 
fact, muscle mass depletion is found in more than half of IBD patients during relapse 
even in patients who would otherwise be classified as well nourished [99]. 
Complementing this evidence are more data suggesting that even in patients in 
remission, body composition analysis as evidenced by body cell mass was reduced in 
patients with CD when compared to healthy controls [100, 101]. 
Although malabsorption and catabolic states are also implicated, these issues underline 
the fact that appetite suppression, early satiety and hence reduced food intake make a 
clinically relevant additional contribution to nutritional imbalance in patients with CD.  
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1.5.2.2  Crohn’s disease and EEC  
 
In human colitis, data are conflicting with different literature quoting opposite changes 
to different EEC subsets. There has been a single report that chromogranin A and 5-
HT expressing cells are increased in both CD and UC [102]. In Crohn’s colitis only, 
PYY and PP cells were reduced whilst enteroglucagon cells were increased. However, 
recent studies in Manchester suggest that all endocrine cell types are reduced in active 
proctitis, and that this persists when the inflammation resolves [unpublished data]. On 
the other hand, increased EC cells have been demonstrated in a single study of CD 
ileitis [103]. More recent reports have suggested an elevated fasting CCK plasma levels 
in IBD patients in remission when compared to controls [104]. In parallel, plasma CgA 
has been shown to be elevated in IBD patients, irrespective of the disease type, state 
and treatment received [105]. In addition, intestinal inflammation seem to effect ghrelin 
levels, with the integrated total plasma ghrelin levels increasing significantly by 25% in 
CD patients post Infliximab treatment, and the post-prandial response of acylated 
ghrelin being restored to normality after treatment [106].  
The most recent data looking at fasting and postprandial gut hormone response to a 
test meal in IBD and diverticulitis have shown a significant increase in postprandial 
CCK response in CD and this correlated with reduced gastric emptying. Postprandial 
plasma GLP-1 and PYY levels in both CD and UC tended to be higher than controls 
but this did not reach significance [107]. 
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1.5.2.3  Crohn’s disease – further associations with EEC 
 
A newly ascribed CD−associated gene, paired-like homebox 2b (Phox2b), is a 
homeodomain transcription factor predominantly expressed in differentiated 
neurones. Gene wide association studies (GWAS) have shown a close association 
between a single nuclear polymorphism in Phox2b and CD [108]. It is potentially 
mechanistically relevant here, since immunostaining suggests Phox2b is expressed by 
epithelial neuroendocrine cells, and it is known to be linked to Delta-Notch signalling.  
Recent data have suggested that EEC may also be an autoimmune target in CD. An 
ileal complementary deoxyribonucleic acid (cDNA) library approach was used to 
identify ubiquitination factor 4A (Ube4a), a ubiquitin-protein ligase, as a target for 
antibodies in serum from CD. Subsequent immunolocalisation suggested that the 
target protein was more strongly expressed in EEC of CD patients, who displayed an 
increased predisposition for active, penetrative and stricturing disease, and were more 
likely to require surgery [109]. 
Increased expression of regenerating protein-like protein (RELP) in the inflamed 
mucosa of IBD samples has been noted. Double immunofluorescence staining 
demonstrated co-localisation of RELP with CgA in neuroendocrine cells. Inflammatory 
mediators might be involved in the regulation of RELP gene expression. This would 
explain the accumulation of RELP in EEC and goblet cells and further supports a role 
for EEC in the inflammatory response in the GI epithelium [110]. 
Mitogen-Activated Protein Kinase (MAPK) signalling is central to the inflammatory 
cascade in IBD with nuclear factor kappa B (NfκB) sitting at the top of this pathway. A 
downstream product of c-Raf in the MAPK cascade is phospho-MEK, which through 
immunohistochemistry has been co-localised to macrophages and neuroendocrine cells 
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in inflamed CD samples. Semapimod (CNI-1493), an inhibitor of the MAPK signalling 
cascade through direct and specific inhibition of c-Raf, has been used in clinical trials in 
patients with resistant CD with good effect. Colonic biopsies from patients with CD 
responsive to semapimod exhibit decreased phospho-MEK signalling, again illustrating a 
possible role of EEC in the inflammatory pathway in IBD [111]. 
Taken together these data suggest a complex regulation of EEC development and 
differentiation operating under immune control. The increased EEC population may 
have biological consequences, most simply in mediating the altered gut motility, 
sensation and secretory activity noted in IBD. It may also have a disadvantageous effect 
of inhibiting food intake in the short and long term leading to nutritional imbalance.  
 
1.5.2.4  A role for EEC in the inflammatory pathway 
 
The evidence presented above describes a probable correlation between an increased 
EEC activity and intestinal inflammation. Such linkage has been shown both in murine 
and human models of intestinal inflammation. Are EEC just mere bystanders to the 
inflammatory process? Or do they play a role in controlling the inflammatory activity in 
such a milieu? 
Recent data from the human EEC line STC-1 and from CD suggest that EEC offer a 
physiological component in the innate immune response. Toll-like receptors (TLR) 
have been recently identified on EEC. These receptors have a pivotal role in aiding 
cells of the innate immune system to sense microbial pathogens. TLR are differentially 
distributed in multiple cell types, but are chiefly expressed by dendritic cells, 
macrophages and myofibroblasts [112]. TLR recognise a broad range of pathogen-
derived components, signalling to induce the expression of pro-inflammatory genes and 
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cytokines as a co-ordinated immune response. This, in conjunction with phagocytosis-
mediated antigen presentation, instructs the development of antigen-specific adaptive 
immunity, especially via Th1 cells [113].  
The presence of TLR on EEC assigns a novel role for these cells as innate immunity 
sensors in addition to their standard role as nutrient sensors. Whether these 
receptors are biologically important in humans, play a constitutive role in mucosal 
immunity or only become active in certain pathophysiological circumstances are all 
currently unknown.   
IEC were shown to co-express TLR1, TLR2, TLR4, co-localising with multicytokeratin 
(a marker for intestinal epithelial cells (IEC)), and serotonin (a marker for EEC) in IEC 
immunoreactive to TLR1, TLR2, TLR4 antibodies. A murine EEC line, STC-1, was also 
shown to express mRNA transcripts for TLR 1, TLR 2, TLR 4, TLR 6 and the co-
receptor MD-2. In the same cell line, the TLR4 ligand lipopolysaccharide induced the 
phosphorylation of ERK1/2 and MAPK and activated NF-κB activation, the pivotal 
downstream signalling target of TLR occupancy. STC-1 exposure to lipopolysaccharide 
(LPS) also triggered a Ca2+ flux and induced the expression of the proinflammatory 
cytokine TNFα and the anti-inflammatory cytokine TGF-β, in conjunction with 
increased CCK secretion [114]. Similar results have been shown by Palazzo, with TLR 
5 and 9 also evident [115]. In vivo studies are now essential to clarify the roles of TLRs 
in primary EEC, in health and disease. 
Recent and timely work has illustrated the role of TLR sensing in the human EEC cell 
line LCC-18 [116]. FA-stimulated CCK secretion was abrogated in LPS/flagellin (TLR 
4/9 agonists) treated-EEC. This is thought to have a defensive role in case of the 
luminal presence of pathogens. LPS and flagellin stimulation of this EEC line increased 
the expression of immunomodulatory molecules such as chemokine (C-X-C motif) 
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ligand 1 (CXCL1), Chemokine (C-C motif) ligand 20 (CCL20), granulocyte-
macrophage colony-stimulating factor and interferon alpha-inducible protein 6. It is 
interesting to note that these stimulated EEC express IL-32, a pro-inflammatory 
cytokine able to stimulate the nucleotide-binding oligomerization domain 2 (NOD2) 
pathway and hence tissue necrosis factor alpha (TNFα) and the inflammatory cascade. 
It has been thus shown for the first time that human EEC express TLR and that these 
cells therefore may have a proinflammatory role to play in IBD. 
1.6 EEC in gut mucosal repair 
 
The epithelial barrier is also a key component in host defence. A further 
preproglucagon splice product, GLP-2, is secreted by enteroendocrine L-cells in the 
distal small intestine and has been shown to improve intestinal wound healing in a 
TGF-β mediated process - small bowel responding better than large bowel.  
Proliferation and migration of epithelial cells in ‘wounded’ IEC-6 confluent monolayers 
was enhanced when TGF-β was added to cell lines incubated with GLP-2 [117]. GLP-2 
has also been shown to ameliorate the barrier dysfunction induced by experimental 
stress and food allergy [118, 119].  
GLP-2 receptors have been noted in the vagal afferent cell bodies of the nodose 
ganglion, enteric neurons, EECs and nerve fibres in the myenteric plexus. The role of 
GLP-2 in maintaining mucosal integrity is vagally mediated as experiments using 
capsaicin mediated vagal afferent ablation show, supported by increased c-fos 
immunoreactivity in the nucleus of the tractus solitarius in response to GLP-2 [120].  
Again, L-cells are activated by luminal nutrients, and the barrier compromise observed 
with total parenteral nutrition (TPN) may partly reflect regulatory peptide 
hyposecretion in the absence of enteral luminal stimuli. Moreover, GLP-2 
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administration enhances enteric adaptation in rodent short bowel models [121-123]. 
Exogenous GLP-2, and a synthetic analogue, Teduglutide, have shown potential 
beneficial effects on short bowel adaptation in clinical trials [124]. In addition, GLP-2 
has been shown to decrease mortality in indomethacin-induced murine enteritis. GLP-
2 treated mice suffered fewer intestinal ulcerations and enhanced epithelial 
proliferation than controls [125]. GLP-2 has been shown to exert these actions by 
stimulation of GLP-2 receptors on enteric neurons which co-express nitric oxide 
synthase and vasoactive intestinal polypeptide. Both these neurotransmitters are 
vasoactive and thus improve blood supply to the healing mucosa [126]. 
Alterations in GLP-2 expression have been noted in IBD as well. Total GLP-2 levels are 
decreased in CD but unchanged in ulcerative colitis [127]. More detailed examination 
of this peptide suggest that levels of the bioactive form of GLP-2(1-33) are increased in 
IBD, arguably due to a decrease in activity of the enzyme dipeptidyl peptidase 4 (DP4) 
which converts active GLP-2(1-33) to its inactive isoform GLP-2(3-33) [127]. More 
recent data suggest otherwise though, as similar tissue and plasma GLP-2 levels (total 
and bioactive respectively) were noted in patients with active IBD [128]. Thus, possibly 
in IBD, GLP-2 may have a role in maintaining the mucosal integrity. This needs further 
exploration. Earlier reports have underlined the roles of PYY, neurotensin and 
bombesin in mucosal healing as well [129-131]. 
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1.6.1 Enteroendocrine hormone metabolism – a role for DP4 
 
Some of the appetite-controlling enteroendocrine hormones contain proline or alanine 
in their penultimate polypeptides. These are GLP-1, GLP-2, PYY and GIP. This specific 
yet common biochemical feature makes these peptides the key substrates of the serine 
type protease DP4. DP4 or otherwise known CD26 is a widely expressed enzyme that 
preferentially cleaves N-terminal dipeptides from polypeptides with such a structural 
make up. The cleaving process alters the biochemical activity of these gastrointestinal 
peptides. In the case of GLP-1, GLP-2 and GIP a decrease in activity occurs after DP4 
metabolism [132-136]. The converse is true for PYY [137, 138] (see figure 7). This 
enzyme has a role in controlling appetite, insulin secretion and gut mucosal integrity. 
Due to its fundamental role in harnessing the enteroendocrine system a thorough 
understanding of its functions is paramount.  
This membrane-bound glycoprotein is a unique multifunctional protein, acting as a 
receptor, binding and proteolytic molecule and also expressed on the cell surface of 
various cell types like capillary endothelial cells [139], enterocytes [140] and Caco-2 
cells [141]. Proteolytic cleavage of the membrane bound DP4 results in a soluble form 
that exists as a homodimer that has a molecular weight in the region of 210-220kD 
[142]. Its multifunctionality permits arbitrary roles in the immune system (see figure 8).  
 66 
Figure 7. A diagram showing the metabolic effects of DP4 on the gut enteroendocrine 
hormones. It inactivates GLP-1, GLP-2, GIP but activates PYY. This enzyme has a role in 
controlling appetite regulation, insulin secretion and gut mucosal integrity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  A simplified diagram showing the three main functions of DP4. 
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It has an immunoprotective effect through the induction of T cell activation and 
inhibition of corticosteroid release [143, 144]. It also cleaves chemokines such as 
eotaxin, which is essential in the recruitment of a Th-2 cytokine response [145]. 
Simplistically, DP4 inhibits a Th-2 cytokine response. This adds to the observation that 
DP4 defines a Th-1 phenotype by the finding that an increase in expression in 
CD26/DP4 correlates with an enhanced production of Th-1-like cytokines like IFNγ 
[146, 147]. Based on the experimental and clinical data available, the apparent 
contradictory effects of DP4 on the immune system may be explained by its bimodal 
action on the immune system. Finally, DP4 increases nociception by enhancing the 
effects of substance P and inactivation of µ-agonistic peptides [148, 149]. 
DP4 expression and activity vary throughout the gastrointestinal tract. mRNA, protein 
DP4 expression and enzyme activity are highest in the jejunum and ileum with minimal 
expression recorded in the duodenum and colon as evidenced by early work on 
human tissue [140]. Such high mRNA expression in the terminal ileum has been 
recorded in Sprague-Dawley rats as well with DP4 expression decreasing following 
intestinal resection. This is possibly a mechanistic reflex to promote intestinal 
adaptation through the increased mucosal availability of bioactive GLP-2 (1-33) [150].  
A change in GLP-2 activity through DP4 modulation might not always have a positive 
outcome. Experiments with two human colon cancer cell lines (SW480, HT29) have 
shown that co-culturing these cells with a mixture of GLP-2 and the DP4 inhibitor 
P32/98 increased their migratory activity and pro-migratory period. On a therapeutic 
level such modulation might lead to an increased proliferation of harbouring intestinal 
tumours in human subjects as has already been shown in mice treated with Gly2-GLP-
2 (a DP4 resistant GLP-2 analogue) [151, 152]. 
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1.6.1.1 DP4 in inflammatory disease 
 
DP4 enzyme activity has been looked at in a number of inflammatory states. In IBD a 
significant decrease in enzyme activity has been observed and negatively correlated 
with disease activity markers such as the CD activity index (CDAI) and C-reactive 
protein (CRP). A higher proportion of IBD patients co-expressed CD25 (IL-2 receptor 
α chain) and CD26 on their T-cells highlighting the role of DP4 in T cell activation 
through a Th-1 cytokine response.  
No difference is noted in DP4 enzyme activity between CD and UC, precluding the 
use of this biomarker as a diagnostic tool in differentiating between these two 
inflammatory bowel diseases [153-155].  
DP4 has a potential role in modulating intestinal inflammation in IBD. DSS mouse 
models of intestinal inflammation have shown clinical and histological improvement 
upon treatment with DP4 inhibitors [156]. Mice treated with DSS and a DP4 inhibitor 
showed clinical improvement when compared to DSS treated wild type (WT) mice but 
not when compared to DP4 -/- mice highlighting that DP4 inhibition can exert 
protective effects by inducing a conformational change in DP4.  This, in turn initiates 
downstream signaling pathways leading to a decreased production of the 
proinflammatory cytokines and increased production of the anti-inflammatory cytokine 
TGF-β (possibly through an increase in Treg (T regulatory) cells). DP4 inhibition 
understandably led to an increase in GLP-2 (1-33) in this study [157]. 
In rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) a decrease in 
plasma DP4 expression is observed as well. In both inflammatory states a positive 
significant correlation was noted between DP4 plasma expression and enzyme activity. 
The serine protein expression and enzyme activity was negatively correlated to the 
disease activity in both diseases. In SLE, the serum CD26 expression positively 
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correlated with CD26 expression on T cells. Mechanistically, attenuation in disease 
activity in RA through TNFα blockade upregualted DP4 enzyme activity [27, 158, 159].  
In summary, a decrease in DP4 enzyme activity has been noted in inflammatory 
diseases such as IBD, RA and SLE. A decrease in circulating enzyme expression has 
been noted in SLE and RA but no data are available on the tissue and plasma 
expression of DP4 in IBD. A correlation has been noted between protein expression 
and enzyme activity in the rheumatological diseases but this has yet to be studied in 
IBD. 
Is the alteration in DP4 expression/activity a secondary reaction to an inflammatory 
state or is DP4 pivotal in controlling the initial immune response? Observations 
obtained from the murine models of intestinal inflammation indicate that harnessing 
DP4 activity and expression seem to be essential in controlling disease activity. The 
observed attenuation in DP4 expression and activity might be a contributory attempt 
by an unstable immune system to restore normality. 
 
1.7 Intestinal epithelial integrity  – a model to study 
 
GLP-2 and DP4 have an important effect on intestinal homeostasis. Detailed 
mechanistic studies on the effects of GLP-2 on epithelial barrier integrity require 
cellular models. In the section below I will discuss the cellular model used in the 
experimental work described in this thesis – the Caco-2 cell monolayer model. 
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1.7.1 Caco-2 cells – an introduction 
 
In the 1970s, a collection of cell lines was established from GI tumours to perform 
further studies. One of these cell lines, the Caco-2 cell line showed spontaneous 
differentiation in long term culture [160]. This cell line was established from a 
moderately well differentiated colonic adenocarcinoma from a 72-year old patient 
[161]. First studies on this cell line showed, that upon differentiation these cells 
express several morphological and biochemical characteristics of small bowel 
enterocytes. These cells grow in a monolayer, show a cylindrical polarisation, feature 
microvilli on the apical surface, tight junctions in between the cells and express small 
intestinal hydrolase activity on the apical side [160]. Although some of the enzyme 
expression is similar to the human foetal colon at 15th week gestation, these enzymes 
are not expressed by the adult human colon. Further work [160], suggested that Caco-
2 cells behave as foetal ileal enterocytes. Other polarised characteristics expressed by 
these cells are membrane receptors for growth factors and several transport activities 
for both membranes.  
To better reproduce the intestinal mucosa, Caco-2 cells are cultured on permeable 
membranes, which allow free access to ions and nutrients across the monolayer (see 
Figure 9). The integrity of the monolayer is monitored by measuring the transepithelial 
electrical resistance (TEER) and the permeability of marker molecules. Such conditions 
have been optimised and subsequently become standard in most laboratories [162, 
163]. The monolayers exhibit a barrier function as judged by high TEER values (200-
600 Ùcm2, grown on polycarbonate filters) and a minimal permeability of small 
molecules such as mannitol (m.w. 182 g/mol), Lucifer yellow (453 g/mol), polyethylene 
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glycol (4000 g/mol), inulin (5000 g/mol), and dextran (70000 g/mol) [162]. However, 
barrier disruption causes increasing permeability to molecules of increasing size. 
Caco-2 cells reach confluency within three to six days and then stationary growth after 
being in culture for ten days. Differentiation is thus completed within three weeks 
[160, 164]. 
1.7.1.1  Factors effecting Caco-2 cell growth 
 
Variables effecting Caco-2 cell growth which are relevant to this thesis will now be 
described in separate sections.  
1.7.1.1.1 Number of passages 
 
Several authors have reported that the number of passages effects several functions 
and features of these cells. TEER has been shown to increase in later passages of the 
cell monolayer with a decrease in the paracellular passage of mannitol as well. The 
increase in TEER can be possibly explained by an increase in proliferation noted in later 
passages [165-167]. The number of passages can also influence metabolic activities. A 
significant variability in cytochrome precursor (CYP)3A4 has been observed depending 
on the passage number and/or culture conditions [168]. A possible explanation for 
such differences in cellular behaviour associated with passage number could be 
ascribed to the intrinsic cell population heterogeneity. Caco-2 cells are characterised 
by subpopulation of cells with different morphologies, leading to natural selection of 
faster cell-subpopulations on repeated passages [165, 167].  
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Figure 9. Caco-2 cells growing as a monolayer on a permeable membrane in a Transwell 
insert. From Google Images. 2011. 
 
1.7.1.1.2 Paracrine and autocrine factors 
 
Caco-2 cells express a number of different growth factors and their receptors 
including epidermal growth factor (EGF). The receptor affinity, level of expression and 
related cellular responses are strongly modulated by the degree of cellular 
differentiation [169]. Insulin-like growth factor (IGF-1) and nerve growth factor (NGF) 
are expressed by Caco-2 cells as well [170, 171] with well differentiated cells 
expressing more binding sites for IGF-1 than less differentiated cells. IGF-1 binds 
specifically to Caco-2 cells and increases cell proliferation in a dose dependent manner. 
Since Caco-2 cells secrete growth factors with autocrine actions and the foetal calf 
serum (FCS) added to the culture medium contains several growth factors, the 
frequency of medium change might have an effect on cell growth and differentiation. 
Daily medium changes increase the antioxidant defences of Caco-2 cells compared to 
less frequent changes, while not affecting alkaline phosphatase activity, a marker of 
differentiation [172].  
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1.7.1.1.3 Seeding density 
 
Seeding density is an important factor in the time course of expression of 
differentiation related traits as differentiation only starts when the cells are confluent. 
Multiple densities have been quoted but higher seeding densities have been used to 
ensure all areas are confluent at approximately the same time [173]. Seeding density 
does not seem to have any effects on TEER and paracellular permeability but has been 
shown to have a negative on the formation of a monolayer [174]. Using an 
intermediate density of 6 x 104 cells /cm2, good differentiation can be achieved within 
three weeks of incubation.  
 
1.7.1.1.4 Time of culture – cell differentiation 
 
Caco-2 cell differentiation follows a strictly conserved time course as regards 
morphological and biochemical characteristics of the absorptive enterocytes. Despite 
this, morphological and functional differentiation may not be coupled [175] (see figure 
10). In addition Caco-2 cells differentiate in a mosaic fashion, with different cells 
differentiating at a different rate. In light of this heterogeneity, high TEER and low 
mannitol permeability only reach a peak at day 21 [176]. Small bowel enterocyte 
markers increase as differentiation ensues. However these events may follow different 
patterns for different clones under different culture conditions [177]. Thus the 
persistence of some colonic phenotypes must be considered in some Caco-2 cells. 
Important genes of enterocytic phenotype that increase upon differentiation, are brush 
border proteins such as DP4 and tight junction protein claudin 7 [178].  
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1.7.1.1.5 Influence of medium composition 
 
In all Caco-2 cell lines the presence of serum in medium stabilised paracellular 
permeability as measured by mannitol flux but generally had no effect on TEER [179]. 
Glutamine is the most abundant amino acid in the blood and is essential for gut 
homeostasis and growth factor dependent stimulation of enterocytes. In a Caco-2 cell 
culture, glutamine deprivation induces its de novo synthesis. Glutamine inhibition 
arrests protein synthesis [180]. Glutamine has also been reported to have a direct 
effect on tight junction protein synthesis and localisation [181]. pH has a strong effect 
on modulating motility, proliferation and differentiation [182]. In a pH range from 7.0-
8.5, Caco-2 cell proliferation peaks at pH 7.2 and displayed a significant decrease at all 
other values. The influence of medium composition is very relevant in the case of 
CYP3A4, the main CYP450 present in small intestinal epithelial cells. It is not 
expressed in Caco-2 cells under standard conditions, but growing this cell line in a 
serum free medium reduces CYP3A4 activity by approximately 70%.  
1.7.1.1.6 Filter support 
 
The nature of support might interfere with Caco-2 cell functions; in particular the filter 
material, filter coating and pore size. Significant differences are observed in TEER 
values and paracellular marker passage with the polyethylene-terephtalate membrane 
supports producing high TEER and low values for paracellular passage [174]. Pore size 
and their density in filters of different materials may influence permeability as well 
[183]. For a summary of the factors affecting Caco-2 cell growth see figure 11. 
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Figure 10. Morphological and functional differentiation of Caco-2 cells may not be coupled 
[184]. 
 
Figure 11. Factors influencing performance of Caco-2 cells. Adapted from Sambuy, Cell Biology 
and Toxicology, 2005 [185]. 
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1.7.2 Gut epithelial integrity – The role of tight junctions 
 
Tight junctions are intercellular permeability seals, which regulate diffusion of particles 
with size and charge selectivity. In ultrathin section electron microscopy tight junctions 
are visualised as intercellular areas where the plasma membranes are closely opposed. 
Many molecular components of the tight junctions have been identified and among 
these are the claudin family of proteins, which are key components for the structure 
and function of the tight junctions [186-188]. Claudin molecules interact with each 
other between cells and polymerise within the plasma membrane to generate tight 
junction strands. Occludin and tricellulin are other types of transmembrane domain-
containing proteins, which are incorporated into or localised very close to the claudin 
base tight junction strands [189-191]. In addition, immunoglobulin superfamily 
membrane proteins with two extracellular Ig-like domains, including junctional 
adhesion molecules (JAM) are also localized at the tight junction [192, 193].  
On the cytoplasmic side of the plasma membrane, the membrane associated guanylate 
kinase (MAGUK) family proteins zona occludens (ZO)-1, ZO-2 and ZO-3 bind to the 
c-terminal cytoplasmic domain of claudins, occludins, tricellulin and JAM [194-196]. 
MAG-1, MAG-3, MUPPI and PATJ are PDZ (PSD-95, discs large, ZO-1) domain-
containing proteins that bind to tight junction associated proteins [197-202]. Cingulin is 
another cytoplasmic tight junction associated protein and is concentrated relatively far 
from the plasma membrane tight junctions [203]. Of all the proteins, the ZO family of 
proteins and cingulin interact with f-actin, which is located on the intracellular side of 
the tight junctions [204-209]. Claudins and ZO proteins are directly involved in the 
formation of tight junction strands, while occludin and tricellulin interact with claudins 
 77 
to modulate the formation of the tight junction strands. Figure 12 summarizes the tight 
junction protein interactions.  
 
Figure 12. Schematic representation of the basic structural configuration of the tight junction 
proteins. ZO-1 or ZO-2 (scaffolding proteins) are important for clustering of claudins and 
occludin, resulting in the formation of tight junctional strands. The role of the other scaffolding 
proteins (ZO-3/MAGI/MUP1) is less clear. The ZOs, cingulin, MUPP1 and MAG1 can provide 
a direct link to the actin cytoskeleton.  
 
1.7.2.1 The Claudin proteins 
 
The Claudin proteins were the first proteins to be identified from the tight junction 
proteins. They are made up of approximately 24 members in humans and mice [186-
188]. They are 21-28-kD proteins and consist of four transmembrane domains, two 
extracellular loops, amino- and carboxyterminal cytolpasmic domains and a short 
cytoplasmic turn as seen in figure 13. The carboxyl motif binds to the plaque ZO 
proteins [205]. 
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The most important function for claudins is to generate tight junction strands and 
important loss-of-function studies have highlighted their essential role in this process. 
Inhibition of claudin function through the addition of Clostridium perfringens enterotoxin  
 
 
 
Figure 13. The basic essential structure of claudins with a carboxyl end which binds to the 
scaffolding ZO proteins. From Furuse, Cold Spring Harbor Perspectives in Biology, 2009 [210]. 
 
 
and experiments on claudin-11 deficient mice have confirmed that claudins are pivotal 
in assembly of these strands [211-213]. 
1.7.2.2  Occludin 
 
Occludin is a 65-KD protein with a very similar tertiary structure to the claudins but 
with a different amino acid sequence. The carboxy-terminal cytoplasmic region of 
occludin binds to the ZO proteins, comprising the MAGUK family plaque proteins 
[196, 206, 214, 215]. Loss-of-function studies have highlighted that occludin plays a 
lesser role in tight junction band formation than claudins. Occludin-deficient mice are 
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viable and occluding-deficient epithelial cells feature normal tight junction bands [216, 
217]. 
1.7.2.3  The MAGUK family of tight junction proteins 
 
Underneath the plasma membranes the PDZ domain-containing cytoplasmic proteins 
interact with the integral tight junction proteins, claudins and occludins to form 
cytoplasmic plaques. Their role is mainly to act as scaffolding for the tight junction 
bands to interact. ZO-1, ZO-2 and ZO-3 form this family of proteins. The MAGUK 
family of proteins consist of PDZ domains, a SH3 domain, and a guanylate kinase 
(GUK) domain from their amino-termini [218]. Multiple domains of ZO-1, ZO-2 and 
ZO-3 are involved in the complex interactions with the tight junction proteins. Table 2 
below, gives a brief summary of the interactions between these proteins and the rest 
of the tight junction proteins. Out of the three MAGUK proteins, ZO-1 and 2 are the 
most indispensible with the role of ZO-3 not yet clear. Disruption of The ZO-1 gene 
and RNA deletion of ZO-2 in ZO-3 deficient mice resulted in deficient tight junction 
formation. Re-expression of either ZO-1 or ZO-2 recovered normal tight junction 
protein formation while the re-introduction of ZO-3 did not [219]. 
 
MAGUK protein Tight junction protein   
ZO-1, ZO-2, ZO-3 Claudins Itoh et al. 1999 [205] 
ZO-1 Occludin, JAM-A, cingulin, 
ZONAB 
Furuse et al. 1994; Fanning et al. 
1998; Bazzoni et al. 2000; Itoh et 
al. 2001; Li et al. 2005; 
Corndenonsi et al. 1999; Balda et 
al. 2003. [206, 214, 220-224]. 
ZO-1, ZO-2, ZO-3 Actin filaments Itoh et al. 1997, 1999b; Fanning et 
al. 1998, 2002; Wittchen et al. 
1999. [204-208]. 
Table 2. Specific interaction between the MAGUK proteins and the tight junction and 
cytoskeleton proteins.  
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1.7.2.4  Cytokine induced tight junction dysfunction  
 
It is well established that in patients with CD, intestinal permeability is abnormal and 
this is possibly due to defective tight junctions. In fact, defective tight junction barriers 
have been proposed as a possible aetiological factor for this intestinal inflammation. 
The fact that relatives of patients with IBD have abnormal intestinal permeability too 
suggests a primary generic aetiology to this problem. These findings give credence to 
the theory that abnormal intestinal permeability might play an aetiopathological role in 
IBD [225-228].  
The importance of TNF-α in CD has been highlighted for the last decade through both 
experiments on mouse models of intestinal inflammation and pivotal human 
therapeutic trials using the chimeric monoclonal antibody to TNF-α, Infliximab [229, 
230]. Apart from activating an endogenous inflammatory cascade, TNF-α has a role in 
altering the intestinal epithelial tight junction barriers. TNF-α has been shown to 
increase permeability in a number of epithelial models [231-233]. Thus, it is to no 
surprise that TNF-α could be a possible aetiological chemokine in the increased 
intestinal permeability recognised in CD. 
Work on Caco-2 cell models has shown that the effects of TNF-α on altered tight 
junction permeability are regulated through NF-κB activation. TNF-α is associated with 
a concentration and time-course increase in tight junction permeability in Caco-2 
cultures, an effect abolished by the use of the NF-κB inhibitors curcumin and 
triptolide. The increase in tight junction permeability is associated with a decrease in 
ZO-1 expression and an alteration in its junctional localisation [234]. The NF-κB 
dependent effects of TNF-α on the decreased TEER and altered permeability described 
thus far have been shown to apply for IL-1β as well [235]. 
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NF-κB, in turn affects tight junction expression and permeability through an alteration 
in MLCK. Phosporylation of MLCK leads to contraction of actin-myosin, redistribution 
of the tight junction proteins and an increase in intestinal permeability. Myosin and 
actin form a dense ring that encircles the cell at the level of the tight junction. F-actin 
peri-junctional reorganisation leads to the re-distribution of ZO-1 and occludin with 
effects on claudin 1 and 2 being limited [236-238].  
TNF-α induction of MLCK is mediated by binding of the activated NF-κB p50/p65 
dimer to the downstream κB binding site on the MLCK promoter region. NF-κB 
p50/p65 activation of the MLCK promoter then leads to a stepwise increase in MLCK 
transcription, expression and activity, and MLCK-mediated opening of the intestinal 
tight junction barrier [239]. Pertinently, mucosal MLCK expression is upregulated in 
IBD [240].   
Glucocorticoids are used universally in the treatment of IBD [241, 242] and they have 
been shown to attenuate intestinal permeability in patients with active disease [243]. 
Their site of action is specifically MLCK. Interaction between the glucocorticoid 
molecule and its receptor forms a glucocorticoid GR complex. In a Caco-2 model, 
glucocorticoid inhibition of the TNF-α induced increase in MLCK protein expression is 
due to the binding of the GR complex to a glucocorticoid receptor (GRE) binding site 
on the MLCK promoter region, suppressing the TNF-α induced activation as shown in 
figure 14 [244]. 
Immune mediated cross talk at the MLCK level is another potential pathway for 
altered intestinal permeability. In vivo experiments with CA-MLCK mice has shown that 
MLCK activation induces an upregulation of IL-13 which in turn leads to an increase in 
selective cation paracellular flux through an increase in claudin 2 expression. This 
pathway is unaffected by MLCK inhibition in vitro. The TNF-α/MLCK dependent 
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alteration in permeability increases the non-selective passage of cations and 
macromolecules [245].  
The TNF-α induced alteration in tight junction permeability has been shown in murine 
models of intestinal inflammation as well. Adoptive transfer of CD4+CD45RBhi T cells 
was associated with increased epithelial MLCK expression and MLC phosphorylation 
as well as morphologic tight junction disruption.  
TNF-α induced alteration in tight junction function is dependent on IFN-γ synergism. 
TNF-α induced barrier dysfunction in a Caco-2 model occurs only in monolayers 
pretreated with IFN-γ. This is possible through an increase in TNF receptor (TNFR)1 
and TNFR2 expression. Blocking antibody studies went on to show that TNFR2 was 
required for TNF-α barrier dysfunction and not TNFR1 [246, 247].  
 
 
Figure 14. Proposed mechanism of the glucocorticoid modulation of the TNF-α induced tight 
junction dysfunction. From Boivin, Am J Physiol Gastrointest Liver Physiol, 2006. [244].  
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The role of NF-κB is further strengthened by loss-of-function studies, where pro-
inflammatory cytokine induced tight junction disruption is attenuated in Caco-2 
monolayers with the use of NF-κB inhibitors, berberine and pentoxyphylline. 
Monolayer permeability as measured by TEER is restored as well by tight junction 
protein (ZO-1 & occludin) expression and localisation as studied by western blotting 
and confocal microscopy [248, 249]. These views are not universal. Tight junction 
dysfunction was abolished in TNF-α/IFN-γ exposed Caco-2 cells pretreated with low 
dose sulphasalazine. The dose used was below that known to inhibit NF-κB function. 
This work suggests that there might be an alternative pathway for TNF induced- 
MLCK activation [247].  
Apart from being only an NF-κB inhibitor, berberine is also an inhibitor of protein 
kinase A. Protein kinase A has been shown to be involved in the transcription of 
occludin. Ross River Virus (RRV) infection of Caco-2 monolayers causes an attenuation 
of the tight junction barrier through the disappearance of occludin.  Treatment of the 
RRV infected cells with a protein kinase A inhibitor restored the distribution of 
occludin and tight barrier function [250]. 
Taken together these data illustrate a possible physiological explanation for the 
observed increase permeability in intestinal inflammation. This process is TNFα/IFNγ 
dependent. By modulating their expression, or inhibiting NF-κB activation, tight 
junction modulation could be potentially arrested. The role of GLP-2 in the 
maintenance of mucosal integrity has been outlined, though the precise physiological 
pathway how this happens is still unclear. The effect of GLP-2 on the epithelial barrier 
and tight junctions has never been studied. If in addition to its other intestinotrophic 
properties, GLP-2 had an effect on tight junction expression and function, it would be 
of great therapeutic benefit to crosslink these two parallel yet distinct physiologies.  
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1.8 Conclusion 
 
In my introduction I have set the scene for the ensuing work presented in the rest of 
my thesis. The dysregulation of the enteroendocrine system in intestinal inflammation 
has been clearly described. There is extensive literature highlighting the association 
between intestinal inflammation and alteration in the gut-brain-EEC axis. Most data are 
derived at the cellular and the animal level with very little evidence available at the 
human level. The data are sparse, contradicitory, and clearly incomplete. 
The key aim of my work was to carry out a detailed examination of the 
enteroendocrine system at the tissue and plasma level in chronic human intestinal 
inflammation, focussing on CD. 
The association between active CD, anorexia and weight loss is robust.  
Malabsorption, sepsis, immunosuppressive therapy and multiple surgical resections 
offer more obvious and common explanations for the anorexia so commonly 
witnessed in clinical practice. Despite this, the evidence available to us from the murine 
models of intestinal inflammation cannot be ignored. It would be very surprising if the 
enteroendocrine system was not involved in the loss of appetite in CD.  
EEC expression in CD will be examined at the mRNA and protein level and this will be 
compared to normal controls. Both changes in tissue and plasma will be described. 
GLP-2 and its metabolising enzyme DP4 are potential important therapeutic targets in 
IBD. Background data on the DP4 enzyme activity in IBD are available. Tissue 
expression in other inflammatory states has been studied. A clear gap is present in the 
literature regarding the tissue and plasma expression of such an important peptide for 
the enteroendocrine system. In my thesis I have tried to fill this gap as much as 
possible. 
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GLP-2 expression in IBD has been studied and it has already been tested at the 
bedside in patients with short bowel syndrome. It is timely that a phase 1 trial on the 
use of GLP-2 in IBD has just been completed. Despite this, the molecular explanation 
for its role in protecting intestinal mucosal integrity in an inflammatory milieu is lacking. 
Using the Caco-2 monolayer as a model of mucosal barrier in intestinal inflammation I 
have tried to dissect its role in controlling the tight junction proteins. 
The enteroendocrine system is a very important axis in intestinal inflammation. It has 
ramifications in appetite control and in the maintenance of gut mucosal integrity. 
Possible therapeutic targets should be further considered with an aim to further 
decrease the disease burden in IBD.  
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2 Chapter 2. Methodology 
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2.1 Chapter aim and structure 
 
In this chapter the main methodology of the work that embodies this thesis will be 
discussed. Work has been carried out on both human tissue and Caco-2 cells: the 
relevant techniques will be discussed separately for clarity’s sake. 
2.2 Ethical approval and basic protocol 
Ethical approval was obtained from Central Manchester Research Ethics Committee 
(07/H1008/180) in October 2007 with notices of major amendment submitted in 
March 2008 and January 2010. Site-specific approval was obtained from the Stoke-on-
Trent local research ethics committee while Research and Development approval was 
obtained from the University Hospital of North Staffordshire (UHNS).  
2.3 Basic protocol and patient recruitment 
I obtained all tissue from patients with active CD and controls undergoing endoscopic 
procedures for clinically indicated reasons. Four extra biopsies were sought for 
research purposes for histology. Tissue from the terminal ileum was used in this study 
from both patients and controls. This was due to the localization of the GLP-1 and 
PYY expressing L cells in the distal ileum [251]. Tissue was fixed in 10% formalin for 
24-48 hours and later embedded and mounted in paraffin. Sections were cut with a 
microtome at a thickness of 3µm and mounted on adhesive slides (Surgipath, Surgipath 
Medical Industries, INC. Richmond, USA). These were left overnight on a hot plate, 
and then dried for 24-48 hours in an oven at 37°C. For quantitative polymerase chain 
reaction (qPCR), one to two other tissue samples were stored in ‘RNA later’ (Qiagen, 
Crawley, UK) and then stored at -80°C until further processing. Plasma samples were 
obtained from both patient and healthy controls for gut hormone estimation. These 
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were stored at -20°C until further processing. At the time of the study, patients were 
also asked to fill in a validated visual analogue score (VAS) questionnaire relating to 
satiety and fullness as well as a CDAI (filled in by a professional). A list of patients with 
CD, recruited for the study is given below (table 3). The VAS have been collected only 
for patients recruited for the test meal study. Results will be presented in chapter 4.  
Patients were divided in two cohorts. Patients who had small bowel involvement and 
ileocaecal disease have been grouped together under the small bowel group. Patients 
with predominant colonic disease with no small bowel disease have been grouped 
under the large bowel cohort. 
 
No Age Sex Site W CDAI CRP Medical Rx Surg. Rx 
1 66 M a/SB 18.8 100 36.7 Steroids nil 
2 21 M a/SB 17.6 86 32 5-ASA nil 
3 62 F a/SB 0 45 0.2 5-ASA nil 
4 34 F a/SB 0 204 10.1 Steroids R hemi 
 
5 
 
44 
 
F 
 
a/SB 5.8 
 
205 1.8 Infliximab 
R hemi + 
revisions 
6 69 M a/SB 7.1 125 1 5-ASA nil 
 
7 
 
57 
 
F 
 
a/SB 
   
9.1 
 
120 11.2 
5-ASA/ 
methotrexate 
 
R hemi 
8 28 M a/SB 5.7 37 15 nil nil 
 
9 
 
48 
 
F 
 
a/SB 0 
 
66 24 
azathioprine/ 
steroids 
 
nil 
10 38 M a/SB 22.8 291 24 Steroids nil 
 
11 
 
49 
 
F 
 
a/SB 0 
 
44 13.8 
azathioprine/ 
steroids 
R hemi + 
revisions 
12 32 F a/SB 8.4 112 6.1 nil R hemi 
 
 
13 
 
 
22 
 
 
M 
 
a/SB + 
a/LB 0 73 26 Adalimumab 
R hemi + 
sigmoid 
colectomy 
14 26 F a/SB 0 17 6.1 nil R hemi 
 
 
15 
 
 
47 
 
 
M 
 
 
a/SB 10 200 8.7 
Azathioprine/ 
5-ASA/ 
Steroids 
 
 
SB resection 
16 27 F a/SB 4.3 203 23 5-ASA R hemi 
17 68 M a/SB 0 205 4.1 Adalimumab R hemi 
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No Age Sex Site W CDAI CRP Medical Rx Surg. Rx 
18 26 M a/SB 14.5 135 7.3 Nil nil 
19 33 M a/SB 3.1 222 <5 Nil nil 
 
20 
 
53 
 
F 
 
a/SB 
 
0 
 
135 
 
<5 
 
Steroids 
R hemi + 
revision 
 
21 
 
54 
 
F 
 
a/SB 
 
10 
 
81 
 
<5 
Steroids + 
5-ASA 
 
R hemi 
22 36 M a/SB 0 116 12.1 nil nil 
23 22 F a/SB 27 211 12.4 nil nil 
 
24 
 
47 
 
F 
 
a/SB 
 
0 
 
125 
 
<5 
 
nil 
R hemi + 
revision 
25 66 F a/SB 5.4 113 1.8 5-ASA R hemi 
26 40 F a/SB 0 n/a 60 nil R hemi 
27 30 F a/SB 0 n/a 6.6 5-ASA nil 
28 23 M a/SB 55 160 0.5 nil nil 
 
29 
 
30 
 
F 
 
a/SB 
 
10 
 
132 
 
13 
Azathioprine 
+ 5-ASA 
 
nil 
 
 
30 
 
 
25 
 
 
F 
a/SB 
+ 
a/LB 
 
 
16.7 
 
 
206 
 
 
22.4 
 
 
nil 
 
 
nil 
31 59 F a/SB 4.3 385 22.8 nil nil 
32 60 M a/SB 0 57 <5 nil nil 
 
 
33 
 
 
53 
 
 
F 
 
 
a/SB 
 
 
22.7 
 
 
187 
 
 
2 
 
 
Steroids 
R hemi + 
SB 
resection 
34 23 F a/SB 0 137 36 nil nil 
35 67 F a/SB 20.2 84.2 74 Steroids nil 
 
 
36 
 
 
66 
 
 
F 
a/SB 
+ 
a/LB 
 
 
7 
 
 
173 
 
 
33.7 
 
 
nil 
 
 
nil 
37 41 F a/SB 0 101 n/a 5-ASA R hemi 
 
38 
 
39 
 
F 
 
a/SB 
0 
 
 
60 
 
2.5 
5-ASA/ 
steroids 
 
nil 
 
 
Mean 
42.9 
(21-
69) 
 
25F/ 
13M 
 
 
N/A 
8 
(0-
55) 
138 
(17-
385) 
17.2 
(0.5-
74) 
 
 
N/A 
 
 
N/A 
 
39 
 
29 
 
M 
 
a/LB 
 
0 
 
150 
 
3.6 
5-ASA/ 
Azathioprine 
 
nil 
 
40 
 
50 
 
M 
 
a/LB 
 
0 
 
124 
 
0.2 
5-ASA/ 
steroids 
 
nil 
41 60 F a/LB 0 42 0.8 5-ASA nil 
42 26 F a/LB 12.3 83 130 nil nil 
43 41 F a/LB 9.7 137 n/a Infliximab nil 
44 24 M a/LB 1 225 <0.5 Infliximab nil 
 
45 
 
43 
 
F 
 
a/LB 
 
12.1 
 
108 
 
28.6 
 
6-MP 
Diversion 
colostomy 
46 33 F a/LB 19.4 240 6 5-ASA nil 
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No Age Sex Site W CDAI CRP Medical Rx Surg. Rx 
 
47 
 
48 
 
F 
 
a/LB 
 
0 
 
134 
 
8.8 
Azathioprine/ 
Infliximab 
 
nil 
48 32 M a/LB 8.7 280 17.6 Azathioprine nil 
49 38 F a/LB 0 150 43 5-ASA nil 
 
 
50 
 
 
41 
 
 
M 
 
 
a/LB 
 
 
9.05 
 
 
262 
 
 
29.6 
Azathioprine/ 
5-ASA/ 
steroids 
 
Partial sigmoid 
colectomy 
 
 
Mean 
38.75 
(24-
60) 
 
7F/ 
4M 
 
 
N/A 
6 
(0-
19.4) 
161 
(42-
280) 
26.8 
(0.2-
130) 
 
 
N/A 
 
 
N/A 
51 44 M i/SB 0 29 0.7 Steroids R hemi 
 
52 
 
50 
 
F 
 
i/SB 
 
0 
 
93 
 
5 
5-ASA/ 
steroids 
 
R hemi 
 
 
53 
 
 
50 
 
 
F 
 
 
i/SB 
 
 
3 
 
 
126 
 
 
<5 
Azathioprine/ 
5-ASA/ 
steroids 
 
R hemi + 
revisions 
54 27 M i/SB 0 5 7.5 5-ASA R hemi 
55 27 F i/SB 0 83 n/a nil R hemi 
 
 
Mean 
39.6 
(27-
50) 
 
3F/ 
2M 
 
 
N/A 
 
0.6 
(0-3) 
 
67 (5-
126) 
4.4 
(0.7-
7.5) 
 
 
N/A 
 
 
N/A 
56 51 M i/LB 0 85 0.6 nil nil 
57 35 F i/LB 13.7 63 76 5-ASA nil 
58 52 F i/LB 2.5 115 n/a 6-MP R hemi 
 
59 
 
28 
 
F 
 
i/LB 
 
3.3 
 
361 
 
15 
5-ASA/ 
Azathioprine 
Subtotal 
colectomy 
 
 
Mean 
41.5 
(28-
52) 
 
2M/ 
2F 
 
 
N/A 
4.9 
(0-
13.7) 
156 
(85-
361) 
30.5 
(0.6-
76) 
 
 
N/A 
 
 
N/A 
Table 3. Details of CD patients recruited in this study. Sex, age, predominant site of disease, 
percentage weight loss (W) since previous remission period, activity scoring (CDAI, CRP or 
ESR) present medical treatment regime and past surgical treatment are recorded. Site of 
disease and disease activity was assessed through independent endoscopic examination, 
histological assessment and magnetic resonance small bowel (MRI) enterocolyisis as clinically 
indicated. a/SB = active small bowel CD, a/LB= active large bowel CD, i/SB = inactive small 
bowel CD, i/LB = inactive large bowel CD. CRP normal if <5. 
 
 
Sex 34 female / 26 male patients 
Age 
Mean 
 
46 (19-83) 
Table 4. Summary of the healthy controls recruited for this study. 
 
Only patients without prior history of surgery or anti-TNF treatment were recruited 
for later test meal studies as infliximab has been shown to affect leptin [252] and 
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ghrelin [106] plasma levels. Even in the presence of a normal CRP or CDAI; if clinical 
activity was deemed present through more robust evidence such as endoscopic 
examination, histological evidence or MRI enterocolysis, these patients were recruited 
with their respective active groups. As for the normal control group, patients with 
known irritable bowel syndrome, active diverticular disease and colonic polyps or 
malignant disease on the index endoscopic examination were excluded from the study.  
2.4 Histology 
To complement immunohistochemistry, haemotoxylin and eosin (H&E) staining was 
carried out on sections as per protocol. Sections were dewaxed and hydrated in 
graded xylene and industrial methylated spirit (IMS). Sections were then dipped in 
haematoxylin for three minutes, rinsed in running tap water for five minutes, 
acid/alcohol (1% Hydrochloric acid/70% IMS) for three seconds, rinsed again in running 
tap water for five minutes, eosin (5g/L) for one minute and finally sections were rinsed 
in distilled water for one minute and passed through xylene/IMS once again and 
mounted. 
2.5 Immunohistochemistry 
 
Different immunohistochemistry protocols will be outlined separately. Up to nine 
separate visual fields were examined per section. The number of cells stained per field 
were counted together with the number of crypts and or villi. The mean EEC peptide 
cell expression was calculated per crypt/villus unit per high power field (x40). Mean 
expression was then calculated per section. Only cytoplasmic staining was considered 
as positive staining. Negative controls were included in trial runs. To control for intra-
assay variability some sections were stained repeatedly on separate runs to ensure the 
validity of the results.  
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2.5.1 CD 4 immunohistochemistry 
 
Inflamed terminal ileal CD samples were compared to an equal number of controls. 
Sections were left on a hot plate for ten minutes and hydrated and dewaxed in xylene 
and industrial IMS. Sections were then washed in 1% tris-buffered solution (TBS) for 20 
minutes. Endogenous peroxidase activity was exhausted by supplying an excess of 
hydrogen peroxide diluted in 0.6% methanol. This was applied twice for five minutes 
and then the slides were washed twice in TBS for five minutes. 
Ethylenediaminetetraacetic acid (EDTA) at pH 8 was used as the antigen retrieval (AR) 
agent. Slides were put in solution and warmed in a microwave oven at low energy for 
ten minutes. After a TBS wash, a 3% block (w/v) with mouse serum (Vector Labs, 
Peterborough, UK) bovine serum albumin (BSA) (3%) was applied for 60 minutes at 
room temperature (RT).  
Primary antibody was then applied for 30 minutes at room temperature (RT) (NCL-L-
CD4-368)(Novocastra Labs, Newcastle-upon-tyne, UK) at a 1:100 dilution. Following a 
TBS wash, a peroxidase labeled polymer solution was applied for 30 minutes at RT 
(DAKO Envision Rabbit Immunohistochemistry kit. DAKO, Ely, UK). Thereafter, a 
substrate chromagen solution was applied from five to ten minutes (DAKO).  
After two final five minute TBS washes, sections were counterstained with nuclear fast 
red (Vector labs) for three minutes, dehydrated with four, two minute washes with 
100% IMS and then dewaxed with four, five minute 100% xylene washes. Slides were 
mounted with a glass coverslip using Pertex mounting medium (Histolab, Sweden).  
2.5.2 CgA immunohistochemistry 
 
Tissue from active small bowel CD, colonic CD and inactive disease were studied 
along with controls. A similar technique to the one described above was applied for 
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CgA immunohistochemistry. Trypsin was used as an AR step but in this case, it was 
applied prior to the peroxidase block as previously optimised. 
A 3% block (w/v) with goat serum (Vector Labs) and BSA (3%) was applied for 60 
minutes at RT. A polyclonal Rabbit Anti-Human Antibody was used (DAKO A0430, 
Denmark), at a concentration of 1:2000 and left overnight at 4°C. On the following 
day, slides were washed for five minutes twice in TBS and a secondary biotinylated 
antibody (Vector labs mouse ABC kit) was applied for 30 minutes. After two, five 
minute TBS washes, AB reagent was applied for 30 minutes. Slides were then washed 
twice in TBS for five minutes and chromagen (Vector labs SG peroxidase substrate kit) 
was applied for five minutes. After two final five minute TBS washes, sections were 
counterstained with nuclear fast red, dehydrated and then dewaxed. Slides were 
mounted as described above. 
2.5.3 PYY immunohistochemistry 
 
PYY immunohistochemistry was carried in a similar fashion. The only notable 
difference was that the peroxidase block and the serum/BSA block were carried out in 
one step as indicated by optimizations carried out by Phoenix Pharmaceuticals, Inc. 
(Burlingame, CA, USA). See table 5. 
Solution A 
5mls TBS 
1% BSA – 0.05g 
2% goat serum – 100µl 
0.05% Tween20 2.5µl 
Put 250µl of 30% hydrogen peroxide in 2.5ml of Solution A 
Table 5. Peroxide and serum/BSA block in PYY immunohistochemistry 
 
Solution A was applied to the section for 30 minutes at RT. A rabbit anti-human PYY 
(3-19) antibody was used for this experiment. The pellet was reconstituted in 100µl of 
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distilled water on arrival. The antibody concentrate was then stored at 4°C for future 
use. The antibody was used at a concentration of 1:400.  
2.5.4 Phox2b immunohistochemistry 
 
A rabbit anti-human polyclonal antibody was used for this experiment (P0371, Sigma, 
St. Louise, USA). The pellet was reconstituted in 86µl of ammonium persulfate solution 
provided. The solution was diluted 1:10 in TBS and then glycerol added to a final 
concentration of 50%. BSA to a final concentration of 1% was added. The antibody 
solution was stored in 100µl aliquots at a final concentration of 1:20 at 20°C.  
Sections were dipped in the AR (EDTA PH 8) and heated in a microwave set at high 
energy for 2.5 minutes and then heated twice for five minutes with the microwave on a 
medium setting. In between each step, the container with the slides was topped up 
with the AR fluid to ensure that the sections did not dry out. Intrinsic peroxidase 
activity was exhausted by applying a solution of 3% Hydrogen peroxide using 30% 
methanol as a diluent. Blocks with 5% (w/v) goat serum and 1% BSA were applied for 
60 minutes at RT. Primary antibody was then applied at a concentration of 1:250 and 
incubated at 4°C overnight. On the following day, the secondary antibody was applied 
as described above. In this protocol DAB (Vector labs SG peroxidase substrate kit) 
was used as a substrate reagent. This was applied for five minutes. It was prepared by 
adding two drops of buffer to 5 mls of PBS. Afterwards, four drops of DAB, two drops 
of hydrogen peroxide and two drops of nickel were added. After each addition the 
solution was vortexed. Sections were then counterstained, dehydrated, de-waxed and 
mounted as described above. 
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2.5.5 GLP-1 immunofluorescence 
 
Sections were dewaxed and hydrated as described above. After a 15 minute wash in 
TBS, sections were dipped in the AR solution (citrate pH 6). Sections were heated in a 
microwave as described above. This step was followed by a further wash for ten 
minutes in TBS. Plasma membranes were then solubilised with 0.1% Tx-100 for 60 
minutes. After a further ten minutes wash, a 10% (v/v) donkey serum (Sigma-Aldrich, 
UK) and 3% (w/v) BSA block were applied for 60 minutes at RT. Following a further 
ten minutes wash, the primary antibody (GLP-1 goat anti-human primary antibody, sc-
7782, Santa Cruz Biotechnology, Inc, Heidelberg, Germany) was applied at a 
concentration of 1:100 on the sections overnight and left at 4°C. 
The following day, sections were washed once again and the secondary antibody 
(donkey anti-goat secondary antibody, sc-2024, Santa Cruz) was applied (concentration 
1:100) for 60 minutes at RT. Following a 10 minute TBS wash, 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Paisley, UK) was then applied for a few seconds. 
Sections were then washed one final time and then mounted using VectaMountTM AQ 
(H-5501, Vector, Burlingame, USA). The slides were left to dry and then stored at 
4°C. Fluorescence was detected using a fluorescence microscope Keyence BZ-8000 
(Keyence, Osaka, Japan). 
2.5.6 Double immunofluorescence 
 
For clarity and simplicity this section is presented in table form in the appendix section. 
Primary antibodies used were similar to the ones described above. Donkey anti-goat 
secondary antibodies (Jackson laboratories, Maine, USA) and goat anti-rabbit 
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antibodies (compliments of Dr Catherine O’Neill) were used in these experiments at 
the concentrations described. 
2.6 Molecular studies 
 
Two separate protocols will be described for the molecular studies undertaken in this 
thesis. In section 2.6.5 a separate protocol used on RNA derived from Caco-2 cells 
will be described. Work in that section, was carried out by the Centre of Integrated 
Genomic Research in the University of Manchester.   
2.6.1 RNA extraction technique 
 
Tissue stored in RNA later at -80°C, was later thawed to RT. Tissue was weighed and 
only 2-3mg of tissue was used, with the rest being refrozen to -80°C. Total RNA was 
extracted from tissue using Qiagen’s RNeasy micro system (Qiagen, Crawley, UK).  
The biopsy was placed in an Eppendorph tube containing 350µl of manufacturer’s 
buffer RLT. This was homogenised using a hand-held homogeniser (Sigma, UK) for 3-5 
minutes until a clear solution was created. The supernatant was then transferred to a 
new microcentrifuge tube, using only the supernatant in subsequent steps. 350µl of 
70% ethanol were added to the lysate. This was mixed by pipetting. The sample was 
then transferred to an RNeasy spin column and this was centrifuged at 10,000rpm for 
15 seconds. The follow through was collected and stored on ice for protein extraction. 
350µl of the manufacturer’s buffer RW1 was added to the spin column and this was 
centrifuged for 15 seconds at 10,000rpm. This time the follow through was discarded.  
10µl of DNase stock solution was added to manufacturer’s buffer RLD and the mix 
was then added to the RNeasy column and left to incubate for 15 minutes at RT. 
Following that, 350µl of buffer RW1 was added to the spin column and then spun at 
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10,000rpm for 15 seconds. At this point both the follow through and the collection 
tube were discarded. The RNeasy miniElute spin column was then placed in a new two 
ml collection tube. 500µl of manufacturer’s buffer RPE were added to the spin column 
and spun for 15 seconds at 10,000 rpm. Again, this time both follow through and 
collection tube were discarded. 
The RNeasy miniElute spin column was placed in a new two ml collection tube. 500µl 
of buffer RPE was added to the spin column and this was spun for 15 seconds at 
10,000rpm. The follow through was discarded and 500µl of 80% ethanol were added 
to the spin column. This was spun at 10,000rpm for two minutes. Again, both follow 
through and collection tubes were discarded. Finally, the spin column was placed in a 
third collection tube. The lid of the spin column was removed and this was spun at full 
speed (13,000rpm) for five minutes to evaporate any excess alcohol. Again, both follow 
through and collection tubes were discarded. The RNeasy spin column was placed in a 
new 1.5 ml collection tube. 14µl of sterile water were pipetted on the membrane of 
the spin column and this was spun at full speed for 60 seconds. The RNA was thus 
collected in the collection tube and stored in aliquots at -80°C until further use. 
2.6.2 RNA bioanalysis 
 
A Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, USA) was 
used to estimate RNA purity and concentration. Absorbance was read at 220-350nm 
wavelengths. The 260:280nm ratio was used as an indicator of RNA purity. The 
Nanodrop software algorithm produced an estimate of RNA concentration from 
absorbance spectra. Results were issued as ng/µl. 
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2.6.3 cDNA synthesis 
 
Eight samples from CD patients and eight controls were used for cDNA synthesis and 
subsequent qPCR. An ImProm-IITM Reverse Transcription System (Promega 
Corporation, Madison, USA) was used. Five µl of Mixture B (see table 6), positive and 
negative controls were plated on a reaction plate (EU Frosted Non-skirted Thin wall 
96 x 0.2ml; Bioplastics, Geneflow Ltd, Staffordshire, UK). The plate was placed on a 
preheated (70°C) temperature controlled heating block for five minutes. Afterwards, 
the plate was immediately chilled for five minutes on ice. The plate was spun for ten 
seconds in a centrifuge to precipitate any condensation and thus maintain the original 
volume. The plate was stored on ice. 
MIXTURE A   
Magnesium chloride 4 µl 
X5 Buffer 1 µl 
dNTP 1 µl 
Rnasin 0.5 µl 
RTase 1 µl 
Nuclease free water 4.5 µl  
Total at 15ul/sample  
MIXTURE B  
Template RNA Up to 4µl; 
not exceeding 
1ug 
Oligo dT 1 µl 
Nuclease free water As applicable 
Total 5 µl 
POSITIVE CONTROL  
1.2kb Kanamycin +ve control 2 µl 
Oligo dT 1 µl 
Nuclease free water 2 µl 
Total 5 µl 
NEGATIVE CONTROL  
Template RNA 0 µl 
Oligo dT 1 µl 
Nuclease free water 4 µl 
Total 5 µl 
Table 6. Details of Reverse Transcription reaction mixtures 
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Step Temperature Time 
Annealing 25°C 5 minutes 
Extension 42°C 60 minutes 
Inactivation 70°C 15 minutes 
Table 7. Block settings for Reverse Transcription 
 
15µl of Mixture A (see table 6) was then added to each well in the plate. The plate was 
replaced in the temperature controlled heating block and the steps described in table 7 
applied. 
2.6.4 Quantitative Polymerase Chain Reaction 
 
Primer sequences were designed to each targeted gene coding sequence (Eurofins 
MWG Operon, Ebersberg, Germany). qPCR was performed using the SYBR green 
core kit (Eurogentec, Southampton, UK) following the manufacturer's instructions and 
an Opticon qPCR thermal cycler (Bio-Rad, Hemel Hempstead, UK). Table 8 gives 
details regarding the primer sequences, and table 9 illustrates details of the mastermix. 
Table 10 shows the settings applied to the thermal cycler as per protocol. 138µl of 
each primer was added to each mastermix. For each primer set an optimal dilution 
was determined (50pmol/µL), and melting curves were used to determine product 
specificity. Each sample was serially diluted over three orders of magnitude, and for 
each primer set all samples were run on the same 96-well plate. Expression ratios 
were determined relative to a standard sample and normalized using a value from 
primer sets of housekeeping genes, 18s, glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH), Hypoxanthine phosphoribosyl transferase (HPRT) and YWAHZ [253].  
When possible, primers were designed across exons to exclude gDNA amplification 
using the primer 3 website (http://frodo.wi.mit.edu/primer3/). The primers were 
submitted to Basic Local Alignment Search Tool (BLAST®) 
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(http://www.ncbi.nlm.nih.gov/BLAST/) to check for non-specific binding.  Where 
primers showed homology to other regions within the human transcriptome the assay 
was redesigned and the new primers submitted to BLAST.  They were then purchased 
from Eurofins (Ebersberg, Germany). Where genes had only one exon (ngn-3 and 
Math-1) each sample was run with a negative RNA control. As a routine, as part of 
primer optimisation, each set of primers was first run alongside negative controls to 
exclude primer dimer amplification. Multiple optimization steps were carried to find 
the optimal annealing temperature and cDNA concentration.  
 
Primer Name Sequence 5’-3’ 
CgA sense  AAC AGC CCT ATG AAT AAA GGG G 
CgA antisense  CTC AAG AAC CTC TGA GAG TTC A 
PYY sense  TAT GGT GTT CGT GCG CAG GC 
PYY antisense  ACA GGT CTG GGC CCT CCG A 
GLP-1 sense  AGG GCA CAT TCA CCA GTG ACT ACA 
GLP-1 antisense  GCC AAG TTC TTC AAC AAT GGC GA 
IFN-γ sense  GTC CAA CGC AAA GCA ATA CA 
IFN-γ antisense  GCA TCT GAC TCC TTT TTC GC 
GAPDH sense TGC ACC ACC AAC TGC TTA GC 
GAPDH antisense GGC ATG GAC TGT GGT CAT GAG  
YWAHZ sense ACT TTT GGT ACA TTG TGG CTT CAA 
YWAHZ antisense CCG CCA GGA CAA ACC AGT AT 
HPRT sense TGA CAC TGG CAA AAC AAT GCA 
HPRT antisense GGT CCT TTT CAC CAG CAA GCT 
18 s sense AGT CCC TAC CCT TTG TAC ACA 
18s antisense GAT CCA AGG GCC TCA CTA AAC 
NGN-3 sense  TAA GAG CGA GTT GGC ACT GAG CAA 
NGN-3 antisense  TTT GAG TCA GCG CCC AGA TGT AG 
Ube4a sense CCA GCT AGC CCA GAT GAC TC 
Ube4a antisense  TGG GAT CAC TGT TGT CCA GA 
DP4 sense  CAA ATT GAA GCA GCC AGA CA 
DP4 antisense  CAC GGC TAT TCC ACA CTT GA 
Table 8.  Details of primers used in qPCR experiments.   
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Component Volume (µl) X96 (µl) Final (µl)(15%more) 
10x Buffer 2.5 240 276 
50mM MgCl 1.75 168 192.75 
5mM dNTP 1 96 110.4 
HotGoldStar Enzyme 0.125 12 13.8 
PCR grade Water 11.375 1092 1255.8 
Diluted SYBR Green I 0.75 72 82.8 
Total Mix 17.5 1680 1932 
Table 9. Typical mastermix mixture 
 
Step Temperature Time 
HotGoldStar Activation               95°C 10min 
Denaturation                             95°C 15s 
Annealing  60°C 30s 
Extension 72°C 30s 
Plate read   
Repeat x39 cycles              
Incubate 72°C 10min 
Melting curve 72-92°C reading every 0.3C, hold for 1 sec 
Table 10. Thermal cycler settings for qPCR.  
 
2.6.5 Molecular studies in Caco-2 cells 
 
2.6.5.1 RNA Extraction 
 
Samples in one ml of Trizol (Invitrogen) were removed from -80°C storage and allowed 
to thaw. Samples were fully homogenised using a pipette and incubated at RT for ten 
minutes. 200µl chloroform was added to each sample. Tubes were vortexed to emulsify 
the solution and incubated at RT for two minutes. Samples were then centrifuged at 
12,000xg for 15 minutes. The upper aqueous phase was removed and added to an equal 
volume of 70% ethanol. The samples were added 700µl at a time to an RNeasy column. 
Followed by a short spin, the flow through was discarded and the remaining sample 
added. This equated to two aliquots being added for each sample. Each RNeasy column 
can bind up to 100µg RNA.  The manufacturer’s guidelines were followed from this 
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point, which included a wash with manufacturer’s buffer RW1, two washes with buffer 
RPE, and a final elution in 30µl nuclease free water.   
2.6.5.2  DNAse Treatment 
 
RNA samples were DNase treated using the DNA Free Turbo Kit (Ambion/Applied 
Biosystems).  Briefly 0.1 volume (3µl) of 10X TURBO DNase I Buffer and one µl 
TURBO DNase I (2 U/µl) was added and the RNA incubated at 37ºC for 30 minutes.  
0.1 volume (3.4µl) DNase Inactivation Reagent was added and the samples incubated for 
five minutes at RT with occasional mixing.  Finally the samples were centrifuged at 
10,000xg for 1.5 minutes at RT and the supernatant transferred to a new tube. 
2.6.5.3  Quality Control 
 
RNA was quantified using a NanoDrop ND-1000 UV-visible spectrophotometer 
[Labtech International, Ringmer, UK].  Before RNA measurements were taken the 
ND-1000 was blanked by pipetting 1.2µl of Nuclease free water directly onto the 
optical pedestal, the lid was closed and using surface tension to hold a one mm column 
of liquid in place the background measurement was taken.  The pedestal surface was 
then wiped clean and 1.2µl of undiluted RNA measured.  The NanoDrop software 
displayed the concentration of RNA in ng/µl and assessed the 260/280 ratios enabling 
purity estimations.  A 260/280 ratio between 1.9 and 2.1 indicates pure RNA.   
RNA integrity was assessed using the Agilent 2100 Bioanalyser [Agilent Technologies].  
RNA (1.5µl/sample) and 1.5µl RNA ladder (Ambion Europe Ltd, Cambridgeshire, UK) 
were heat denatured at 70°C for two minutes and placed on ice.  The Eukaryote RNA 
6000 nano-chip was filled with nine µl of gel dye mix into the appropriate well.  The 
chip was placed onto a chip priming station and a plunger depressed for 30 seconds to 
 103 
fill the chip with gel.  A further nine µl of gel dye mix was placed into the two 
remaining gel dye mix wells.  Gel matrix (five µl) was added to each of the sample 
wells and to the ladder well.  The denatured samples and RNA ladder (one µl) were 
then added to one of 12 sample wells.  The chip was vortexed for one minute and 
then run on the Agilent 2100 Bioanalyser.  The 28s and 18s RNA peaks are seen at 
approximately 48 and 42 seconds respectively for the extracted RNA.   The Agilent 
2100 Bioanalyser software assigns an RNA Integrity Number (RIN) to each sample 
using a scale from zero to ten, with a value of zero meaning totally degraded and a 
value of ten meaning highly intact.     
2.6.5.4  Reverse Transcription 
 
RNA was reverse transcribed using SuperScript IIITM RNase H reverse transcriptase 
(Invitrogen Ltd, Paisley, UK) following the manufacturer’s guidelines.   Briefly, 250ng 
Oligo (dT)12-18, 125ng random primers, one µg RNA and one µl dNTP mix (10mM) 
(Invitrogen) were added to a nuclease-free micro-centrifuge tube made up to 13µl with 
RNAse/DNAse free water, incubated at 65°C for five minutes and then chilled on ice.  
The tubes were briefly centrifuged, and four µl 5x first strand buffer, one µl DTT 
(0.1M), one µl RNaseOUTTM and one µl Superscript III RT (200U/µl) were added. The 
tubes were mixed gently and incubated at 25°C for five minutes followed by 50°C for 
60 minutes.  The reaction was terminated by heating the samples to 70°C for 15 
minutes.  The cDNA was stored short term at -20°C. For long term storage the 
cDNA was kept at -80°C. 
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2.6.5.5 Quantitative PCR measurement of gene of interest  
 
 
The Human Universal Probe Library system [254] (Roche, Switzerland), employing 
proprietary locked nucleic acid analogues (LNA) of fluorescence resonance energy 
transfer hydrolysis probes, was used for RT qPCR to measure expression levels in 
genes of interest [12] [12].  Using the Roche Online Assay Design Centre, specific 
primers and an associated probe were selected for the gene of interest [12] transcript. 
Where primers showed homology to other regions within the human transcriptome 
the assay was redesigned and the new primers submitted to BLAST.  Primer sets were 
purchased from Metabion, Planegg-Martinsried, Germany. Dual labelled LNA probes 
were from the Universal ProbeLibrary [Roche Diagnostics].   
2.6.5.6  Quantitative RT-PCR with LightCyclyer 480 System. 
 
cDNA was diluted one in 20. Each reaction comprised of four µl diluted cDNA, five µL 
2 x LightCycler 480 Probes Master (Roche, Switzerland), 0.1µl forward and reverse 
primer mix (see table 11 for primer sequences) (20µM), 0.1µl Probe (10µM) (Roche, 
Switzerland), and 0.8µl of water.  Samples were then amplified in triplicate on a 
LightCycler® 480 real time PCR machine, and the temperature programme was 95°C 
for five minutes followed by 50 cycles of 95°C for ten seconds and 60°C for 30 
seconds. Target gene expression in a sample was normalised to the geometric mean of 
the two endogenous controls. This is given by ΔCp, where ΔCp is determined by 
subtracting the average endogenous gene Cp value from the average target gene Cp 
value.  [Cp GOI – Cp average (endogenous gene)].   
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2.6.5.7  Gene expression Levels 
 
To compensate for variations in cell number, RNA isolation, reverse transcription and 
PCR amplification efficiency, two endogenous ‘house-keeping’ (HSK) transcripts were 
chosen using the GeNorm algorithm [255] (see figure 15).  A selection of samples 
from all TNF concentrations and time points were screened for eight reference genes: 
actin beta (ACTB), βeta 2 micoglobulin (B2M), GAPDH, hydroxymethylbilane synthase 
(HMBS), HPRT1, ribosomal protein (RPL)32 and succinate dehydrogenase complex, 
subunit (SDHA). Assays were designed using the Roche Universal ProbeLibrary 
system. Table 11 outlines the primer sequences and the probe number for each assay.   
The GeNorm algorithm worked out the stability of each transcript, and sequentially 
removed the least stable transcript until the two most stable transcripts remain. The 
software compared the amount of each gene detected across all samples. In GeNorm 
the threshold for the stability value M is 0.4. Anything below 0.4 is considered to be 
stable. Although this is an arbitrary cut off value, it is widely acce to be a reliable cut 
off value [255].  For this study the most stable reference genes were found to be 
GAPDH and SDHA.  
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Gene Forward Primer Sequence Reverse Primer Sequence 
DP4 CCAAAGACTGTACGGGTTCC ACAAAGAACTTTACAGTTGGATTCAC 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 
ACTB ATTGGCAATGAGCGGTTC GGATGCCACAGGACTCCAT 
B2M TTCTGGCCTGGAGGCTATC  TCAGGAAATTTGACTTTCCATTC 
HPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 
RPL32 GAAGTTCCTGGTCCACAACG GCGATCTCGGCACAGTAAG 
SDHA AGAAGCCCTTTGAGGAGCA CGATTACGGGTCTATATTCCAGA 
HMBS AGCTATGAAGGATGGGCAAC TTGTATGCTATCTGAGCCGTCTA 
RPL13A GAGGCCCCTACCACTTCC TGTGGGGCAGCATACCTC 
GUSB CGCCCTGCCTATCTGTATTC TCCCCACAGGGAGTGTGTAG 
Table 11. Primer sequences and the probe number for each assay 
 
 
Figure 15. Average expression stability values of the control genes as issued by the GeNorm 
software. 
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2.7 Plasma gut hormone studies 
 
The following protocol was used to study all the CD patients and healthy controls. 
Methodology and visual analogue scores were validated in previous work [98]. Healthy 
controls were compared to patients with active small bowel and large bowel CD. 
Patients were asked to fast overnight (for at least 10 hours). Heinz chicken or 
mushroom soup (Heinz, Wigan, UK) was used as a test meal. On the morning of the 
test, a ten ml fasting blood sample was drawn in aprotonin/EDTA tubes (BD-361017, 
BD Diagnostics, Oxford). This sample was centrifuged at 4000rpm for five minutes. 
Plasma was pipetted and immediately put on ice. Two further post-test meal ten ml 
samples were taken at 15 and 60 minutes. Plasma samples were stored at -20°C within 
two hours of being taken. Concomitantly, patient symptoms regarding appetite and 
satiety were scored with a validated VAS (appendix). 
Three different enzyme linked immunoadsorbent assay (ELISA) techniques were used 
in the investigation of fasting and postprandial gut hormone profiles.  
2.7.1 Chemiluminescent ELISA - Multiplex ELISA technique 
(Leptin, acylated ghrelin, total GIP, active GLP-1, total PYY) 
 
The ELISA was carried out using a human gut hormone panel LINCOplex Kit (HGT-
68K5; Millipore, Missouri, USA) and read using an electronic plate reader (Bioplex 200; 
Bioplex manager 5.0, Bio-Rad Laboratories Ltd., Hemel Hempstead, UK).  Analytes 
studied were Leptin, Ghrelin (active), GIP (total), GLP-1 (active) and PYY (total). 
Quality controls, assay buffer, wash buffer, matrix solution, and immobilised beads 
solutions were prepared as per protocol. Analyte details were inputted in the software 
to permit analysis. Samples were arranged vertically as indicated on the well map 
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provided and all samples were pipetted in duplicate. Seven serially diluted standards 
were used to automatically generate a seven-point standard curve.   
The filter plate was blocked by pipetting 200 µl of Assay Buffer into each well of the 
microtiter plate. The plate was sealed and mixed on a shaker for ten minutes at RT. 
The assay buffer was removed by vacuuming (<100mHg). Any excess assay buffer was 
removed from the bottom of the plate by blotting onto an absorbent pad. 25 µl of 
assay buffer was added to the zero standard (background) and sample wells, and 25 µl 
of each standard and control were added into the appropriate wells. 25 µl of sample 
plasma was then pipetted into the sample wells. 25 µl of appropriate matrix solution 
was added to the background, standards, and control wells, and 25 µl of mixed assay 
beads added to each well (see table 12). The plate was then sealed, covered with 
aluminum foil, and incubated with agitation on a plate shaker (600 rpm) O/N at 4oC.  
After overnight incubation, the plate and reagents were allowed to warm to RT before 
continuing with the assay. The fluid was gently removed by vacuuming. The plate was 
then washed three times with 200 µL/well of 1X wash buffer, removing the wash 
buffer by vacuum filtration between each wash. 50ul of detection antibody cocktail was 
pipetted into each well.  
The plate was sealed, covered with aluminum foil, and incubated with agitation on a 
plate shaker for 30 minutes at RT. 50 µl of Streptavidin-phycoerythrin (SAPE) was then 
added to each well containing the 50 µl of detection antibody cocktail. The plate was 
then sealed again, covered with aluminum foil, and incubated with agitation on a plate 
shaker for 30 minutes at RT. The contents were then gently removed by vacuum. 
Subsequently, the plate was then washed three times with 200µl/well 1X wash buffer, 
removing the wash buffer by vacuum filtration between each wash.  
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Finally 100µl of sheath fluid was added to all wells. Each plate was sealed again, covered 
with aluminum foil. The beads were then re-suspended on a plate shaker for five 
minutes. The plate was then read on the Luminex instrument and results analysed. 
 
 Standard (µl) Controls (µl) Samples (µl) 
Assay Buffer   25 
Standard/Control 25 25  
Samples   25 
Matrix Solution 25 25  
Mixed Beads Solution 25 25 25 
Total 75 75 75 
Table 12. Details of the immunoassay procedure. 
 
2.7.2 Colorimetric ELISA 
 
In these ELISA experiments (Millipore), colorometric change rather than luminescence 
was used to calculate peptide concentration in the sample wells.  
2.7.2.1 General overview 
 
Soluble antigen present in the sample or standard bound to antibodies adsorbed to the 
microwells. A biotin-conjugated monoclonal antibody bound to antigen captured by 
the first antibody. Following incubation, unbound biotin conjugated was removed 
during a wash step and streptavidin-horseradish peroxidase (HRP) was added to the 
biotin-conjugated antibody. Following incubation unbound Streptavidin-HRP was 
removed during a wash step, and substrate solution reactive with HRP added to the 
wells. A coloured product formed in proportion to the amount of antigen present in 
the sample. The reaction was terminated by addition of acid and absorbance was 
measured at 450nm.  
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2.7.2.2  sCD26 ELISA protocol 
 
A standard curve was prepared from six sCD26 standard dilutions with sCD26 
concentrations ranging from 500 to 15.6ng/ml. Plasma samples were diluted 5-fold with 
sample diluent. 50 µl of diluted biotin-conjugate secondary antibody was added to all 
wells. The plate was incubated for three hours on a plate shaker at RT. In between 
each step appropriate washes with a wash buffer were undertaken. 100 µl of diluted 
streptavidin-HRP was added to all wells and incubated for one hour at RT. 100 µl of 
TMB substrate solution was added to all wells and left for 10 minutes or until a blue 
colour had formed in all wells. 100 µl of stop solution was then added to all wells. The 
acidification of the well contents turned the colour to a luminescent yellow. Since the 
absorbance is directly proportional to the amount of captured CD26, the latter was 
derived by interpolation from the reference curve generated by known standard 
concentrations in the same assay. The results were calculated using the parametric 
logistic function on Microsoft Excel (Windows XP, Microsoft, USA).  
2.7.3 Total GLP-2 ELISA 
 
The basic mechanism of the GLP-2 ELISA (Millipore) is identical to the CD26 kit. 50µl 
of assay buffer were added to all blank wells and sample wells. 50 µl of matrix solution 
was added to blank wells, standard wells and to quality control wells. A serial standard 
dilution was prepared as previously described. 50 µl of undiluted sample was added to 
each well. The plate was sealed and incubated for two hours on a plate shaker at RT. 
In between each step appropriate washes were carried out as previously described. 
100 µl of detection antibody was added to each well. The plate was incubated for one 
hour at RT. Thereafter, 100µl of enzyme solution was added to each well for 30 
minutes. Finally, 100µl of substrate solution was added to each well. When the colour 
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change in all wells was deemed sufficient, 100µl of acidic stop solution was added and 
absorbance read at 450nm and 590nm on a plate reader. The increase in absorbance 
between these two readings was directly proportional to the captured GLP-2 
concentration. Using the standard curve generated, GLP-2 concentrations were 
calculated for all sample wells as already described. 
2.7.4 Chemiluminescent ELISA – Total GLP-1 
 
The data presented in this section was commissioned to the Biochemistry department, 
Addenbrookes Hospital, Cambridge. Plates purchased from Meso Scale Discovery 
(MSD, Gaithersburg, USA) were used for this experiment. The wells in this plate were 
pre-prepared with antibodies to active and total GLP-1. After addition of plasma to the 
test wells, the GLP-1 peptide bound to these antibodies. Subsequently, a solution 
containing a labelled detection antibody—anti-GLP-1 labelled with an electro-
chemiluminescent compound, MSD SULFO-TAG™ tag was added to the mix. The 
labelled antibody bound to the already captured GLP-1 peptide completed a peptide-
antibody sandwich (see figure 16), and addition of a buffer, created the necessary 
chemical environment for voltage induced electroluminescence. Results were read by 
the appropriate software off an 8-point standard curve in a plate reader  - SECTOR® 
Imager 6000 (MSD).  
 
Figure 16. Schematic of the antibody recognition sites for the Total GLP-1 assay on GLP-1 
protein amino acids 1-37 (from MSD total GLP-1 (vers 2) assay kit manual).  
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Preparation of Blocker A solution, standards, detection antibody solution and read 
buffer was carried out prior to starting the experiment. All reagents were warmed up 
to RT. 150 μl of Blocker A Solution was added to each well. The plate was incubated 
at RT with vigorous shaking (300–1000 rpm) for one hour. 
After appropriate washing with (phosphate buffer solution + Tween 20) PBS-T 
solution, 25 µl of samples or standards were added to the appropriate wells. 25 μL/well of metabolic assay working solution were the dispensed. The plate was 
incubated at RT with vigorous shaking for two hours. After PBS-T washes, 25	  μL/well 
of detection antibody solution was added. The plate was incubated for one hour. After 
a final wash, 150	   μL of the manufacturer’s buffer T was added to each well and the 
plate was then read on a SECTOR® plate reader. 
2.8 Tissue Protein studies 
 
Protein was extracted from human terminal ileum tissue at endoscopic examination. 
The tissue was collected in RNA later and then stored at -80ºC. In addition, protein 
was extracted from Caco-2 cells. The protocol used was similar to that used on 
human tissue. These will be described, and major differences highlighted. 
2.8.1 Protein extraction from human tissue 
 
Tissue was thawed on ice for a few minutes. It was then washed twice in ice cold PBS. 
One ml of ice-cold tissue extraction buffer was prepared in a separate Eppendorph. 
Sodium Dodecyl Sulphate (SDS) (Fisher Scientific, Loughborough, UK) was added to a 
final concentration of 0.2%. 30µl of protease inhibitor (Sigma) was finally added to the 
solution. This was then vortexed and 100µl transferred to a Dounce homogeniser 
(VWR international, Leicestershire, UK).  The whole procedure was undertaken on 
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ice. The tissue sample was subsequently immersed in the protein extraction solution, 
and homogenised with 20 vertical strokes of the loose pestle and 20 vertical strokes of 
the tight pestle. Two to three rotational strokes were applied at the end. The solution 
was then left to stand on ice for 30 minutes. The Dounce container was flicked every 
10 minutes to re-suspend the pellet. The whole solution was then transferred to a 
fresh Eppendorph tube. This was centrifuged at 13,000 rpm for 15 minutes at 4°C. The 
supernatant was then transferred to a new container. This was aliquoted in 10µl 
volumes and stored at -20ºC until further use. 
2.8.2 Protein extraction from caco-2 cells 
 
Protein extraction from Caco-2 cells was performed in a similar way to the procedure 
described above. The cells were washed with ice cold PBS as described above. The 
extraction buffer solution was prepared as described above with the only difference 
that protease inhibitor was added to a final volume of 1:100. One hundred µl of the 
extraction buffer solution was added to each well containing Caco-2 cells. The cells 
were scraped and homogenised with the inverted end of a 100µl pipette tip. The 
process was repeated twice. Centrifugation and storage was carried out as described 
in section 2.8.1. 
2.8.3 Protein concentration assay – BCA 
 
Protein concentration was analysed using a BCA assay. Five % SDS was prepared. A 
2mg/ml BSA was prepared in the five % SDS solution. The standards were prepared as 
per details in table 13. 
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Standard concentration µg/ml BSA 5% SDS 
0 0 100 
250 12.5 87.5 
500 25 75 
750 37.5 62.5 
1000 50 50 
1500 75 25 
2000 100 0 
Table 13.  Details for the standard preparation in BCA assay.  
 
A BCA solution was prepared by mixing 50 parts of solution A to one part of solution 
B (Thermo Scientific, Rockford, USA). 25µl of standards and samples were loaded in 
triplicate on a flat bottom polypropylene 96 well plate (Falcon microtest 96, BD 
Diagnostics, Oxford, UK). 200µl of bicinchoninic acid (BCA) solution was added to all 
wells having standards and samples. The mixture was incubated at RT for 30 minutes. 
The plate was read using a Labtech LT-400 plate reader (Labtech, Sussex, UK) at a 
wavelength of 570nm. The absorbance at this wavelength is proportional to the 
protein concentration in each specific well. Results were calculated using the 
parametric logistic function on Excel from known prepared standards read from the 
same plate.  
2.8.4 SDS-Polyacrylamide gel electrophoresis (PAGE) and Western blotting 
 
Depending on the size of the protein to be detected, a 7.5, 10 or 12% sodium-dodecyl-
sulphate polyacrylamide gel was made (see appendix). Samples were heated with 
sample buffer to denature the proteins and then loaded in equal amounts to each of 
the wells along with three µl of broad range molecular weight marker (BioRad; 
Hertfordshire, UK).  
In case of protein derived from gut tissue the sample and Laemmli buffer were warmed 
together at 37ºC for five minutes in a water bath. For all protein derived from Caco-2 
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cells, the protein and Laemmli buffer mix were heated at 100ºC for two minutes. In 
both instances, Laemmli buffer was added to a final concentration of 1:4.  
The proteins were electrophoretically separated for one hour at 150V and then 
transferred (100V for one hour) onto polyvinylidene fluoride (PVDF) membranes for 
western blot analysis. The membranes were blocked using the appropriate blocking 
solution for one hour before incubation with the primary antibody at the appropriate 
concentration overnight at 4oC (see table 14 for relevant details). The membranes 
were washed three times in 5% fat-free milk in TBS and then incubated for 25 minutes 
at RT with the appropriate secondary antibody (Goat anti-mouse IgG (H &L) HRP 
conjugate and Goat anti-rabbit IgG (H &L) HRP conjugate (Biorad; Hercules, CA, USA) 
1:5000 in 5% milk in TBS). Membranes were then washed three times in 5% milk/TBS, 
and then twice in TBS.  
The membranes were visualised by adding Amersham™ ECL plus Western Blotting 
Detection System reagent (ECL; GE Healthcare Ltd, UK). Reagents A and B were 
mixed in a 1:40 ratio, in a volume enough to cover the membrane. The mixture was 
added to the membrane for five minutes as per the manufacturer’s instructions. 
Amersham Hyperfilm™ ECL (GE Healthcare Ltd) was then exposed to the 
membranes for the appropriate amount of time and developed using Kodak GBX 
developer and fixer (Eastman Kodak Company, Rochester, NY). For all specific details 
on western blotting please see table below. Results were analysed by densitometry as 
previously described [256].  Equal loading was ensured by examining ß-Actin 
expression for all samples studied. After completion, the membrane was washed twice 
with TBS and then stained with 0.1% Coomassie R-350 (GE Healthcare) in 
methanol:water, 1:1, for one minute, destained for 20 minutes in acetic 
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acid:ethanol:water, 1:5:4, washed with water and air-dried. The dry membrane was 
examined for evidence of equal loading.  
 
Antibody Dilution 
used 
Supplier Catalogue 
no. 
Size 
gel 
used 
Blocking 
step 
Exposure 
time 
Goat anti-
DP4 
1:1000 in 
1% milk 
R&D AF1180 7.5% 5% milk 
for 1 hour 
at RT 
1-5 
minutes 
Mouse 
anti- 
ß-Actin 
1:50000 
in 5% 
milk 
Sigma A5316 12% 5% milk 
for 1 hour 
at RT 
1 minute 
Rabbit 
anti-
Claudin 1 
1:1000 in 
5% milk 
Invitrogen 71-7800 12% 5% milk 
for 1 hour 
at RT 
1 minute 
Mouse 
anti-
Claudin 4 
1:1000 in 
5% milk 
Invitrogen 32-9400 12% 5% milk 
for 1 hour 
at RT 
1 minute 
Rabbit 
anti-
Occludin 
1:1000 in 
5% milk 
Invitrogen 71-1500 10% or 
12% 
5% milk 
for 1 hour 
at RT 
1-5 
minutes 
Mouse 
anti-ZO-1 
1:1000 in 
5% milk 
Invitrogen 339100 7.5% 5% milk 
for 1 hour 
at RT 
1-5 
minutes 
Table 14. Relevant data for various antibodies used.  
 
2.9  Cell Culture techniques 
 
Caco-2 cells used in these experiments were between passages 45-55. These were 
taken out of liquid nitrogen storage, immediately thawed to 37°C in a water bath and 
transferred to a T75 flask with 25mls of medium added (MEM, Gibco, Invitrogen)(see 
table 15 for details). After confluency, (7 days), the Caco-2 cells were split and then 
grown in Transwell inserts in 12 well plates (Greiner Bio-one, Gloucestershire, UK). 
All throughout these experiment Caco-2 cell cultures were grown in sterile incubator 
at 37°C and 5% CO2.  
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Name Volume Supplier 
Medium 500ml Invitrogen 
Bovine serum 50ml Invitrogen 
Non-essential amino acids 5ml Invitrogen 
Penicillin/streptomycin 2.5ml Invitrogen 
Glutamine 5ml Invitrogen 
Table 15. Contents of the medium used to grow Caco-2 cells.  
 
2.9.1 Splitting Caco-2 monolayers in T75 flasks 
 
When Caco-2 cells reached confluency they were split with trypsin and re-plated. 
Medium was first suctioned off and the Caco-2 monolayer washed twice with PBS. Five 
mls of 0.25% trypsin (invitrogen) was added and the flask incubated for a further two 
minutes in an incubator at 37°C. This process was intermittently monitored by 
examining the monolayer confluency with a microsocope. When the monolayer was 
split and cells were individual or in small groups, the process was arrested by adding 
five mls of sterile medium. Any cell clumps were split by passing the cell solution 
through a 21G needle.  
2.9.2 TEER measurement 
 
The electrical resistance of Caco-2 intestinal monolayers was measured by using an 
epithelial voltohm-meter (World Precision Instruments, Sarasota, FL, USA). For 
resistance measurements, both apical and basolateral sides of the epithelium were 
bathed with medium solution. Electrical resistance was measured until similar values 
were recorded on three consecutive measurements. The resistances of monolayers 
are reported after subtraction of the resistance value of the filters alone (see figure 
17). 
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Figure 17. Measuring TEER across a cellular monolayer in a 12-well transwell insert.  
 
 
2.9.3 Effects of rhTNFα on DP4 expression 
 
The effects of rhTNFα (R&D) on DP4 expression in Caco-2 cells have been studied by 
exposing them to a rhTNFα containing medium. A concentration/time course has been 
used to identify it’s range of effects (see table 16). The rhTNFα concentrations used in 
this thesis reflect previous similar experimental work [234]. 
 
rhTNFα concentration ng/ml Duration (hrs) 
100 48 
50 24 
25 12 
0 6 
Table 16. TNFα concentration/time course used to study its range of effects on DP4 in Caco-2 
cells. 
 
Initial pilot experiments were performed in 12 well Transwells, with rhTNFα added to 
the basolateral compartment of the wells at the indicated concentrations. After 
growing the Caco-2 cells for 20 days rhTNFα was added to the basolateral chamber in 
the above concentration for 24 and 48 hours in a serum free medium. Prior to adding 
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the cytokine, the medium was always changed to a serum free medium at least an 
hour. In the case of the 48hrs incubation, rhTNFα was added at day 19. The effect of 
this cytokine was examined by measuring the TEER across the monolayer. After 
validating this, the rest of the experimental work was done in duplicate in 6-well plates 
to improve efficiency.  
When Caco-2 cells reached 80% subconfluency, the medium was changed to a serum-
free medium for at least one hour prior to rhTNFα incubation. Thereafter, a rhTNFα 
containing serum free medium was added at the necessary concentration and duration 
as indicated in table 16. The cells were then harvested and protein and RNA DP4 
expression studied as indicated in the sections above.  
2.9.4 Effects of rhTNF α and GLP-2 on TEER and tight junction protein 
expression. 
 
 
The effect of rhTNFα on Caco-2 monolayer integrity has been previously described 
[231-233]. It has an overall negative effect and increases mucosal permeability. In 
contrast, the EEC hormone GLP-2, possesses intestinotrophic effects and earlier work 
on IEC-6 cells has shown a reparative effect on this mucosal cell line [117]. In the work 
described below, I have investigated the protective role of GLP-2 on rhTNFα-induced 
increase in mucosal permeability in the Caco-2 intestinal barrier model.  
GLP-2 (Bachem, Germany) was dissolved in 50% acetic acid to a final concentration of 
53.1mM as indicated. Pilot work was carried out to test the effect of this vehicle on 
the integrity of the Caco-2 cells. Caco-2 cells were grown in 12-well Transwell inserts 
with acetic acid concentration ranging from 10nM to 1000nM. These data, in addition 
to published data on the effect of GLP-2 on this cancer cell line [117] were used to 
decide the effective GLP-2 concentrations to be used in the final experiments.  
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Caco-2 cells were grown in 12-well Transwell inserts up to a maximum of 21 days. 
Experiments were done in duplicate. GLP-2 was added in the basolateral surface of the 
Caco-2 cell Transwell inserts to mimic endogenous GLP-2 effect on mucosal cells. Out 
of 12 Transwell inserts, two wells were used as controls. Two Caco-2 Transwell 
monolayers were grown in a medium containing 10nM of GLP-2. Another two were 
grown in a medium containing 50nM of GLP-2 and another four were grown in a 
medium containing 100nM of GLP-2. This was done to study the dose dependent effect 
of GLP-2 on intestinal growth. At day 20, the medium of the Caco-2 cell culture 
scheduled to be treated with rhTNFα was changed to serum free medium at least one 
hour prior to adding rhTNFα. This cytokine was used at a concentration of 100ng/ml 
in serum free medium as previously described. RhTNFα was added to two control 
wells and two wells with medium containing 100nM of GLP-2. Caco-2 cells were 
incubated O/N in such conditions. Measuring the TEER across the monolayers 
assessed the affect of rhTNFα on barrier function. See table 17 for a tabular summary 
of this experiment.  
Naive  Naïve 
(100nM GLP-2 on day 20) 
10nM GLP-2 10nM GLP-2 
50nM GLP-2 50nM GLP-2 100nM GLP-2 100nM GLP-2 
Naive  
(TNFα on day 20) 
Naïve 
(TNFα on day 20) 
100nM GLP-2 
(TNFα on day 20) 
100nM GLP-2 
(TNFα on day 20) 
Table 17. Tabular description of the TNFα and GLP-2 experiment. n=3. 
 
To look for an unexpected acute effect of GLP-2 on Caco-2 cell monolayer integrity, 
this peptide was added to the basolateral chamber of one of the naïve cultures 
overnight at day 20. TEER was measured after 12 hours. These experiments were 
done in triplicate. At the end, the Caco-2 cells were harvested for protein extraction 
and subsequent western blot experiments to assess tight junction protein expression.  
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2.10  Conclusion 
 
The data will be divided into four results chapters. The results from the experiments 
done at the tissue level examining EEC peptide and mRNA expression will be 
presented in chapter three.  
In chapter four, I will illustrate the changes observed in the gut peptides at the plasma 
level. These two bodies of data will contain all the human data relevant to EEC 
expression and appetite regulation.  
In chapter five, I will present the results of the experiements done on DP4 expression 
in the Caco-2 model and in CD. This chapter will encapsulate all the data from 
western blotting, qPCR and ELISA experiments on this peptide. 
In the last result chapter, the preliminary data on the TEER and tight junction protein 
expression in Caco-2 cell exposed to rhTNFα and GLP-2 will be laid out. 
I will finish the thesis with a general discussion and conclusion in chapter seven.  
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3 Chapter 3 – Enteroendocrine cells in Crohn’s disease: 
human tissue studies 
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3.1 Chapter Introduction 
 
Preliminary work has shown that intestinal inflammation induces an up-regulation in 
EEC expression. The data described in section 1.5.2.2 are incomplete and sometimes 
contradictory. The work presented in this and subsequent sections represents my 
attempts to advance this field, and fill some key gaps present in the literature. EEC 
form the initial component of the EEC-gut-brain circuitry. An increase in expression of 
EEC at the tissue level would theoretically increase the overall activity of this circuitry 
and hence amplify brain signaling in the relevant appetite and satiety centres.  The 
decrease in appetite and altered satiety witnessed so commonly in patients with 
intestinal inflammation might be, at least in part, explained by such alterations induced 
in the enteroendocrine system. 
3.2 Methodology  
 
Changes in EEC at the tissue level will be described in two main ways in this section. 
First, the number of EEC peptide positive cells was counted per high power field (x40). 
Data are expressed as cell number per crypt number per high power field as 
previously described in detail in the methods chapter [93]. This normalization has been 
done to take into account any possible change in morphology (oedema and crypt 
destruction) due to the inflammation in CD patients. Nine readings have been taken 
per section and the mean produced to reflect the reading in that sample. Changes in 
CD are compared to controls. 
Second, I have quantified EEC expression at tissue level at the RNA level as well. Key 
EEC peptides and the important transcription factor ngn-3 have been studied. These 
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results will be discussed separately. Statistical analysis has been carried out with 
GraphPad Prism (La Jolla, USA).  
3.3 Hypothesis 
 
My key hypothesis is that enhanced expression of EEC occurs in active CD with an 
exaggerated intestinal hormone secretion in response to feeding.  
This might provide a contributory mechanism towards the unexplained symptoms of 
e.g. poor appetite, hypophagia, bloatedness, and a component of associated 
malnutrition, which are typical of this subset of patients even in the absence of 
mechanical luminal obstruction. If successful, this laboratory based experimental work 
could possibly pave the way for future more clinically oriented research. Modulation of 
EEC expression could lead to an improved quality of life in such group of patients. In 
addition, some recent discoveries described in sections 1.5.2.3 and 1.5.2.4 suggest that 
EEC may play innate immunological roles, and express genes that are implicated in CD 
GWAS data. 
3.4 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM). Multiple 
comparisons were carried out with a one-way one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test. Two group were compared with an unpaired 
student’s t-test when data was parametric and Mann Whitney U test when data was 
non parametric.  
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3.5 EEC CgA expression in CD  
 
The abundance of EEC expressing the generic marker CgA was studied by counting 
the number of positive cells/crypt/high power field as described above. Tissue studied 
in this section was from the terminal ileum, since this is the key area for the secretion 
of satiety peptides PYY and GLP-1. Four groups are described: active small bowel 
disease, active large bowel disease, inactive CD and controls.  
 
 
 
  
                      500µm 
Figure 18. Representative immunohistochemistry images showing CgA expression in normal 
ileum (a) and CD tissue (b) A 2-fold increase in CgA expression is noted in SB CD tissue when 
compared to controls. Pictures at x40 hpf. SB CD = active small bowel CD.  
 
 
 
 
 
 
 
 
 
 
a b 
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  SB CD LB CD  Inactive 
CD 
Control
s 
Sig 
CgA  
cells/hpf 
2 ± 0.3 n=21* 1.1± 0.2  
n=6* 
1.7 ± 0.2 
n=9* 
1.2 ± 0.1 
n=20* 
p=0.
03* 
Samples 
studied 
2,3,4,5,6,8,9,10,12,14,15
,17,20,22,25,26,27,28,29
, 30,33, 
39,40,42,43, 
49, 57 
16,41,51,52,
53,55,56,57,
58 
  
Table 18. CgA expression in the four different groups studied. Data shown as mean +/- SEM. 
The difference is significant between all groups (*p=0.03), with the difference between active 
SB CD group and controls being the most significantly; p<0.05. ANOVA with post hoc tukey 
test.  LB CD = active large bowel CD.  
 
 
 
Figure 19. CgA expression in the 4 different groups studied. SB CD (n=21), LB CD (n=6), 
Inactive CD (n=9) and controls (n=20). Data shown as mean +/- SEM. The difference is 
significant between all groups (p=0.03), with the difference between active SB CD group and 
controls being the most significantly; *p<0.05. VCU = villus crypt unit. 
 
 
Approximately one CgA staining cell per crypt per high power field was noted in 
control tissue derived from the healthy terminal ileum. An approximate two-fold 
increase was seen in the active SB CD group with lesser changes noted in the LB CD 
group and in inactive disease (see figures 18,19 and table 18). The increase in cells is 
therefore confined to the site of inflammation, since there is no increase in terminal 
ileal CgA cells in the presence of colitis. The data also suggest that active inflammation 
is the key driver, although the inactive group still displayed around a1.5-fold increase in 
CgA positive cell abundance when compared to controls. Given that this EEC 
* 
* 
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hyperplasia is also observed in other models of GI inflammation it is unlikely that the 
increase in EEC expression in CD is a disease-specific phenomenon. Moreover, the 
most likely explanation for persistent upregulation in the inactive group would be 
some residual inflammatory activity leading to the changes observed. Quiescence was 
defined through endoscopic, radiological, biochemical and histological studies, but it is 
likely that all CD tissue still has some inflammatory activity at the molecular level. 
3.6 EEC expressing GLP-1 in CD 
 
The work on CgA expression in CD was a pilot study for the more detailed 
histological work. Given that a significant change was found only in the SB CD group, 
only this and the control group were studied in the ensuing experimental work on 
human tissue.  
GLP-1 expression in CD was studied using immunoflourescence. The number of GLP-1 
expressing cells was calculated as previously described. A significant 2.5-fold increase in 
GLP-1 expression was noted in the SB CD group when compared to controls. (see 
table 19, figures 20 and 21).  
 
 SB CD Controls Sig 
GLP-1 0.2 ± 0.05  0.08 ± 0.02  p=0.0489* 
Table 19. GLP-1 expression in the SB CD group (n=8) and controls (n=11). The eight SB CD 
patients studied in this section (2,3,4,5,8,9,10,12) were studied in sections 3.5, 3.7, 3.8, 3.9 
and 3.10.1 too. No further samples study as this cohort size proved powerful enough to 
achieve a significant result. Data are shown as mean +/- SEM. A significant (*p = 0.0489) 
value 2.5-fold increase in GLP-1 expression was noted in SB CD group when compared to 
healthy control tissue. Unpaired t-test. 
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 500µm 
 
Figure 20. Representative immunofluorescence images showing GLP-1 expression in normal 
ileum (a) and SB CD tissue (b) A 2.5-fold increase in GLP-1 expression is noted in SB CD 
tissue when compared to controls. Pictures at x40 hpf. 
 
 
 
 
 
 
 
 
Figure 21. GLP-1 positive cells in the terminal ileum were enumerated using 
immunofluorescence.  Data are shown as mean +/- SEM. A significant (*p = 0.0489) 2.5-fold 
increase in GLP-1 expression was noted in SB CD group (n=8) when compared to healthy 
control tissue (n=11).  
 
 
 
 
 
 
 
 
a b 
* 
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3.7 EEC PYY expression in CD 
 
I found no change in tissue PYY expressing cells between SB CD tissue and control. My 
pilot study showed that PYY expression in both groups was very similar (SB CD = 
0.5±0.1cells/VCU/hpf; n=5 vs Controls = 0.6±0.1cells/VCU/hpf; n=6). Samples 3, 4, 5, 8 
and 9 were studied. These negative data are interesting since both PYY and GLP-1 are 
co-expressed by the same basic cells type in the terminal ileum, the L-cell. This 
differential observation suggests that there may be selective or preferential processing 
of gut hormone type rather than a simple upregulation of all EEC lineages and their 
products. 
3.8 NGN-3 expression in CD 
 
Ngn-3 is a very important transcription factor, pivotal in stem cell to EEC 
differentiation. Together with MATH-1, it decides an EEC fate as opposed to a goblet, 
paneth or absorptive cell line fate. Ngn-3 expression was quantified in both SB CD and 
control groups. Ngn-3 has only one exon, so same primer set has been used on RNA 
negative controls to exclude any samples with genomic DNA contamination. Due to 
the small number of samples used, it was assumed that the data were non-parametric 
and the Mann-Whitney test was used in all statistical comparison in the qPCR work.  
Ngn-3 gene expression showed a significant 1.8-fold upregulation (p=0.048) in SB CD 
tissue as compared to controls (SB CD n=7 vs controls n=5), with CD tissue showing 
a median Ngn-3/housekeeper (HSK) gene expression of 1.91 and controls 1.2. See 
figure 22 for details. Other transcription factors have been studied (math-1, neuro D, 
Nkx2.2, Phox2b, Islet-1 (Isl-1), insulinoma-associated 1b (Insm-1), paired box gene 6 
(Pax-6), Foxa-1, Foxa-2, Gfi1 and GATA-4) but due to their low level of expression, no 
sensible data could be obtained [23, 28, 31, 108].  
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Figure 22. (A) The central role of Ngn-3 is noted in the stem cell to EEC differentiation. (B) 
Graphic representation of mean +/- SEM ngn-3 expression in the SB CD (n=7) and control 
group (n=5). A 1.8-fold significant increase (*p=0.048) in Ngn-3 expression is seen in the SB 
CD group. Samples 2-9 were studied.  
 
 
 
 
* 
 
A 
 
B 
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3.9 RNA expression of EEC gut peptides 
 
mRNA expression of the key gut peptides, CgA, PYY, GLP-1 and also the novel EEC 
marker Ube4a was quantified in SB CD tissue (terminal ileum) and controls. As noted 
above, this was also attempted extensively for Phox2b but did not prove to be 
technically possible. 
Samples from eight patients or controls were used in each group. Data were 
compared using the Mann-Whitney statistical test. The most significant changes were 
for CgA (3.33-fold increase; p=0.009), GLP-1 (2.7-fold p=0.05) and Ube4a (2.2-fold 
p=0.02) as shown in table 20 and figure 23. In agreement with the 
immunohistochemistry data, PYY did not show any change at the mRNA level.  
 
 SB CD Controls Significance 
CgA 2.782 ± 0.77 0.834 ± 0.2 p=0.009 
GLP-1 5.190 ± 1.54 1.91 ± 0.55 p=0.05 
Ube4a 2.57 ± 0.47 1.18 ± 0.19 p=0.02 
PYY 1.71 ± 0.41 2.15 ± 0.38 p=0.4987 
Table 20. CD group (n=8) compared to normal controls (n=8). Tissue expression of key EEC 
peptide gene products and the marker Ube4a were analysed by qPCR. Mean ± SEM data for 
gut peptide peptide/HSK gene expression ratio. Samples 2-9 were studied. P values in table.  
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Figure 23. Graphical representation of the gut peptide peptide/HSK gene expression ratio. CD 
group (n=8) was compared to normal controls (n=8) each time. Graphical data represents 
mean +/- SEM. A 3.3-fold increase in CgA expression is noted in the CD group (*1, p=0.009). 
A 2.7-fold increase in GLP-1 expression is noted in the CD group (*2, p=0.05) and a 2.2-fold 
increase in Ube4A expression (*3, p=0.02) noted in the same group. No change for PYY 
noted (*4, p=0.4987). C=Controls, U=Ube4a. 
 
3.10  Phox2b co-localization to CgA and GLP-1 expressing cells  
 
As Phox2b was a novel candidate EEC marker, it was essential to co-localize this 
peptide to EEC by using known EEC markers such as GLP-1 and CgA. As shown in 
figure 24, this new EEC marker co-localizes to the same GLP-1 and CgA expressing 
EEC, hence supporting its expression in EEC. Being a transcription factor, it is 
expected that Phox2b expression will change according to the level of differentiation 
specific EEC are at. This would explain the variable expression of Phox2b in EEC.  
 
 
 
 
 
 
 
 
*1 
 
*2 
*3 
*4 
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500µm 
 
Figure 24. (a) CgA/GLP-1 double immunofluorescence. (b) GLP-1/Phox2b double 
immunofluorescence. Pictures at x40 hpf. Phox2b colocalizes to the same GLP-1 and CgA 
expressing EEC, hence supporting its expression in EEC. 
(a) CgA/GLP-1 
(a) GLP-1 – 
Cy5 
(a) CgA – FITC 
      (b)Phox2b/GLP-1 
      (b) Phox2b-FITC       (b) GLP-1-Cy5 
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3.10.1 Phox2b EEC expression in CD 
 
Phox2b expression was studied through immunohistochemistry techniques as 
previously described. Phox2b expression in the SB CD group was compared to 
controls. The data sets were compared using an unpaired t-test.  
 SB CD Controls  
Phox2b 0.3 ± 0.06 0.2 ± 0.04  *p=0.1841 
Table 21. Table describing Phox2b expression in between the two groups. Data shown as 
mean +/- SEM. The SB CD group (n=9) was compared to controls (n=9). Samples 17 and 20 
were studied in this section in addition to the ones mentioned in table 19. No significant 
change in Phox2b expression was noted between the two groups (*p=0.1841).  
 
 
 
Figure 25. Graphical representation of Phox2b expression between the two groups. Data 
shown as mean +/- SEM. The SB CD group (n=9) was compared to controls (n=9). No 
significant change in Phox2b expression was noted between the two groups (*p=0.1841). 
 
 
Given the low numbers of Phox2b positive cells, no convincing increase in Phox2b 
expression was noted in SB CD when compared to controls. Though the study may be 
underpowered, this did not reach statistical significance (see figures 25 & 26, and table 
21). Phox2b is a neuroendocrine transcription factor, which has been co-localized to 
EEC and ascribed to CD through gene wide association studies [108]. Thus an up-
regulation in CD might be expected. Immunohistochemistry was the only way I could 
* 
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quantify tissue expression of Phox2b as despite extensive efforts qPCR proved 
impossible due to its low expression both in my hands and in the published literature 
[108]. 
 
 
 
                                       500µm 
  
Figure 26. Photographic representation of Phox2b immunohistochemistry in terminal ileal 
tissue in (a) SB CD (n=9) and a (b) normal control group (n=9). A non-significant change in 
Phox2b expression is noted in both groups.  Pictures at x40 hpf.  
 
 
3.11 CD4 Immunohistochemistry  
 
The role of CD4 expressing cells has been shown to be pivotal in the intestinal up-
regulation of EEC. CD4 immunoneutralisation arrests the positive EEC response 
witnessed in parasitic models of intestinal inflammation [84]. In addition, Trichuris muris 
induced colitis drives colonic EC proliferation; an observation which is absent in CD4 
knockout mice [85]. The role of CD4 positive cells in CD is thus important if we want 
to link intestinal inflammation and an EEC response.  
Because of the intensity of CD4 expression in the tissue studied, a scoring system 
validated for use in other tissues has been used to quantify CD4 expression [257]. The 
intensity and extent of staining were assessed with a six-point scale in which a score of 
zero indicated no staining, a score of one minimal staining, a score of two low-to-
a b 
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moderate levels of staining, a score of three moderate staining, a score of four high 
levels of staining, and a score of five maximal staining. 
The work in this pilot study showed a trend towards an increased expression in CD4 
in CD samples when compared to controls. 80% of the CD sections showed 
moderate-to-severe scoring as opposed all of the controls showing mild to moderate 
CD4 expression as shown in table 22 and figure 27. This indicates an increased CD4 
response in the majority of CD samples, supporting a potential role for CD4 in EEC 
up-regulation in CD.  
This work indicates that an appropriate inflammatory drive is present in the CD group 
to institute an EEC response. Inflammatory activity was otherwise graded with 
independent histological, endoscopic, biochemical and radiological assessments.  
 
 
Score Number Tissue Type 
Severe 3 CD 
Moderate 1 CD 
Mild to moderate 3 Controls 
Mild 3 2 Control 
1 CD 
Minimal 0 - 
None 0 - 
 
Table 22. CD scoring as per previously validated 6-point scale [257]. 80% of the CD sections 
showed moderate-to-severe scoring as opposed all of the controls showing mild to moderate 
CD4 expression.  
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                                                                                                                500µm                    
                                                                                                                
Figure 27. CD4 immunohistochemistry (a-d) & H&E histology (e,f) A grade was used to 
quantify CD4 expression, where grade 0=no expression, grade 1=minimal expression, grade 
2=mild expression (a), grade 3=mild to moderate expression (b), grade 4=moderate 
expression (c), grade 5=severe expression (d) (Griffiths, C. et al.1993) . Section ‘e’ is the H&E 
complementary section of picture ‘c’, while section ‘f’ is the H&E complementary section of 
picture ‘d’. Pictures at x40 hpf. 
 
 
 
c 
e 
d 
f 
a b 
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3.12 IFN-γ expression in CD  
 
As a representative inflammatory cytokine IFN-γ expression in the SB CD group was 
quantified through qPCR. IFN-γ is a pivotal Th1 predominant cytokine and its 
expression has been studied in the same SB CD group cohort that was used for the 
qPCR experiments.  
 
 SB CD Controls Fold 
change 
Sig. 
IFN-γ 3.1 ± 1.4 1.75 ± 0.4 1.77 *p=0.6126 
Table 23. IFN-γ/HSK gene expression ratio in the SB CD (n=8) and control groups n=8). Data 
is represented as mean +/- SEM. No significant (*p=0.6126) increase in expression is noted 
in the SB CD group. 
 
 
 
 
Figure 28. Graphic representation of the IFN-γ/HSK gene expression ratio in the SB CD (n=8) 
and control groups (n=8). Data are represented as mean +/- SEM. No significant 
(*p=0.6126) increase in expression is noted in the SB CD group. 
 
 
IFN-γ expression in the group studied suggested as expected a ~1.8-fold increase in 
expression (table 23 and figure 28). This was not significant due to the variability in 
expression as evidenced by the large standard error in the CD group. Together with 
other data quantifying intestinal inflammation in the studied SB CD group, this 
information supports the possibility that even modest and non-significant intestinal 
inflammation is enough to induce a positive EEC response. However, study of a 
broader panel of cytokines may prove more informative.  
* 
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3.13  Summary: EEC changes at the tissue level in CD 
 
In this chapter, significant changes in EEC numbers and products have been shown 
though immunohistochemistry and qPCR experimental work. However, this is not true 
for every target chosen, suggesting that there may be biological selectivity in this 
process.  
The generic EEC marker, CgA was significantly upregulated, both at the tissue peptide 
level (two-fold increased expression) and the mRNA level (3.3-fold increased 
expression). This change was most pronounced in the SB CD group with no change 
noted in the LB CD group. The tissue studied was endoscopically derived from the 
terminal ileum in all group sets. Thus in the SB CD group there was much closer 
proximity between the area studied and the site of inflammation. These data do not 
correspond to evidence from work conducted on mice with TNBS ileitis. Distal 
colonic sampling showed an increase in proximal 5-HT and GLP-2, thus prompting the 
authors to suggest possible ‘hard wiring’ controlling EEC expression [94]. Systemic 
effects of circulating inflammatory mediators might also have been responsible. Similar 
results were noted in mice with DSS colitis. An intense inflammatory reaction was 
present in the distal colon with EC hyperplasia more evident in the proximal colon 
[95]. The hypothesis was postulated that a ‘closed circuitry’ exists between the 
inflammatory pathway and EEC expression. Irrespective of the site of the inflammation, 
EEC hyperplasia in a site anatomically different from the one inflamed could still occur.  
My evidence does not directly support this, as an increase in ileal EEC expression failed 
to occur in colonic disease. However, CD is a chronic disease, due to immune 
dysregulation and gene-environment interactions. This cannot be modeled using acute 
severe chemical injury as in the mouse models.  Samples from patients with inactive 
disease still featured an increase, albeit non-significant of CgA expressing EEC. Rather 
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than assuming that EEC hyperplasia is a CD-specific phenomenon, it would be safer to 
say that such tissue still had some clinically irrelevant but biologically active degree of 
microscopic inflammation.  
CgA EEC hyperplasia was accompanied by an increase in GLP-1 expressing cells. These 
two EEC peptides, were co-localized to same cell (together with the neuroendocrine 
transcription factor – Phox2b) as our dual immunofluorescence experiments have 
shown. An increase in tissue peptide expression was associated with a significant 
increase in GLP-1 expression at the mRNA level as well.  
PYY did not show a change in expression in both experimental modalities used. PYY 
and GLP-1 are both expressed from the same L cell but different transcription factors 
dictate their cell fate. Pax-6, Foxa-1 and 2 and Isl-1 are important for an L cell faith but 
for specific PYY expression the transcription insm-1 is needed [31, 258]. These 
transcription factors have been studied by using qPCR but their expression level was 
too low to glean any meaningful data. Ngn-3, which is a pivotal transcription factor in 
the EEC differentiation is significantly upregulated. This is expected following the 
change in end peptide EEC expression seen. 
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3.13.1 In Summary 
 
The work in this section has shown an increase in EEC expression in intestinal 
inflammation as evidenced by an increase in tissue expression of EEC markers; CgA, 
GLP-1 and Ube4a and EEC relevant transcription factor, ngn-3 and Phox2b. Such 
changes might have a primitive protective role; inducing hypophagia in intestinal sepsis 
through their anorectic properties and increased colonic propulsion to expel intestinal 
toxins.  
The next step, would be to investigate if this increase in tissue expression is translated 
at the plasma level as well. This will be dissected in the forthcoming chapter.  
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4 Chapter 4. Plasma peptide assay studies 
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4.1 Chapter Introduction 
 
Significant changes in EEC abundance and gene expression at the tissue level have been 
described in the previous chapter. EEC peptides signal to areas in the hindbrain such as 
the nucleus of tractus solitarius and the area postrema to control appetite and satiety. 
They do this in a paracrine fashion through the vagal nerves and an endocrine fashion 
through the systemic circulation. 
Changes at the tissue level would have little clinical significance to eating behaviour 
unless translated into altered function at the plasma or brainstem level.  
In this chapter, I present the fasting and postprandial levels of small intestinal EEC gut 
peptides GLP-1, PYY and GIP. Other gut hormones that have a role in controlling 
appetite and satiety such as ghrelin and leptin, will be discussed also. 
In addition GLP-2, an intestinotrophic EEC hormone has been studied. This is secreted 
in parallel to GLP-1, since they are cleaved from the same precursor. The only two 
earlier reports in the literature issued conflicting results with both a decrease [127] 
and no change [128] in bioactive GLP-2 at the tissue and plasma level being reported. 
Ideally, experimental interventions would be undertaken to explore whether gut 
hormones are directly responsible for symptoms generated. Unfortunately this is not 
possible at this time in patients.  However, plasma peptide levels have been correlated 
to specific patient symptoms as measured by previously validated VAS and disease 
activity scores in a search for potential links or biomarkers in the clinical problem of 
malnutrition in IBD.  
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4.2 Hypothesis 
 
I have documented increased numbers of tissue EEC. It is postulated that plasma gut 
hormones will be altered in patients with intestinal inflammation, both fasting and 
postprandially.  
This might lead to a decrease in appetite and abnormal satiety patterns through 
increased hindbrain signalling in the area postrema just outside the blood-brain-barrier. 
This process could in part underpin the altered appetite and satiety witnessed in IBD. 
4.3 Experiment plan and patient selection 
 
As described in the methods section 2.7 patients were fasted overnight. They were fed 
a test meal and postprandial plasma hormone level assessed (see figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Protocol used for test meal and subsequent blood sampling. Plasma was collected 
in aprotonin/EDTA tubes as per time points above (in minutes). For details of VAS see 
appendix. 
 
Patients were recruited for this study depending on the localisation and severity of 
their disease burden. Twelve patients with active SB CD (table 24) and five patients 
 
           
VAS scores and blood samples 
Oral administration of test meal 
0  15 30  60 -5 -600 
10hr overnight fast 
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with LB CD (table 26) were available for this study together with thirteen normal 
controls (table 25).  
No Age Sex %W CDAI VAS CRP Medical Rx Surg 
Rx 
21 54 F 10 81 34 0 Steroids/5-ASA L R 
hemi 
5 44 F 5.8 205 32 1.8 Infliximab L R 
hemi 
6 69 M 7.1 125 32 1 5-ASA nil 
7 57 F 9.1 120 23 11.2 5-ASA/MTX L R 
hemi 
1 66 M 18.8 100 36 36.7 Steroids nil 
11 49 F 0 44 33 13.8 Thiopurines/steroids L R 
hemi 
18 26 M 14.5 135 36 7.3 Nil nil 
23 22 F 27 211 29 12.4 Nil nil 
28 23 M 55 160 38 0.5 Nil nil 
29 30 F 10 132 24 13 Thiopurines/5-ASA nil 
30 25 F 16.7 206 27 22.4 Nil nil 
31 59 F 4.3 385 29 22.8 Nil nil 
Mean 
± 
SEM 
43.7 
± 
5.1 
 
 
8F/4M 
 
14.9 
± 4.2 
158.7 
± 
25.4 
 
31 ± 
1 
11.9 
± 
3.2 
 
 
n/a 
 
 
n/a 
Table 24. Relevant descriptive data for SB CD patients recruited for this study. Patient 
numbers correspond to the ones in table 3. The patient on infliximab was studied when 
symptomatic just prior to the next infusion. %W=%weight loss. The mean VAS was used in 
the subsequent data analysis since there was no obvious change from baseline.  
 
No Age Sex %W CDAI VAS Medical Rx Surgical 
Rx 
1 29 F 0 n/a 0 n/a n/a 
2 44 M 0 n/a 2 n/a n/a 
3 34 M 0 n/a 1 n/a n/a 
4 35 M 0 n/a 0 n/a n/a 
5 40 F 0 n/a 15 n/a n/a 
6 48 F 0 n/a 9 n/a n/a 
7 32 M 0 n/a 5 n/a n/a 
8 26 M 0 n/a 0 n/a n/a 
9 55 M 0 n/a 0 n/a n/a 
10 20 M 0 n/a 3 n/a n/a 
11 31 F 0 n/a 6 n/a n/a 
12 57 F 0 n/a 20 n/a n/a 
13 28 F 0 n/a 0 n/a n/a 
Mean 36.9 ± 3 6F/7M 0  5 ± 2   
Table 25. Relevant data for control subjects recruited for this study. The mean VAS used was 
used since there was no apparent change fom baseline. 
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No Age Sex %W CDAI VAS CRP Medical Rx Surg 
Rx 
42 26 F 12.3 83 31 130 nil nil 
46 33 F 19.4 240 41 6 5-ASA nil 
47 48 F 0 134 30 8.8 Azathioprine/Infliximab nil 
48 32 M 8.7 280 30 17.6 Azathioprine nil 
50 41 M 9.05 262 29.6 16 Azathioprine/5-
ASA/steroids 
Partial 
sigmoid 
colectomy 
Table 26. Relevant data of patients with active LB CD that have been studied below. Patient 
numbering as per table 3.  
 
Activity was scored independently by endoscopic, histological and radiological 
investigations. Every effort was done not to recruit patients with a history of extensive 
abdominal surgery or present anti-TNFα treatment. This was due to the known effects 
of this treatment on ghrelin [106], leptin [252] and other EEC hormone plasma levels 
and a potential variable effect of intestinal surgery on EEC hormone responses [74, 75, 
77]. Four patients in the SB CD group had a prior limited right hemicolectomy. 
Although it would have been ideal to avoid this, it proved impossible to recruit a 
substantial number of SB CD without any history of surgery. The single patient on 
infliximab was studied when symptomatic, one day prior to the next infusion. 
Based on the data presented in sections 3.5, 3.6 and 3.9, where a significantly higher 
tissue SB EEC expression was found in patients with active SB CD than LB CD, it was 
postulated that this would be the same at the plasma level. The EEC hormones of 
interest are PYY and GLP-1 as these are secreted from the L cells which mainly lie in 
the distal ileum, hence only patients with active SB CD, which would provide the 
strongest inflammatory drive for an EEC response were recruited. In addition, to GLP-
1, PYY and GIP responses were also assayed since this is a proximal small bowel 
hormone to serve as a control from a non-inflamed segment.  
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To confirm this, a pilot study in LB CD patients (details in table 27) was carried out 
and showed that plasma PYY and GLP-1 levels were very similar to controls. This 
corresponded to the tissue studies. These data are showed in table 26. 
 LB CD Controls Significance 
Total PYY 11050 ± 6281  10700 ± 1886  p=0.4902 
Total GLP-1 1636 ± 585.7  1216 ± 275.4  p=0.1148 
Table 27. Total PYY and GLP-1 levels in LB CD (n=5) and normal controls (n=13 and 16 for 
PYY and GLP-1 respectively) groups. Data are presented as mean AUC ± SEM. No statistically 
significant difference was noted for total PYY (p=0.492) and active GLP-1 (p=0.1148). 
 
Due to the small number of patients recruited in the LB CD cohort and the lack of any 
effect it was decided to exclude them from subsequent EEC hormone studies and 
concentrate on the active SB CD group and matched controls. 
A subgroup of patients from the SB CD group were re-studied once they had received 
treatment (which did not include surgery or biologics). It is unclear what is the effect 
of bowel preparation and colonic insufflation on the vagal tone and consequent EEC 
response to food intake, so all the test meal studies were done at a separate day from 
the endoscopy. This approach differs from other published work [128].  
4.4 Statistical analysis 
 
Similar published data have been analysed in a non-parametric fashion [104-106], only 
one publication used parametric testing [107], with the author describing the statistical 
analysis as exploratory. Due to the small patient number and heterogeneity of the 
group and the plasma gut hormone levels, the data in this section was analysed in a 
non-parametric fashion.  
Two non-paired groups were compared using the Mann-Whitney test, while two 
paired groups were analysed with the Wilcoxon paired test. Three groups were 
compared with a Kruskall-Wallis test and repeated measures were analysed by using a 
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Friedman test. Post-test analysis was carried out with a Dunn’s multiple comparison 
test. Correlations were carried out with the appropriate Spearman or Pearson test, 
with all correlations to symptom visual analogue scores deemed non-parametric [259]. 
P values of less than 0.05 were deemed significant. P values less than 0.1 were 
described as trends. All analysis was carried out on GraphPad Prism. 
 
4.5 Patient symptom scores 
 
The subjective appetite scores were filled out prior to the test meal. Patients with SB 
CD had altered appetite as evidenced by the 6-fold significant difference in the VAS 
scores at baseline (figure 30). The VAS scores did not change significantly 
postprandially, in either the SB CD group or the controls. In the SB CD group the 
score increased non-significantly from 28.5±3 (fasting) to 32±2.6 at 15 minutes 
(p=0.25; n=12; Wilcoxon matched paired test). In the normal control group the score 
changed from 2.6±1 (fasting) to 4.4±2.4 at 15 minutes (p=0.25; n=13; Wilcoxon 
matched paired test). No further changes were noted up to 60 minutes. Given that the 
meal induced no particular increase in scores, mean scores will be discussed in the 
sections below. This was an unexpected negative finding; my hypothesis having 
anticipated that the meal would induce enhanced VAS scores in the group with active 
CD. 
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Figure 30. Graphic representation of the mean VAS scores ± SEM. An approximate 6-fold 
difference is observed between the SB CD (n=12) and the normal control group (n=13); 
(*p<0.0001); Mann Whitney test).  
 
4.6 Plasma total PYY 
 
The pre- and postprandial PYY responses were assessed as a specific time point 
analysis. See tables 28, 29 and figures 31 and 32 for data presented as per individual 
time points and area under the curve. 
Min SB CD Controls Fold Change Significance 
0 328.6 ± 116.9  173.6 ± 34.81  1.89 p=0.3412 
15 410.2 ± 121.7  177.2 ± 30.62  2.32 **p=0.0240 
60 365.3 ± 82.57  181.4 ± 32.70  2.01 *p=0.0439  
Table 28. Comparison of postprandial PYY responses as per time point (0, 15 and 60 
minutes) in the SB CD (n=12) and normal control groups (n=13) studied. Date presented as 
mean units (pg/ml) ± SEM.  Significant differences were noted at 15 (**p=0.0240) and 60 
min (*p=0.0439). Mann Whitney test. 
 
 
 
* 
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Figure 31. Graphic representation of the postprandial PYY responses in the SB CD (n=12) and 
normal control groups (n=13) studied. Significant differences were noted at 15 (**p=0.0240) 
and 60 min (*p=0.0439). Mann Whitney test used. 
 
 
 
Total PYY SB CD Controls Fold Change Significance 
 22990 ± 5585  10700 ± 1886  2.15 *p=0.0419  
 
 Table 29. Integrated postprandial PYY responses. Data are presented as mean ± SEM for 
the SB CD (n=12) and control (n=13) groups. A significant difference (*p=0.0419) is noted 
between the two groups. Mann Whitney test.  
 
 
Figure 32. Graphic representation of the integrated postprandial PYY responses. Data are 
presented as mean ± SEM for the SB CD (n=12) and control (n=13) groups. A significant 
difference (*p=0.0419) is noted between the two groups. Mann Whitney test. AUC = area 
under the curve 
 
 
** 
 
	  	  	  	  	  	  	  	  	  	  * 
* 
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These time points were compared to each other in the SB CD group and although the 
overall mean values were found to be different (p=0.0458; Friedman test), no 
difference between the time points could be found (Dunn’s post comparison tets 
p>0.05). This implies that the appetite disturbance observed in CD is a state that is not 
dependent upon eating, but present even in the fasted condition. This was an 
unexpected finding and requires careful further evaluation. 
 To further decrease the effect of multiple comparisons, the total PYY assayed during 
the test was compared in both groups by measuring area under the curve (see table 29 
and figure 32). A significant ~2-fold change was noted (p=0.0419; MW test).  
It is noteworthy that the test meal used acted too weakly to elicit any significant 
response in controls, and was selected deliberately in order to achieve this. In the 
research planning phase, there was a concern that a strong nutrient stimulus may have 
proven less able to distinguish between the groups. Nonetheless, the soup acted as an 
adequate stimulus in patients with active SB CD, triggering a further rise from the 
elevated baseline, and at a much earlier time point than generally seen for PYY. This 
finding possibly suggests that PYY EEC cells in SB CD are more responsive to nutrient 
stimulation than healthy controls, or that malabsorbed nutrients are arriving 
inappropriately and prematurely at this distal site, thereby activating the classical ‘ileal 
brake’ mechanism in an exaggerated manner. This explanation may also reconcile the 
elevated PYY levels seen in the ELISA data, despite the lack of increase in PYY-
expressing cells or of PYY mRNA. Significant correlations were noted between plasma 
PYY and symptoms of nausea and bloating in CD groups, perhaps in keeping with the 
role of PYY as an anorectic hormone (figures 33 and 34) but with aversive symptoms 
developing at enhanced levels of PYY or in the presence of inflammation. However, it 
is important not to suggest causality unless an interventional study with a probe such 
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as a PYY antagonist could be undertaken. The more complex symptoms of appetite 
and vomiting showed interesting trends towards associations, but failed to reach 
statistical significance.  No correlations to weight loss and stool frequency were noted. 
Unsurprisingly, the non-significant postprandial rise in plasma PYY was accompanied 
with stable postprandial VAS scores. This might also be explained by the fact that any 
postprandial change in anorectic symptoms could be too subtle to be experienced by 
patients in a chronically anorectic or nauseated state, which may reflect high circulating 
PYY levels.  
An association between PYY and the grade of inflammation was not found, with no 
relationship between the gut hormone and CDAI or CRP.  
 
 
Figure 33. A significant correlation was noted between integrated PYY secretion and mean 
nausea scores in the CD group. 95% CI=0.03100 to 0.8637, p=0.0359; n=17. (Spearman 
test). 
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Figure 34.  A significant correlation was noted between integrated PYY secretion and mean 
bloating scores in all patients studied. 95% CI=0.1404-0.6589, p=0.0372. n=30. (Spearman 
test).  
4.7 Active and Total GLP-1 in CD 
 
Both the biologically active peptide and total GLP-1 have been studied. Active GLP-1 is 
metabolised to its inactive metabolite by the serine type protease DP4. As discussed in 
section 1.6.1, DP4 dynamics are altered in CD and hence discussing both active and 
total GLP-1 could shed more light on the DP4 in intestinal inflammation. 
4.7.1 Active GLP-1 in CD 
 
The specific time points assessed between the two groups were as per tables 30 and 
31, and figures 35 and 36 below. 
Min CONTROLS SB CD Significance  
0 22.96 ± 7.979  13.56 ± 2.424  p=0.6437 
15 26.21 ± 7.994  18.31 ± 4.533  p=0.3014 
60 17.40 ± 3.118  16.73 ± 3.214  p=0.7235 
Table 30. Comparison of postprandial active GLP-1 responses as per time point (0, 15 and 60 
minutes) in the SB CD (n=12) and normal control groups (n=13) studied. Date presented as 
mean units (pg/ml) ± SEM. No significant differences noted.  Mann Whitney test used. 
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Although not significant, there is a trend to reduced levels of GLP-1 in the SB CD 
group in the early part of the study. In addition, the two groups have been compared 
by assessing the area under the graph as indicated in the table below. 
 
Figure 35. Graphic representation of the postprandial active GLP-1 responses in the SB CD 
(n=12) and normal control groups (n=13) studied. No significant differences were noted. 
Mann Whitney test used. A physiological rise and fall is noted in GLP-1 plasma levels, with 
significant differences between the three studied time points in the control group (*p<0.0047, 
Friedman test; Dunn’s post test p<0.05 for all groups). In the SB CD group, plasma GLP-1 
levels rose significantly immediately after the meal (**p<0.0127; 0 vs 15 min p<0.05 - 
Friedman test; Dunn’s post test), but levels failed to drop postprandially within the time limit 
studied. 
 
Active GLP-1 SB CD CONTROLS significance 
 1027 ± 220.2  1347 ± 353.1  NS 
Table 31. Integrated postprandial active GLP-1 responses. Data are presented as mean ± 
SEM for the SB CD (n=12) and control (n=13) groups. No significant differences noted. 
Mann Whitney test.  
 
 
Figure 36. Graphic 
representation of the 
integrated postprandial 
active GLP-1 responses. 
Data are presented as 
mean ± SEM for the SB 
CD (n=12) and control 
(n=13) groups. No 
siginificant differences 
noted. Mann Whitney 
test. 
* 
** ** 
* 
	  * 
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No significant differences were observed between the groups but there was a 
noticeable trend for active GLP-1 levels to be higher in controls than in the disease 
group (figures 35 and 36). 
A physiological rise and fall is noted in GLP-1 plasma levels between the three time 
points in the control group (p<0.0047, Friedman test; Dunn’s post test p<0.05 for all 
groups). In the SB CD group, plasma GLP-1 levels rose significantly immediately after 
the meal (p<0.0127; 0 vs 15 min p<0.05 - Friedman test; Dunn’s post test), but levels 
failed to drop postprandially within the time limit studied. However since overall levels 
are lower, it is unlikely that GLP-1 is playing a role in the appetite disturbance in CD. 
Plasma PYY and GLP-1 levels are independent of each other under normal 
circumstances but in intestinal inflammation, a significant correlation is noted (figures 
37 and 38). The EEC response to an inflammatory milieu overrides the physiological 
response to food intake. This association was found to be notable in small bowel 
disease.  
 
Figure 37. Significant correlation between integrated PYY and GLP-1 responses in SB CD. 
R2=0.1503, 95% CI=0.03178-0.6563, p<0.0001. n=12 (Pearson’s test). 
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Figure 38. No correlation between integrated PYY and GLP-1 responses in controls. R2= 
0.002111, 95% CI= -0.5183 to 0.5823, p=0.8815. n=13 (Pearson’s test). 
 
 
4.7.2 Total GLP-1 in CD 
 
Total GLP-1 was assessed pre- and postprandially as indicated above. Very little 
difference is noted between the two groups (see table 32, 33 and figures 39 and 40). 
The test meal had no effect on GLP-1 in controls (see figure 39), although significant 
changes have been noted in the bioactive peptide in this group (see figure 39).  
min CONTROLS SB CD Significance  
0 23.85 ± 6.834  14.57 ± 2.012  p=0.45 
15 21.97 ± 5.1  19.04 ± 2.211  p=0.7915 
60 16.69 ± 3.486  15.34 ± 1.936 p=0.9699 
Table 32. Comparison of postprandial total GLP-1 responses as per time point (0, 15 and 60 
minutes) in the SB CD (n=17) and normal control groups (n=15) studied. Date presented as 
mean units (pg/ml) ± SEM. No significant differences noted.  Mann Whitney test used. 
 
In the SB CD group, the test meal had a significant effect on total GLP-1 levels with a 
significant postprandial rise and fall noted in the plasma levels (p<0.0004, 0 vs 15; 
p<0.001, 15 vs 60; p<0.05, Friedman test with Dunn’s posthoc test). The greater 
similarity between the responses for active and total GLP-1 in SB CD (see figure 41) 
might point towards a decreased expression of the enzyme DP4 in the SB CD group. 
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This would partially explain the delayed postprandial plateau effect seen in active GLP-
1 in the SB CD group.  
 
Figure 39. Graphic representation of the postprandial responses in total GLP-1 in the SB CD 
(n=17) and normal control groups (n=15) studied in the three time points studied 0, 15, 60 
minutes. No significant differences were noted between the two groups. In the SB CD group, 
the test meal had a significant effect on total GLP-1 levels with a significant postprandial rise 
and fall noted in the plasma levels (p<0.0004, 0 vs 15; p<0.001, 15 vs 60; p<0.05, 
Friedman test with Dunn’s post hoc test). 
 
Total GLP-1 SB CD CONTROLS Significance 
 1025 ± 118.2 1216 ± 275.4 p=1 
Table 33. Integrated postprandial total GLP-1 responses. Data are presented as mean ± SEM 
for the SB CD (n=17) and control (n=15) groups. No siginificant differences noted. Mann 
Whitney test. 
 
 
Figure 40. Graphic representation of the integrated postprandial total GLP-1 responses. Data 
are presented as mean ± SEM for the SB CD (n=17) and control (n=15) groups. No 
siginificant differences noted. Mann Whitney test. 
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Figure 41. Both total (T) and active GLP-1 (A) fasted levels and postprandial responses in SB 
CD and controls. Absolute values should not be directly compared as the assays used were 
different. However the broad pattern of response is clearly the same for active and total GLP-
1. 
4.8 Acylated ghrelin in CD 
 
Ghrelin responses in the CD group were notably different from controls with a 
paradoxical postprandial increase noted in the disease group rather than the normal 
decrease after a meal that was seen in the control group (see figure 42 and table 34). 
70.5% (12/17) of CD patients showed a positive response as opposed to 15.4% (2/13) 
in the control group. Generally a trend towards higher ghrelin levels is noted in 
intestinal inflammation, reflecting the anti-inflammatory role of this gut hormone (see 
figures 42, 43 and tables 34, 35). Due to wide variation in this heterogeneous group of 
patients these interesting trends did not reach statistical significance.  
min CONTROLS CD Fold 
Change 
Significance 
0 46.25 ± 11.91  63.91 ± 15.31  1.38 p=0.3941 
15 42.13 ± 9.101  137.9 ± 53.18  3.27 p=0.1311 
60 32.63 ± 7.033  118.2 ± 38.69 3.62 p=0.0777 
Table 34. Comparison of postprandial acylated ghrelin responses as per time point (0, 15 and 
60 minutes) in the CD (n=17) and normal control groups (n=13) studied. All SB CD (n=12) 
and LB CD (n=5) patients were studied. Data presented as mean units (pg/ml) ± SEM. No 
significant differences noted although the ghrelin plasma level at 60 minutes nearly reached 
significance.  Mann Whitney test used. 
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Figure 42. Graphic representation of the postprandial responses in acylated ghrelin in CD 
(n=17) and normal control groups (n=13) studied. In CD ghrelin has a paradoxical positive 
postprandial response. No significant differences noted although the ghrelin plasma level at 
60 minutes nearly reached significance.  Mann Whitney test used. 
 
GHRELIN CONTROLS CD Fold 
Change 
Significance 
 2425 ± 467.1  7277 ± 2471  3 p=0.1015 
Table 35.  Integrated postprandial total acylated ghrelin responses. Data are presented as 
mean ± SEM for the CD (n=17) and control (n=13) groups. The data shows a trend for the 
mean ghrelin to be higher in the CD group as compared to controls. Mann Whitney test. 
 
 
Figure 43. Graphic representation of the integrated postprandial acylated ghrelin responses. 
Data are presented as mean ± SEM for the CD (n=17) and control (n=13) groups. The data 
shows a trend for the mean ghrelin to be higher in the CD group as compared to controls. 
Mann Whitney test. 
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Postprandial integrated ghrelin responses showed an approximate 3-fold increase in 
the CD group as compared to controls. Again, this trend did not reach significance 
probably due to the large standard error noted in the study group.  
Unlike PYY, ghrelin showed significant correlation with disease activity, specifically the 
CDAI (p=0.013) and stool frequency (p=0.006) (figures 44 and 45). This may highlight 
its alternative role as an anti-inflammatory peptide, although this is speculative at this 
juncture. No correlation to nausea, appetite, percentage weight loss from last 
remission or CRP was noted.  
 
 
Figure 44. Significant correlation was observed between ghrelin responses and CDAI. 
R2=0.3261, 95% CI=0.1420-0.8195, p=0.0133. n=17. (Pearson’s test).  
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Figure 45. Significant correlation was observed between ghrelin and stool frequency, a marker 
of disease activity. R2=0.3850, 95% CI=0.2162-0.8432, p=0.006. n=17. (Pearson’s test). 
 
4.9 Leptin in CD 
 
No significant difference was found between controls and CD in plasma leptin levels 
and levels remained constant postprandially (see table 36). 
 
LEPTIN CD CONTROLS FOLD CHANGE p 
 168100 ± 62510 158100 ± 57160 1.06 0.6453 
Table 36. Integrated plasma leptin. Data are presented as mean ± SEM for the CD (n=17) 
and control (n=13) groups. All SB CD (n=12) and LB CD (n=5) patients were studied. No 
significant difference was noted between the two groups studied. Mann Whitney test. 
 
No significant correlation was noted between leptin and the inflammatory scores used 
in this study. As expected, a strong positive correlation was noted between leptin and 
body mass index (BMI) (figure 46) and a significant negative correlation was noted with 
weight loss (figure 47). This implies that there is no disease related association, but 
that leptin levels are a marker of adipocyte mass in CD just as in health. It’s role as a 
marker of nutritional status may however warrant further exploration. 
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Figure 46. Significant correlation between integrated leptin responses and BMI in all study 
recruits. n=29. 95% CI= 0.1014 to 0.7131, p=0.0120. (Spearman test).  
 
 
Figure 47. A significant negative correlation was noted between integrated leptin responses 
and weight loss in CD patients. n=18. R2=0.3293, 95% CI=-0.8209 to -0.1460, p=0.0128; 
(Pearson’s test). 
 
4.10  GIP in CD 
 
In the case of GIP no significant changes were noted in between groups as the table 36 
and figure 48 indicate. Our test meal acted as a potent stimulus for this proximal gut 
hormone as shown in the immediate postprandial rise in GIP levels, which thereby 
serves as a useful internal positive control in these studies.  
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GIP is secreted from K cells in the proximal GIT. It was presumed that the patients 
recruited for this study had no proximal inflammation. They were all known cases of 
distal small bowel disease or colonic disease. No clinical investigations were carried to 
prove this as it was clinically unnecessary and difficult to justify ethically for this study 
alone.  Since duodenal CD is rare, not typical of the age group studied and likely to be 
highly symptomatic, this is a reasonable assumption and it therefore seems that distal 
small bowel inflammation has no effect on proximal gut hormone secretion as shown 
by data in table 37 and figure 48.  
 
GIP CONTROLS SB CD Significance 
0 1211 ± 238.6  2116 ± 943.5 p=0.6833 
15 6386 ± 929.9  6910 ± 1435  p=0.8918 
60 5355 ± 1011  4795 ± 656.2 p=0.6833 
Table 37. Comparison of postprandial GIP responses as per time point (0, 15 and 60 
minutes) in the SB CD (n=12) and normal control groups (n=13) studied. Date presented as 
mean units (pg/ml) ± SEM. No significant differences were noted.  Mann Whitney test used. 
 
 
 
 
Figure 48. Graphic representation of the postprandial responses in GIP in the SB CD (n=12) 
and normal control groups (n=13) studied. No significant difference was noted.  
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4.11 Total GLP-2 in CD 
 
The total GLP-2 response to a test meal was studied in the SB CD groups and 
controls. No difference was found and there is no postprandial change in GLP-2 with 
the two groups studied per time point analysis and as integrated GLP-2 secretion 
throughout the test. See table 38, 39 and graphs 49 and 50.  
 
min CONTROLS SB CD Significance 
0 4.018 ± 0.3442  4.005 ± 0.1998  p=0.5679 
15 4.261± 0.4092 4.079 ± 0.2224  p=0.8918 
60 4.055 ± 0.2921  3.955 ± 0.2182 p=0.8918 
Table 38. Comparison of postprandial total GLP-2 responses as per time point (0, 15 and 60 
minutes) in the SB CD (n=12) and normal control groups (n=13) studied. Date presented as 
mean units (pg/ml) ± SEM. No significant differences were noted.  Mann Whitney test used. 
 
 
Figure 49. Graphic representation of the postprandial responses in total GLP-2 in the SB CD 
(n=12) and normal control groups (n=13) studied. No significant difference was noted at all 
time points 
 
 
GLP-2 CD CONTROLS Significance 
 241.4 ±12.35  249.2 ± 21.12 p=0.9134 
Table 39. Integrated plasma total GLP-2 results. Data are presented as mean ± SEM for the 
CD (n=12) and control (n=13) groups. No significant difference was noted between the two 
groups studied. Mann Whitney test. 
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Figure 50. Graphic representation of the integrated postprandial total GLP-2 responses. Data 
are presented as mean ± SEM for the SB CD (n=12) and control (n=13) groups. No 
significant difference between the two groups was recognised. Mann Whitney test. 
 
4.12  Gut hormone response in the SB CD group after medical 
treatment: preliminary data. 
 
Six patients who had just received treatment at the time were recruited for this small 
exploratory study. All patients were naïve to surgery or biological treatment. Three of 
these patients were not studied in the SB CD group so matched studies were not 
possible. This cohort will be referred to as the CDr group during this section. The 
same test meal was used and gut hormone plasma response was analysed with a 
multiplex assay as previously described. Patient details are described in table 40. Highly 
significant statistical differences were noted for mean VAS and CDAI as shown in the 
table below.   
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No Age Sex WT CDAI 
pre/post 
Rx 
CRP VAS 
pre/post 
Rx 
Med Rx 
6 69 M 7.1 125/31 1 30/14 Steroids 
18 26 M 14.5 135/0 7.3 36/0 Thiopurines 
7 57 F 9.1 120/28 11.2 23/3 MTX/5-ASA 
31 59 F 4.3 385/35 22.8 29/5 Steroids 
32 60 M 0 57/28 <5 10/8 Steroids 
36 66 F 7 173/95 33.7 32/16 Steroids 
Mean    p=0.0017   p=0.0009   
Table 40. Data for CDr group paying particular attention to changes in CDAI and VAS pre 
and post treatment. Patient numbers as per table 3. Statistical comparisons (Mann Whitney) 
were made with the relevant CDAI and VAS results from the SB CD group. A significant 
difference was noted for both CDAI (p=0.0017) and VAS (p=0.0009). CRP described is in 
active disease. Only patient 7 had a history of surgery (right hemocolectomy).  
 
4.12.1 Total PYY responses 
 
The response in total PYY in the three groups studied was compared. In contrast to 
the elevated PYY levels observed in active disease, the response in the treated group 
was now very similar to healthy controls. Total PYY plasma in the SB CD group 
reached statistical significance at 15 and 60 minutes. See table 41 and figure 51. 
 
min SB CD (A) CDr (B) Controls (C) Significance 
0 328.6 ± 116.9 157.9 ± 44.95 173.6 ± 34.81  p=0.4156 
15 410.2 ± 121.7 177.7 ± 57.09  177.2 ± 30.62  **p=0.0464; 
A vs B&C 
p<0.05 
60 365.3 ± 82.57  142.5 ± 35.22  181.4 ± 32.70  *p=0.0350; A 
vs B&C 
p<0.05 
Table 41. Comparison of postprandial PYY responses as per time point in the SB CD (n=12), 
CDr (n=6) and control (n=13) groups. Data are shown as mean units (pg/ml) ± SEM. A 
significant difference was noted between the three groups at 15 minutes, with the PYY levels 
in the SB CD group being significantly higher than controls and CDr (**p<0.05). Same applies 
for plasma PYY levels at 60 minutes (*p<0.05). Comparisons were carried out with a 
Kruskall-wallis and Dunn’s post-comparison tests.  
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The PYY response was again assessed as area under the curve as seen in table 42 and 
the corresponding graph in figure 52. A ~2-fold difference is noted between the SB CD 
group and the other cohorts.  
 
Figure 51. Graphic representation of the postprandial PYY responses to the test meal in the 
three groups studied - the SB CD (n=12), CDr (n=6) and control (n=13) groups. Data are 
shown as mean units (pg/ml) ± SEM. A significant difference was noted between the three 
groups at 15 minutes, with the PYY levels in the SB CD group being significantly higher than 
controls and CDr (**p<0.05). Same applies for plasma PYY levels at 60 minutes (*p<0.05). 
Comparisons were carried out with a Kruskall-wallis and Dunn’s post-comparison tests. 
 
 
Total PYY SB CD  CDr Controls Significance 
 22990 ± 5585  9722 ± 2735  10700 ± 1886  *p=0.0322 
Table 42. Integrated total PYY secretion in the three groups the SB CD (n=12), CDr (n=6) 
and control (n=13) groups. Data are shown as mean AUC ± SEM. There is a significant 
difference between all the groups as shown by the significant p value (*p=0.0322). 
Comparisons were carried out with a Kruskall-wallis and Dunn’s post-comparison tests.  
 
** 
 * 
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Figure 52 Graphic representation of the integrated total PYY secretion in the three groups the 
SB CD (n=12), CDr (n=6) and control (n=13) groups. Data are shown as mean AUC ± SEM. 
There is a significant difference between all the groups as shown by the significant p value 
(*p=0.0322). Comparisons were carried out with a Kruskall-wallis and Dunn’s post-
comparison tests.  
 
4.12.2 Active GLP-1 responses 
 
Active GLP-1 responses were assessed after the test meal in the treated group. Plasma 
levels dropped significantly in the CDr group especially at 60 minutes post-prandially 
(see table 43 and figure 53). The integrated GLP-1 response to the test meal was 
measured by studying the area under the curve. GLP-1 secretion in the SB CD group 
and controls were very similar. The treated group showed a tendency to have lower 
GLP-1 levels (see table 44 and figure 54).  
 
 
 
 
 
 
 
* * 
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min SB CD (A) CDr (B) Controls (C) Significance 
0 13.56 ± 2.424  6.833 ± 0.5725  22.96 ± 7.979  p=0.0876 
15 18.31 ± 4.533  12.83 ± 2.713  26.21 ± 7.994  p=0.2894 
60 16.73 ± 3.214  7.667 ± 0.5270  17.40 ± 3.118  *p=0.0372; A 
vs B 
**p<0.05; C 
vs B 
***p<0.001 
Table 43.  Active GLP-1 response to the test meal in the three groups studied – SB CD 
(n=12), CDr (n=6) and normal controls (n=13) at the three time points – 0, 15 and 60 
minutes. Data are shown as mean ng/ml ± SEM. No significant difference is noted at 0 and 
15 minutes. Significant differences were noted at 60 minutes (*p=0.0372) between all 
groups. The difference between the mean values for CDr and Control groups (**p<0.001) is 
more significant than the mean for the SB CD and CDr groups (***p<0.05). Data analysed 
with Kruskall Wallis test with a Dunn’s post-hoc test.  
 
Figure 53. Graphic representation of the active GLP-1 response to the test meal in the three 
groups studied – SBCD (n=12), CDr (n=6) and normal controls (n=13) at the three time 
points – 0, 15 and 60 minutes. Data are shown as mean ng/ml ± SEM. No significant 
difference is noted at 0 and 15 minutes. Significant differences were noted at 60 minutes 
(*p=0.0372) between the SB CD, control groups and CDr group.  
 
 
Active  
GLP-1 
SB CD CDr Controls Significance 
 1027 ± 220.2  608.8 ± 93.72 1347 ± 353.1  p=0.1528 
Table 44. Active GLP-1 response to the test meal in the three groups studied – SB CD (n=12), 
CDr (n=6) and Controls n=13). Data are expressed as mean AUC ± SEM. No significant 
difference is noted between the means of the three groups studied. Data was analysed with a 
Kruskall Wallis test with a Dunn’s post-hoc test. 
* 
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Figure 54. Graphic representation of active GLP-1 response to the test meal in the three 
groups studied – SB CD (n=12), CDr (n=6) and Controls n=13). Data are expressed as mean 
AUC ± SEM. No significant difference is noted between the means of the three groups 
studied. Data was analysed with a Kruskall Wallis test with a Dunn’s post-hoc test. 
 
 
The immediate post-prandial plasma levels of GLP-1 rose approximately 2-fold in the 
CDr group and then dropped to near pre-prandial levels at 60 minutes. There was a 
significant difference between the three measurements in this group (p=0.0120; 
Friedman test) with the 0 to 15 minute change showing the highest significance 
(p<0.05; Dunn’s test). This observation shows that treatment of SB CD reverts the 
post-prandial GLP-1 response back to normal i.e. with a sudden sharp rise and a 
delayed postprandial drop as seen in the normal controls.   
4.12.3 Acylated ghrelin responses 
 
Following medical treatment in the six recruited SB CD patients the postprandial 
response in the Cdr group changed back to a normal negative response as opposed to 
the positive noted in SB the CD group (see table 45 and figure 55). 83.3% (5/6) of the 
CDr recruits had a negative postprandial response as opposed to the 70.5% (12/17) 
who had a positive response in the CD group. This figure is more in line with the 
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84.6% (11/13) of the controls who had a normal negative postprandial ghrelin 
response.  
The trends described in this section are interesting but none of the results reached 
statistical significance. Total ghrelin response to the test meal in the three groups was 
not significantly different as seen in table 46.  
min CD CDr CONTROLS Significance 
0 63.91 ± 15.31  380.2 ± 239.5  46.25 ± 11.91  p=0.3493  
15 137.9 ± 53.18  189.1 ± 83.28  42.13 ± 9.101  p=0.2944 
60 118.2 ± 38.69 99.42 ± 43.82  32.63 ± 7.033  p=0.4288 
Table 45. Plasma acylated ghrelin responses to the test meal in the three groups studied – CD 
(n=17), CDr (n=6) and normal controls (n=12) at the three time points – 0, 15 and 60 
minutes. Data are shown as mean ng/ml ± SEM. No significant differences are noted. Data 
analysed with Kruskall Wallis test.  
 
 
Figure 55. Graphic representation of the plasma acylated ghrelin responses to the test meal in 
the three groups studied – CD (n=17), CDr (n=6) and normal controls (n=12) at the three 
time points – 0, 15 and 60 minutes. Data are shown as mean ng/ml ± SEM. No significant 
differences are noted.   
 
GHRELIN CD CDr CONTROLS Significance 
 7277 ± 2471 n=17 10760 ± 4553 n=6 2425 ± 467.1 
n=13 
p=0.2766 
Table 46. Integrated analysis for acylated ghrelin response to the test meal in the three 
groups studied – CD (n=17), CDr (n=6) and Controls n=12). Data are expressed as mean 
AUC ± SEM. No significant difference is noted between the means of the three groups 
studied. Data was analysed with a Kruskall Wallis test. 
 
 172 
4.12.4 Leptin and GIP responses 
 
No change was noticed in leptin or GIP responses to the meal in the treated group, as 
shown in figures 56 and 57 respectively. These data corroborate what has been 
concluded in sections 4.9 and 4.10. Leptin seems to have no place as a plasma 
inflammatory biomarker in CD. No changes noted in GIP, indicating that the ‘closed 
circuitry’ described in murine experimental models of intestinal inflammation in the 
introduction may not hold true in human intestinal inflammation. 
 
 
 
 
Figure 56. Graphic representation of the integrated plasma leptin levels during the test meal. 
Data are represented as mean ± SEM. No significant difference is noted between the three 
groups studied – CD (n=17), CDr (n=6) and control group (n=13). Analysed with Kruskall 
Wallis test.   
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Figure 57. Graphic representation of the plasma GIP responses to the test meal in the three 
groups studied – SB CD (n=12), CDr (n=6) and normal controls (n=13) at the three time 
points – 0, 15 and 60 minutes. Data are shown as mean ng/ml ± SEM. No significant 
differences are noted.   
 
4.13 Discussion 
 
In this chapter, significant changes have been characterised in the plasma levels of the 
representative EEC hormones that were studied in SB CD. The key finding was that 
total PYY was higher in patients with active CD, but that this was present from 
baseline. A small rise additional in PYY occurred after the meal in the SB CD group but 
not in healthy controls. No association was found with other symptoms, which may be 
considered as more complex or composite, such as vomiting and appetite. After 
treatment, PYY levels reverted back to normality and responded in a similar fashion to 
the normal controls to the test meal. Although this probably reflects resolution of 
inflammation, it is possible that the medication employed may be exerting a direct 
effect on EEC. However, in this descriptive clinical study it would not be ethically 
permissible to withhold treatment simply to observe the natural history. Larger studies 
stratified according to treatment type are now necessary in order to define whether 
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there is a drug-specific effect, or a global improvement consequent upon the resolution 
of inflammation. 
It is also important to note that the rise in PYY was seen from baseline, and sustained 
through this short study. In other research PYY is usually studied over long time 
periods, but this was not pertinent here since the symptoms induced by the test meal 
were active during the one hour postprandial period studied. 
Active GLP-1 levels were similar in all groups studied, albeit with a trend to lower 
values in the CD group. The mean value was lower still in the treated CD cohort.  
The close similarity between active and total GLP-1 responses to the test meal in the 
SB CD group might indicate that in intestinal inflammation expression of the enzyme 
responsible for its degradation, DP4, is attenuated. This hypothesis will be dissected in 
the next chapter.  
The postprandial changes in plasma acylated ghrelin were unexpected and novel. 
Elevation in fasting plasma ghrelin has been previously described but its postprandial 
response to a test meal has not been yet investigated. In intestinal inflammation, ghrelin 
showed a positive postprandial response, which is highly unusual. No precedent for 
this appears to exist. The direction of response can be taken as broadly indicative of 
disease activity as 70.5% (12/17) of CD patients showed a positive response as 
opposed to 15.4% (2/13) in the control group. After treatment, only 16.7% (1/6) still 
had a positive postprandial response. The potential role of enhanced ghrelin secretion 
secondary due to its anti-inflammatory properties is attractive given its strong 
correlation to the CDAI and stool frequency, markers of disease activity. However, it 
may simply be another gut peptide indirectly upregulated by active inflammation and 
not necessarily playing a biologically adaptive role. 
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GIP was used in this study as a control. It is a restricted proximal small intestinal 
peptide and secreted from a region unlikely to be diseased in the population studied. A 
robust early response to the meal was observed, and no changes in plasma GIP were 
noted between the test groups. This negative finding is important since it shows that 
this is not a nonspecific effect on gut hormones, especially when taken together with 
the enhanced levels of its neighbour ghrelin, secreted from the adjacent non-inflamed 
stomach. In murine models of intestinal inflammation, a regulatory ‘closed circuit’ has 
been postulated since gut hormones are upregulated at sites distant to inflammation 
[94]. This ‘circuitry’ is responsible for inducing an EEC response in the gut irrelevant of 
the anatomical site of the inflammation, which may further link mechanisms of 
inflammation and appetite control. This hypothesis does not seem to hold true in CD.  
Finally, my data suggest that leptin, contrary to previous publications [260, 261], 
behaves solely as an adipokine in intestinal inflammation. It presents a good biomarker 
of adiposity rather than inflammation as it has strong correlations with BMI, percentage 
weight loss but lacks significant differences within the disease groups 
The hypothesis that EEC hormones have a role in altering appetite in intestinal 
inflammation has been partially supported by the data in this chapter. PYY and ghrelin 
have shown significant changes.  PYY further displays a strong correlation to associated 
symptoms. This work highlights the need for further studies to dissect the activity of 
these peptides on the key symptoms and on biological targets such as the brainstem 
through pharmacological modulation.  
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5 Chapter 5 – Investigating the role of DP4 in intestinal 
inflammation 
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5.1 Chapter introduction 
DP4 is a pivotal enzyme regulating the functional signalling of multiple biologically active 
peptides. Changes in DP4 activity have been observed in multiple inflammatory 
diseases. A decrease in DP4’s enzymatic activity measured in plasma has been 
described in inflammatory diseases such as IBD, RA and SLE. A decrease in plasma 
protein expression has been noted in SLE and RA but no data are available on the 
tissue and plasma expression of DP4 in IBD [27, 153-155, 158]. A significant positive 
correlation has been shown between protein expression and enzyme activity in these 
rheumatological diseases but this had yet to be investigated in IBD. 
DP4 expression is of great relevance to activity of the EEC peptides described thus far 
in this thesis. Given the EEC changes observed, DP4 might have particular significance 
in IBD.  Unless other factors are also implicated, a decrease in DP4 expression should 
lead to an augmentation of GLP-1/2 and attenuation in PYY biological activity. Changes 
in either direction might have enormous effects on appetite regulation and gut mucosal 
integrity. A complete understanding of DP4 expression is of paramount importance for 
the enteroendocrinologist.  
In this chapter I will discuss DP4 expression in CD, DP4 expression has been studied 
at mRNA, tissue and plasma levels. 
DP4 is expressed by epithelial enterocytes [178]. To date no data exist exploring 
whether proinflammatory cytokines influence DP4 expression. In the light of the 
observations presented in CD, the Caco-2 cell monolayer system has been used as a 
model of the adult intestinal epithelium. It has been exposed to varying concentrations 
of recombinant human rhTNFα for different time periods, thus creating a reductionist 
model of intestinal inflammation. Data showing Caco-2 DP4 expression both at the 
mRNA and protein level will be discussed in the second part of this chapter.  
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5.2 Hypothesis 
 
Based on the evidence presented thus far, I expect a decrease in DP4 expression both 
in CD and in the Caco-2 model.  
5.3 Statistical analysis 
 
Data were analysed in a parametric fashion. Two groups were compared with an 
unpaired student’s t-test, while multiple comparisons were done using one-way 
ANOVA. Post-test analysis was carried out with a Tukey post-test.  
5.4 DP4 expression in CD 
 
5.4.1 mRNA DP4 expression 
 
mRNA DP4 expression was studied in a subgroup of eight CD patients with active 
disease affecting the terminal ileum. This was compared to eight controls. Terminal 
ileal tissue from CD patients showed a 4.5-fold increase in mRNA DP4 expression 
when compared to normal controls (p=0.0205; t- test). See figure 58 for detail. 
 
Figure 58. Graphic representation of mRNA DP4/HSK gene expression ratio in CD and 
normal controls. Eight CD samples were compared to the same number of controls. Data are 
shown as mean DP4 expression normalised to HSK gene expression. SEM is given. Intestinal 
mucosa from CD patients showed a 4.5-fold increase in DP4 expression (*p=0.0205).  
* 
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5.4.2 DP4 protein expression in CD 
 
DP4 protein expression was studied both at the tissue level and plasma level. Results 
will be discussed separately.  
5.4.2.1 Mucosal DP4 expression 
 
Despite a 4.5-fold increase in mRNA DP4 expression, protein expression behaved very 
differently. CD tissue showed a 2.7-fold reduction in DP4 expression when compared 
to normal control tissue. This probably reflects the reduction in plasma enzyme activity 
already witnessed in IBD [153-155]. The data are presented in figures 59 and 60. 
 
C             C            C           CD          CD          CD 
 DP4 (220kDa) 
 β-actin (42kDa) 
Figure 59. Blots representing DP4 and β-actin at the tissue level. CD tissue shows a significant 
2.7-fold reduction in expression when compared to controls; n=3 in each group (*p=0.05; t-
test). 
 
 
Figure 60. Graphic representation of densitometry readings quantifying DP4/β-actin expression 
ratios in the two groups studied (n=3 in each group). CD tissue shows a significant 2.7-fold 
reduction in expression when compared to controls; (*p=0.05; t-test). 
 
* 
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5.4.2.2  Plasma DP 4 expression 
 
Protein expression was also studied in plasma. Twenty-three patients with active small 
and large bowel disease were compared to 17 controls. Plasma drawn after an O/N 
fast for the gut peptide assays was used for this study. Plasma DP4 was 1.5 times lower 
in the plasma from CD patients (p=0.0007; t-test). The data are presented in table 47 
and figure 61. 
Plasma DP4 showed no significant correlation to disease parameters measured 
including CRP and CDAI.  
 
DP4 (ng/ml)  CD Controls Significance 
 371.1±31.92 N=23 558.5±39.98 N=17 *p=0.0007 
Table 47. DP4 plasma level in both groups studied – CD (n=23) and controls (n=17). Data 
are presented in mean ng/ml ± SEM. A significant (*p=0.0007) 1.5-fold decrease in plasma 
DP4 is observed in CD. Unpaired t-test.  
 
 
Figure 61. Graphic display of the DP4 plasma levels studied using an ELISA technique in both 
groups – CD (n=23) and controls (n=17). Data are presented in mean ng/ml ± SEM. A 
significant (*p=0.0007) 1.5-fold decrease in plasma DP4 is observed in CD. Unpaired t-test. 
 
 
 
 
* 
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5.5 DP4 expression in Caco-2 cells 
 
5.5.1 mRNA DP4 expression in Caco-2 cells  
 
 
rhTNFα had a variable effect on mRNA DP4 expression. A concentration of 25ng/ml 
for 48h hours increased DP4 expression approximately 2-fold compared to Caco-2 
cells in control wells. Incubations with rhTNFα for less than 24 hours, irrespective of 
the concentration had little effect on DP4 expression (see table 48 and figure 62).  
Caco-2 cells exposed to 100ng/ml of TNFα for six hours showed a decrease in 
expression by 1.28-fold. mRNA DP4 expression in Caco-2 cells after TNFα exposure 
is thus variable, with an increase shown after low grade rhTNFα exposure and a 
decrease after high grade rhTNFα incubation.  
 
 
Hours/TNFα 
conc 
Mean ± SEM Hours/TNFα 
conc 
Mean ± SEM 
48/100 0.95 ± 1.12 12/100 0.55 ± 0.79 
48/50 2.04 ± 0.59 12/50 -0.36 ± 0.84 
48/25 2.14 ± 0.65 12/25 0.47 ± 0.83 
24/100 1.59 ± 0.32 6/100 -1.28 ± 0.04 
24/50 0.6 ± 0.9 6/50 -0.43 ± 1.01 
24/25 1.39 ± 0.26 6/25 -0.22 ± 0.94 
Table 48. Tabular representation of DP4/HSK gene expression ratios. Expression in each 
treatment group is shown as a ratio to naïve cells where the expression was arbitrarily set at 
one. Data shown as mean ± SEM. Caco-2 cells exposed to 25ng/ml of rhTNFα for 48 hours 
showed the highest DP4 mRNA expression. While Caco-2 cells exposed to 100ng/ml of 
rhTNFα for six hours showed the lowest. Fold changes were calculated with the ΔΔCt method. 
n=3. Changes did not reach significance (p=0.1395; ANOVA test).  
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Figure 62. Graphic representation of DP4/HSK gene expression ratios. Expression in each 
treatment group is shown as a ratio to naïve cells where the expression was arbitrarily set at 
one. Data shown as mean ± SEM. Caco-2 cells exposed to 25ng/ml of rhTNFα for 48 hours 
showed the highest DP4 mRNA expression. While Caco-2 cells exposed to 100ng/ml of 
rhTNFα for six hours showed the lowest. Fold changes were calculated with the ΔΔCt method. 
n=3. Changes did not reach significance (p=0.1395; ANOVA test). 
 
 
5.5.2 Protein DP4 expression in Caco-2 cells 
 
Protein expression followed a very similar pattern to the mRNA response seen above, 
albeit much higher. DP4 expression was increased with all the rhTNFα concentrations 
as long as the incubation was for more than 24 hours. There was no change in protein 
DP4 expression if rhTNFα exposure was for 12 hours or less. See figure 63 & 64 and 
table 49 and 50.  
Caco-2 cells incubated with 25ng/ml of rhTNFα for 48 hours showed a highly 
significant increase in DP4 protein expression when compared to cells incubated in 
rhTNFα for 6-12 hours. See table 50 for details.   
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100/24      50/24      25/24    100/48    50/48      25/48     naive 
 DP4 (110kDa) 
 β-actin (42kDa) 
 100/12     50/12     25/12     100/6       50/6        25/6       naive 
 DP4 (110kDa) 
 β-actin (42kDa) 
Figure 63. DP4 and B-actin protein expression in caco-2 cells after rhTNFα incubation. Blot A 
shows DP4 expression in Caco-2 cells when exposed to rhTNFα for 24 and 48 hours at 
varying concentrations as indicated. DP4 expression in naïve Caco-2 cells is shown on the 
right. Blot B shows corresponding β-actin expression in the same Caco-2 cells. Blot C shows 
DP4 expression in Caco-2 cells when exposed to rhTNFα for 12 and six hours at varying 
concentrations as indicated. DP4 expression in naïve Caco-2 cells is shown on the right. Blot D 
shows corresponding β-actin expression in the same Caco-2 cells. Increased DP4 expression is 
shown in Caco-2 cells after rhTNFα exposure specifically at 25ng/ml for 48 hours (p<0.05 – 
ANOVA test) (n=3).  
 
 
 
Hours/TNFα 
conc 
Mean ± SEM Hours/TNFα 
conc 
Mean ± SEM 
48/100 9.34 ± 4.29 12/100 0.94 ± 0.26 
48/50 14.47 ± 5.9 12/50 0.65 ± 0.12 
48/25 18.12 ± 7.56 12/25 0.47 ± 0.83 
24/100 5.98 ± 1.73 6/100 0.57 ± 0.27 
24/50 4.19 ± 1.36 6/50 0.62 ± 0.28 
24/25 6.76 ± 2.89 6/25 0.27 ± 0.11 
Table 49. Tabular representation of densitometry readings representing DP4 protein 
expression in Caco-2 cells treated with rhTNFα at different conditions. Data has been 
normalised to the corresponding β-actin expression each time. n=3. Data are shown as mean 
expression ± SEM. Data are shown as a ratio to expression in naïve cells. An increased DP4 
expression is evident after rhTNFα exposure for 24-48 hours (with the data for 48 hour 
exposure reaching siginificance – see table 49). Data analysed with one-way ANOVA and 
tukey’s post hoc comparison. Relevant p values are given in table 49.  
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Hours/TNFα conc Mean difference q p value 95% CI of diff 
48/25 vs 12/100 17.18 5.350 p< 0.05 0.8065 to 33.55 
48/25 vs 12/50 17.47 5.441 p< 0.05 1.099 to 33.84 
48/25 vs 12/25 17.66 5.501 p< 0.05 1.290 to 34.04 
48/25 vs 6/100 17.55 5.466 p< 0.05 1.178 to 33.92 
48/25 vs 6/50 17.50 5.451 p< 0.05 1.132 to 33.88 
48/25 vs 6/25 17.85 5.560 p< 0.05 1.479 to 34.22 
Table 50. Statistical analysis comparing mean indicated changes between groups (n=3). A 
significant increase in DP4 expression is evident after rhTNFα exposure for 48 hours 
(irrespective of the rhTNFα concentration) when compared to six and 12 hour exposures. 
Data analysed with one-way ANOVA and Tukey post hoc comparison. 
 
 
 
 
Figure 64. Graphic representation of densitometry readings representing DP4 protein 
expression in Caco-2 cells treated with rhTNFα at different conditions. Data has been 
normalised to the corresponding β-actin expression each time. n=3. Data are shown as mean 
expression ± SEM. Data are shown as a ratio to expression in naïve cells. An increased DP4 
expression is evident after rhTNFα exposure for 48 hours (**) irrespective of the 
concentration when compared to the six and 12 hour TNFα exposures (*p<0.05). Data 
analysed with one-way ANOVA and Tukey post hoc comparison.  
 
 
 
 
 
 
 
 
* 
** 
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5.6 Discussion 
 
DP4 expression in intestinal inflammation is variable. DP4 mRNA transcript expression 
in human intestinal inflammation is increased. A 4.5-fold significant increase has been 
noted in the CD tissue studied when compared to normal controls. Protein 
expression, studied with two modalities to ensure validation has shown a decrease in 
expression in response to intestinal inflammation. A significant ~2-fold decrease in 
protein expression has been shown at the tissue and plasma level in patients with 
intestinal inflammation. 
I have then studied DP4 expression in a Caco-2 model of intestinal inflammation. DP4 
protein derived from Caco-2 cells was detected at 110kDa while the same protein 
extracted from human tissue was detected at 210-220kDa. Reason for this difference 
lies in the preparation of the protein solution prior to the electrophoresis. The protein 
extract from Caco-2 cells was warmed to 100°C for two minutes while the human 
protein extract was warmed to 37°C for five minutes. The human protein still had the 
homo-dimer configuration when studied while the Caco-2 DP4 was a monomer with a 
molecular weight of 110kDa when loaded for electrophoresis [262].  
An upregulation of expression was observed both at the mRNA and more so at the 
protein level. Six to 12 hour exposure of Caco-2 cells to rhTNFα did not lead to an 
increase in DP4 expression at both levels. A longer exposure increased protein 
expression significantly irrespective of the dose of rhTNFα, although 25ng/ml was 
found to be the most effective. 
There are differences in DP4 expression between the acute, reductionist cell line and 
the complex, chronic multipart systems that is human chronic idiopathic intestinal 
inflammation. CD is far more complex than the minimalist cellular model of intestinal 
inflammation. IBD encompasses a chronic state of inflammation with mucosal and 
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submucosal layers present in biopsy specimens along with active components of the 
immune system. 
The disparity in mRNA and protein expression could suggest a modulation at the 
translational level. The attenuation in DP4 activity and expression shown in CD could 
have ramifications in appetite regulation, physiological plasma glucose control and 
mucosal homoestasis in this disease cohort.  
A decrease in DP4 expression would lead to an increase in bioavailable GIP, GLP-1 and 
GLP-2 and a decrease in bioactive PYY. This would lead to an enhanced glucose 
control, improved mucosal integrity and altered appetite regulation in this group of 
patients.  
Is the alteration in DP4 expression/activity a secondary reaction to an inflammatory 
state or is DP4 pivotal in controlling the immune response? The observed attenuation 
in DP4 expression might be an attempt by an unstable immune system to restore 
normality.  
These data highlight DP4 as a candidate biomarker of disease activity in intestinal 
inflammation. Harnessing its expression might be a potential therapeutic target to 
further enhance disease control in CD.  
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6 Chapter 6. The effects of GLP-2 on the gut 
epithelial barrier: a preliminary study 
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6.1 Chapter Introduction 
 
GLP-2 is an intestinotrophic hormone secreted from the L cells in the distal ileum. It 
has been shown to improve gut wound healing in a TGF-β mediated process. 
Proliferation and migration were enhanced in epithelial monolayers grown in the 
presence of TGF-β and GLP-2 [117].  
GLP-2 has been shown to decrease mortality in indomethacin-induced murine 
enteritis. GLP-2 treated mice suffered less intestinal ulceration than controls and 
enhanced epithelial proliferation [125]. Moreover, GLP-2 administration enhances 
enteric adaptation in rodent short-bowel models [121-123]. Exogenous GLP-2, and its 
synthetic analogue, Teduglutide, have shown potential beneficial effects on short bowel 
adaptation in clinical trials [124]. 
The exact mode of action of GLP-2 is still unclear. Although a trophic effect is 
apparent from the work published thus far, this sole explanation might be an 
oversimplification. In the earlier part of this thesis I have found that the EEC producing 
GLP-2 are increased in number in chronic inflammation [84]. This raises the possibility 
that endogenous GLP-2 may be part of the reparative mechanism operating in this 
disease.  
In the work presented in this chapter, Caco-2 cells were grown as a monolayer on 
semi-permeable membranes as a model of the intestinal epithelium. The effects of 
GLP-2 on the growth and differentiation dynamics of this human cell line were 
quantified by measuring the define TEER across the cell monolayer. Caco-2 cells were 
exposed to rhTNFα containing media thus creating a model of intestinal inflammation. 
A protective effect of GLP-2 was exposed by studying its impact on the changes in 
TEER and tight junction protein responses to cytokine exposure.  
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GLP-2 significantly increases TEER in confluent Caco-2 cell monolayers and after the 
onset of stationary growth. This finding indicates that this EEC peptide might improve 
intestinal mucosa integrity by possessing a regulatory role on tight junctions [179].  
Through this minimalistic model of intestinal inflammation, I have shown that GLP-2 
has a positive effect on tight junction expression and a protective effect in intestinal 
inflammation. 
6.2 Hypothesis 
 
GLP-2 will improve intestinal epithelial barrier properties and have a protective role 
on barrier integrity in inflammation by enhancing tight junction stability.  
6.3 Statistical analysis 
 
Data was deemed to be parametric. Two groups were compared by using student’s t-
test, while multiple comparisons were done by using one-way ANOVA followed by 
Tukey’s multiple comparison test. Collective effects of GLP-2 on TEER in Caco-2 
monolayer cultures were also analysed by measuring the area under the growth curve. 
P value of less than 0.05 was deemed significant.  
6.4 Acetic acid vehicle studies 
  
GLP-2 (Bachem, Germany) has been prepared in 50% acetic acid to a final 
concentration of 53.1mM as indicated. Vehicle studies were first carried out to ensure 
no harmful effects of the vehicle on the integrity of Caco-2 cells. This study was used 
to decide the dose of GLP-2 to be used in ensuing studies.  
Acetic acid in a dose of 1000nM was noted to be harmful to the Caco-2 cells as shown 
by the lower TEER measured when compared to the monolayers grown in 10nM 
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acetic acid and naïve cultures. See figure 65. GLP-2 was thus used at a dose of 10, 50 
and 100nM in the following experiments.  
 
 
Figure 65. Details of the vehicle study. TEER in Caco-2 cell cultures grown in varying 
concentrations of acetic acid. A high concentration of acetic acid (1000nM) had a negative 
effect on Caco-2 cells as shown by the drop in TEER for the Caco-2 cell monolayer grown in 
the medium containing acetic acid at a concentration of 1000nM. GLP-2 was thus used at a 
dose of 10, 50 and 100nM in the following experiments. Units=ohms.cm2. 
 
6.5 The effect of GLP-2 on Caco-2 monolayer maturation as 
measured by TEER.  
 
6.5.1 Monolayer maturation in naïve Caco-2 cells as reflected by changes in TEER.  
 
Caco-2 cells reach confluence after three days of seeding. The increase in TEER noted 
from then on is due to maturation of the tight junctions [179]. The maturation of tight 
junctions during intestinal cell differentiation is a crucial factor in the establishment and 
maintenance of the differentiated polarised epithelial cell phenotype. The decrease in 
the permeability of the cell monolayer is a further indicator of tight junction 
maturation. 
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In this study, the Caco-2 cell line tested exhibited maturation of the tight junctions, as 
shown by the increase in TEER and from day six to day 21 from seeding. As seen in 
figure 66, the TEER increased rapidly till approximately day six and from thereon 
steadily increased till the end of the experiment at day 21.  
 
Figure 66. Development of tight epithelial barrier demonstrated by TEER measurement in 
naive Caco-2 cells. n=3. Caco-2 cells reach confluence after three days of seeding. The 
increase in TEER noted from thereon is due to tight junction protein maturation. The Caco-2 
cells were grown in culture till day 21. Units=ohms.cm2. 
 
6.5.2 The effects of chronic GLP-2 exposure on TEER of Caco-2 cell monolayers.  
 
GLP-2 has a distinctively positive effect on cell maturation as evidenced by the TEER 
readings. Very little difference was noted between the naïve cell cultures and the 
Caco-2 cells grown in GLP-2 containing media (10, 50 and 100nM) up until day 14.  
TEER readings in the four groups were significantly different after day 14, with 
measurements at day 17 showing highest readings in cell monolayers exposed to 
100nM GLP-2 when compared to naïve control cells and those exposed to 50nM GLP-
2. See table 51 and figure 67.  
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 Day 
1  
Day 7 Day 10 Day 14 Day 17 Day 21 
Naïve 0±0 1.85 ± 
0.41 
1.86 ± 
0.3 
2.47 ± 
0.45 
*2.43 ± 
0.21 
2.69 ± 
0.17 
GLP-2 
(10nM) 
0±0 1.92 ± 
0.28 
1.91 ± 
0.25 
2.27 ± 
0.23 
2.49 ± 
0.138 
3.19 ± 
0.23 
GLP-2 
(50nM) 
0±0 2.12 ± 
0.166  
2.22 ± 
0.11 
2.45 ± 
0.33 
*2.44 ± 
0.24 
2.92 ± 
0.15 
GLP-2 
(100nM) 
0±0 2.16 ± 
0.30 
2.36 ± 
0.18  
2.47 ± 
0.58 
*3.6 ± 
0.457 
3.53 ± 
0.355 
Table 51. TEER readings in the naïve and GLP-2 treated Caco-2 cells. Readings at day 17 
were significantly different between the four groups studied (p=0.0220). Cells exposed to 
100nM GLP-2 were significantly higher than the naive controls and cells exposed to 50nM 
GLP-2; *p<0.05; one way ANOVA. n=3. Units=ohms.cm2 
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                            Naïve                                                   10nM GLP-2 
 
                        50nM GLP-2                                            100nM GLP-2 
 
                         Combined                                       Combined (days 14-21) 
 
Figure 67. TEER measurements in naive and GLP-2 treated Caco-2 cells. Readings at day 17 
were significantly different between the four groups studied (p=0.0220). Cells exposed to 
100nM GLP-2 were significantly higher than the naive controls and cells exposed to 50nM 
GLP-2; *p<0.05; one way ANOVA. n=3. Units=ohms.cm2. 
 
 
 
 
 
* 
* 
* 
* * 
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To reduce the confounding effects of multiple comparisons, the TEER changes were 
measured compositely as area under the curve. After day 14, cells chronically exposed 
to 100nM of GLP-2 show a persistently higher TEER than naïve control cells and those 
grown in 10nM and 50nM of GLP-2. Chronic exposure of GLP-2 at 100nM has a 
significant effect on increasing the TEER in Caco-2 cells. See figure 68 for details. 
 
 
Figure 68.  TEER changes analysed as area under the curve. The data have been divided into 
two. (A) GLP-2 has very little effect on Caco-2 cell growth up until day 14 as evidenced very 
similar TEER between all groups. (B) After day 14 Caco-2, the AUC measured were 
significantly different from each other (p=0.0111). Caco-2 cells grown in media 
containg100nM of GLP-2 showed significantly higher TEER than other Caco-2 cells studied 
(*p<0.05). This finding possibly indicates an effect of GLP-2 on caco-2 cell maturation and 
tight junction protein expression. One-way ANOVA. n=3. Units=ohms.cm2. 
 
 
6.5.3 The effects of acute GLP-2 exposure on TEER across Caco-2 cell 
monolayers 
 
 
The acute effects of GLP-2 have been studied by incubating naïve Caco-2 cells 
overnight in 100nM of GLP-2 at day 20. TEER measurements showed no significant 
changes, thus precluding any acute effects of GLP-2 on TEER measurements and 
possibly tight junction protein expression.  See figure 69 for details.  
 
 
 * *  * 
B A 
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Figure 69. No significant change in TEER noticed (circled) after overnight incubation of GLP-2 
at 100nM. This precludes any acute effects of GLP-2 on TEER measurements and hence tight 
junction protein expression. Units=ohms.cm2. 
 
 
6.6 Effects of rhTNFα on TEER in Caco-2 cell monolayers 
 
 
The effects of rhTNFα on TEER and tight junction expression in Caco-2 cells have 
previously been shown by others [234]. In this section I have replicated this work and 
investigated if GLP-2 has the capacity to attenuate or prevent the increase in 
permeability noted in Caco-2 cell monolayers after addition of this cytokine. 
RhTNFα drastically drops the TEER across naïve Caco-2 monolayers by 9.3-fold 
(p<0.0001; paired t-test) as shown in figure 70. In GLP-2 treated Caco-2 cells (at 
100nM of 21 days) the TEER still dropped significantly (p<0.0001, paired t-test) but 
only by 1.76-fold as figures 70 and 71 show. Thus, GLP-2 protects the barrier function 
of Caco-2 cell monolayers from the negative effects of rhTNFα. GLP-2 reduces the 
cytokine-induced alteration in TEER across the Caco-2 monolayers by 5.3-fold. This 
protective role could be very important if it occurs in vivo, or therapeutically beneficial 
in medical conditions were recurrent intestinal sepsis and alteration in transepithelial 
permeability is common, including IBD. 
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Figure 70. (A) A drastic and significant (*p<0.0001) 9.3-fold decrease in TEER is noted after 
addition of rhTNFα (100ng/ml) to naïve Caco-2 cell monolayers. (n=6; paired t-test). (B) TEER 
still decreases by 1.76-fold across caco-2 monolayers grown in a GLP-2 containing medium at 
a concentration of 100nM. n=6. Units=ohms.cm2. 
 
 
 
 
Figure 71.  (A) The TEER drop after rhTNFα (100ng/ml) is much larger in the naïve cells than 
the GLP-2 exposed ones as the TEER measurements in graph A show. (B) The resistance of 
the GLP-2 exposed cells (100nM) after rhTNFα exposure is 5.3 fold times higher than in 
naïve cells (*p<0.0001, unpaired t-test; n=6). Units=ohms.cm2. 
N=naïve cells; G=cells grown in a medium containing 100nM of GLP-2; N+T = naïve cells 
exposed overnight to 100ng/nl of rhTNFα (100ng/ml); G+T = Caco-2 cells grown in a GLP-2 
containing medium (100nM for 21days) exposed overnight to 100ng/nl of rhTNFα 
(100ng/ml). 
 
6.7 Is the significant increase of TEER at day 17 in GLP-2 treated 
Caco-2 cells due to an increase in tight junction expression? 
 
 
A significant increase was noted in TEER at day 17 in monolayers exposed to GLP-2. In 
order to explore the molecular basis for this observation, expression of key tight 
junction components was quantified at the protein level at this time point in the Caco-
2 cell differentiation process. 
A B 
A B 
  * 
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Zo-1 and occludin showed a significant increase in expression in GLP-2 treated Caco-2 
cells as shown in table 52 and figures 72 and 73. Occludin expression increased by 1.6-
fold (p=0.0371, unpaired t-test; n=3 in each group), while Zo-1 expression increased 
by 4.7-fold (p=0.0387, unpaired t-test; n=4 in each group) in GLP-2 exposed Caco-2 
cells. 
Protein expression of other representative tight junction proteins claudin 1 and 4 did 
not change with GLP-2 exposure. 
     N       G        N       G        N        G 
 Occludin (60kDa) 
 Zo-1 (220kDa) 
 Claudin 1 (22kDa) 
 Claudin 4 (25kDa) 
 
 β-actin (42kDa) 
 
Figure 72. Immunoblot showing tight junction protein expression at day 17 post seeding in 
Caco-2 cells exposed to 100nM of GLP-2. Occludin expression increased by 1.6-fold 
(p=0.0371, unpaired t-test; n=3 in each group), while the Zo-1 expression increased by 4.7-
fold (p=0.0387, unpaired t-test; n=4 in each group) in the GLP-2 exposed Caco-2 cells. The 
protein expression of the tight junction proteins Claudin 1 and 4 did not change with GLP-2 
exposure. 
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Densitometry readings Naïve  GLP-2 
 (100nM) 
Fold change 
Occludin (n=3) 571.2 ± 43.08 912.2 ± 102.2 1.6 (p=0.0371) 
Zo-1 (n=4) 61.22 ± 12.38 287.6 ± 84.92 4.7 (p=0.0387) 
Claudin 1 (n=3) 672.4 ± 61.27 609.4 ± 65.95 N/A (p=0.5225) 
Claudin 4 (n=3) 496 ± 41.9 472 ± 26.91 N/A (p=0.6584) 
Table 52. Tight junction protein expression was studied by Western blot and measured with a 
densitometer. Significant increases in expression were noted for occludin and Zo-1. The 
expression of the claudin protein 1 and 4 did not change with GLP-2 exposure. Unpaired t-
test.  
 
The changes in expression of occludin and Zo-1 may underpin the increase in TEER 
noted in response to 100nM GLP-2. It is now necessary to understand whether this 
translates to reduced epithelial permeability in vivo, and whether exogenous GLP-2 
might further attenuate the permeability defect observed in inflammation. 
 
                          Occludin                                                        Zo-1 
 
                           Claudin-1                                                    Claudin-4 
 
Figure 73. Graphic summary of the densitometry measurements with arbitrary densitometry 
units depicted on the y-axis. Significant increase in expression were noted for occludin (*n=3; 
p=0.0371) and Zo-1 (**n=4; p=0.0387). The expression of the Claudin protein 1 and 4 did 
not change with GLP-2 exposure at day 17. Unpaired t-test. 
  
* 
  
     ** 
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6.8 The effects of rhTNFα on tight junction protein expression in 
GLP-2 exposed and naïve Caco-2 cells. 
 
 
 
A large significant difference in rhTNFα-induced TEER reduction was observed 
between GLP-2 exposed and naïve Caco-2 cells. This difference is most likely to be 
due to changes in tight junction protein expression. Cytokine-induced occludin 
expression was 2-fold less in naïve cells compared to the GLP-2 exposed Caco-2 
monolayers (p=0.0001, MW test, n=2). Zo-1 expression after overnight cytokine 
exposure in naive cells was significantly less than in GLP-2 exposed monolayers 
(p=0.0001, MW test, N=2). Claudin 1 expression in the cytokine exposed Caco-2 
monolayers was 1.62-fold higher in the GLP-2 treated cells than naïve ones (p=0.1678, 
MW test, N=3) as shown in figures 74 and 75, and table 53. Claudin-4 showed no 
change.  
         N            G         N+T        G+T 
 
 Occludin (60kDa) 
 Zo-1(220kDa) 
 Claudin 1(22kDa) 
 Claudin 4 (25kDa) 
 β-actin (42kDa) 
 
Figure 74.  Immunoblot showing changes noted in Zo-1, occludin, and Caludin-1 in the naïve 
cells after exposure to rhTNFα. Occludin expression was 2-fold less in the rhTNα treated 
naïve cells when compared to the GLP-2 exposed Caco-2 monolayers (p=0.0001, MW test, 
n=2). Zo-1 expression in the cytokine exposed naive cells was significantly less than in GLP-2 
exposed ones (p=0.0001, MW test, n=2). Claudin 1 expression in the cytokine exposed Caco-
2 monolayers was 1.62-fold higher in the GLP-2 treated cells than naïve ones (p=0.1678, 
unpaired t-test, n=3). 
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 N+T/N G+T/G Fold change Significance 
Zo-1 0.351 10.23 
 
29.14 p=0.0001 
Occludin 1.013 
 
2.037 2.01 p=0.0001 
Claudin-1 0.415 1.070 
 
1.62 p=0.1678 
Claudin 4 0.537 0.44 
 
0.819 p=0.7918 
Table 53. Cytokine-induced tight junction expression has been normalised to the expression of 
the control cells (naïve or GLP-2 treated) for each western blot run. This was done so as to 
compare one variable at a time. As n=2 in the Zo-1 and occludin experiments, the data are 
represented as median and results were analysed in a non-parametric fashion. Occludin 
expression was 2-fold less in the rhTNα treated naïve cells when compared to the GLP-2 
exposed Caco-2 monolayers (p=0.0001, MW test, n=2). Zo-1 expression in the cytokine 
exposed naive cells was significantly less than in GLP-2 exposed ones (p=0.0001, MW test, 
n=2). Claudin 1 expression in the cytokine exposed Caco-2 monolayers was 1.62-fold higher 
in the GLP-2 treated cells than naïve ones (p=0.1678, unpaired t- test, n=3). No change was 
noticed for claudin 4.  
 
  
  
Figure 75. Graphic representation of the cytokine-induced tight junction expression. Occludin 
expression was 2-fold less in the rhTNα treated naïve cells when compared to the GLP-2 
exposed Caco-2 monolayers (**p=0.0001, MW test, n=2). Zo-1 expression in the cytokine 
exposed naive cells was significantly less than in GLP-2 exposed ones (*p=0.0001, MW test, 
n=2). Claudin 1 expression in the cytokine exposed Caco-2 monolayers was 1.62-fold higher 
in the GLP-2 treated cells than naïve ones (p=0.1678, unpaired t- test, n=3). No change was 
noticed for claudin 4.  
* 
** 
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6.9 Conclusion 
 
The preliminary data presented here suggest that GLP-2 has a positive effect on tight 
junction protein expression in Caco-2 cells. TEER was used as a functional marker of 
tight junction protein expression. GLP-2 treated Caco-2 monolayers have a higher 
TEER especially after day 14. This property was maximal when the cells had been 
grown in 100nM of GLP-2 from seeding. This was not induced by short term addition 
of the peptide since the effects of GLP-2 on TEER did not apply to overnight ‘acute’ 
GLP-2 incubation. The rhTNFα-induced reduction of TEER and specific tight junction 
protein response has been previously shown in Caco-2 cells [234]. The new data 
presented here replicate the published work, but are also very novel in demonstrating 
a protective effect of GLP-2 on cytokine induced TEER changes.  
TEER decreases 9.3-fold in the naïve cells after O/N cytokine exposure. In the GLP-2 
treated cells, it still decreases, but only by 1.76-fold. This data highlights that GLP-2 
offers a ~5-fold protective effect to cytokine exposure on Caco-2 monolayers.  
The changes in TEER are reflected by similar but selective responses in tight junction 
protein expression, specifically occludin and Zo-1. At day 17, both proteins show a 
significant GLP-2 induced increase in expression. After overnight cytokine exposure, 
Zo-1, occludin and claudin-1 expression were increased in the GLP-2 treated group 
when compared to naïve controls. This finding would possibly explain the attenuation 
in the cytokine-induced TEER drop noticed in the GLP-2 exposed Caco-2 cells.  
These data potentially shed light on a new understanding of the role of GLP-2 in the 
maintenance of gut mucosal integrity. Apart from inducing a trophic effect on epithelial 
cells, this enteroendocrine peptide controls tight junction expression and by so doing 
may exert a protective effect on the gut mucosal integrity in intestinal inflammation. 
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This concept is supported by this preliminary cellular model, but now requires further 
study in vivo and in clinical scenarios.  
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7 Chapter 7. Discussion 
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7.1 Why Crohn’s disease? 
 
Although malabsorption and catabolic states are implicated in the aetiology of weight 
loss and malnutrition in CD, appetite suppression, early satiety and reduced food 
intake make a clinically relevant additional contribution to the nutritional imbalance in 
patients with CD. This is a clinical issue, which requires further study.  
Various models of intestinal inflammation have been used in rodents with varying 
degrees of success in modelling human IBD. Parasitic and chemical models all lead to 
an increase in EEC activity [84, 85, 91, 95]. Similarly in humans, opportunistic infections 
and idiopathic enteritis have both led to preliminary data suggesting that 
enteroendocrine homeostasis might be altered in an inflammatory milieu [98, 102, 103].  
Thus any data identified in this study leading to the identification of potential 
therapeutic and nutriceutical targets may have a broader salience to all diseases leading 
to intestinal inflammation, as well as to an oppositely altered state of appetite, leading 
to overconsumption and obesity. This cohort of patients was also chosen pragmatically 
because of the recurring nature of intestinal inflammation in the disease and the ease of 
access to the relevant pathology through endoscopic procedures and surgery. 
7.2 What have I shown in this thesis? 
 
The plan that I followed was to study the role of EEC and their products in CD is 
novel, and the collective data presented here by a combination of complementary 
methods are unique.  
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7.2.1 EEC peptides and appetite dysregulation  
 
At the tissue level, using immunohistochemistry techniques, GLP-1 and CgA cells 
showed a significant 2.5-fold and 1.8-fold increase in numbers respectively in actively 
inflamed small bowel samples when compared to normal control tissue. Large bowel 
disease and inactive disease showed no significant change. These findings support a 
mechanistic relationship between EEC and intestinal inflammation. Anatomical 
proximity between the location of the intestinal inflammation and EEC seems to be 
important in human intestinal inflammation. The ‘closed circuitry’ described in murine 
models of intestinal inflammation, in which EEC changes are observed at sites distant 
to that experimentally inflamed, might not hold true in human intestinal inflammation 
[94]. However, more complete sampling and homogeneity is achievable in the animal 
models than in clinical research, which is inevitably beset by heterogeneity in the 
patient population and opportunistic access to available material. The changes appear 
to be cell-type specific since PYY expression showed no change with intestinal 
inflammation. Double immunoflourescence techniques permitted co-localisation of 
CgA, Phox2b and GLP-1 expression to the same cells. The differential effects on 
specific cell types, and broadly consistent pattern of gene expression by qPCR, implying 
that there are specific regulatory events at play. 
In addition, EEC constitute 1% of the epithelial lining of the GI tract and thus any 
histological changes will usually be hard to detect in small numbers of sections. CgA is 
a general EEC marker and thus if only a subpopulation of EEC is upregulated in CD, a 
noticeable and significant change might not be apparent unless adequate numbers are 
studied.  
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These results are in agreement with limited earlier data suggesting an increase in CgA 
and 5-HT positive cells in both CD and UC [102]. In Crohn’s colitis only, PYY and PP 
cells were reduced whilst enteroglucagon cells were increased. Preliminary local data 
had suggested that there was a downregulation of all EEC markers in active proctitis 
during a relapse and even in remission [Levison, S. unpublished data]. Therefore, key 
differences may pertain between large and small intestinal biology in the regulation of 
EEC by inflammation. 
Upregulation of EEC transcripts has also been shown at the molecular level with CgA, 
GLP-1, Ube4a, and ngn-3 mRNA showing statistically significant changes. The 
upregulation of these EEC specific markers gives significant credence to of the 
hypothesis that there is increased expression of EEC products in intestinal 
inflammation. Ngn-3 is pivotal in the differentiation of stem cells to EEC [13] but up to 
now data were unavailable as to the expression of this β-HLH transcription factor in 
human tissue in health and disease. Phox2b showed a 1.5-fold increase in expression. 
Although this change did not reach statistical significance, it was a positive trend in the 
same direction. I made extensive attempts to study other transcription factors (math-
1, neuro D, Nkx2.2, Phox2b, Isl-1, Insm-1, Pax-6, Foxa-1, Foxa-2, Gfi1 and GATA-4) 
but, presumably due to their low level of expression, no meaningful data could be 
obtained [23, 28, 31, 108]. 
Previously validated visual analogue scores were used to benchmark a difference in 
satiety between the two groups, and to quantify this. The adipokine leptin has a long 
term effect on satiety and is thus classified as having an effect on ‘traits’ such as 
disinhibition and hunger rather than ‘states’ which are more indicative of short term 
weight control. Thus, one might anticipate that visual analogue scores are more linked 
to the plasma level of GLP-1, PYY and GIP rather than to leptin [37].  
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Although only a small number of time points were studied to control the cost of the 
assays, integrated plasma levels for total PYY and active GLP-1 showed interesting 
changes in the disease groups. Integrated total PYY responses showed a trend to be 
higher in the CD group, and which started in the fasting state. Sub-phenotyping the CD 
group into small and large bowel disease showed significant changes in the PYY 
responses were confined to the small bowel group. The large bowel disease group did 
not differ from the control group. Significant associations were noted between plasma 
PYY and symptoms of nausea and bloating in CD groups. Although correlations cannot 
be taken to suggest causality, this is in keeping with the physiological role of PYY as an 
anorectic hormone especially if a supraphysiological response was occurring in the SB 
CD group. This generates interesting hypotheses for future work, and echoes current 
suggestions that bariatric surgery has at least part of effects mediated by an elevated 
postprandial PYY response, but in the absence of inflammatory disease. After 
treatment of the inflammatory exacerbation plasma PYY dropped to levels similar to 
controls, thus closely linking the inflammatory drive and the EEC peptide response. In a 
pivotal difference from the recent data reported from post-bariatric surgery subjects, 
the SB CD group appear to display an elevated basal PYY even before eating, whereas 
the bariatric population show exaggerated postprandial responses. This may 
correspond to the fundamental distinction between a healthy but obese cohort who 
are inclined to eat (but soon feel full) and an unwell population with CD who feel 
unwell at the outset and disinclined to eat at all.  
Plasma PYY and GLP-1 levels are independent of each other under normal 
circumstances but in intestinal inflammation, a significant correlation is noted. It may be 
that the EEC response to an inflammatory milieu overrides physiological response to 
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food intake. This association was found to be more notable in small bowel disease than 
large bowel disease.  
Surprisingly, active GLP-1 plasma levels in active SB CD were lower than in normal 
controls. The postprandial response in between the two groups was different, with the 
normal controls showing a normal physiological change between all three time points 
measured. This was not the case in active SB CD, where the measured plasma level 
after 15 minutes did not change. Due to the limitations imposed by a three-time point 
measurement approach no major conclusions should be drawn from this experiment 
as yet. After treatment, the postprandial response in active GLP-1 in the CDr group 
reverted back to a normal physiological response with a significant difference between 
the three time points measured. The fact that plasma active GLP-1 levels were lower 
in active SB CD than in normal controls makes it unlikely that GLP-1 is playing a role in 
the appetite disturbance in CD. The close similarity between active and total GLP-1 
responses to the test meal in the SB CD group might indicate that in intestinal 
inflammation DP4 expression is attenuated. In the control group the responses were 
very different.  
The data on GLP-1 and PYY at the tissue and plasma level should be analysed 
separately. The antibodies used to quantify these peptides in immunohistochemistry 
bind to the epitopes in the whole product with its tertiary structure rather than to the 
specific splice products in the ELISA techniques. GLP-1-(1-37) is first cleaved from 
proglucagon with the first NH2 terminal amino acids cleaved subsequently to form 
active peptide GLP-1-(7-36) which is later amidated to form the biologically active 
peptide. This is unstable and is quickly metabolised by DP4 to the truncated inactive 
metabolite GLP-1-(9-36) amide [263]. Both the total and active peptides were 
measured in plasma but precursor and active peptide were studied at the tissue level. 
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Hence any change in metabolism of this peptide might have affected the expression 
levels witnessed.  
Total PYY was quantified in both tissue and plasma. Although this would make for a 
clearer picture, the data on tissue PYY expression reflect tissue total PYY content 
while plasma studies are taking into account L cell PYY secretion which may be 
influenced by the sensitivity of nutrient sensing. Plasma PYY levels are not a direct 
measure of L cell secretion. Further work quantifying the expression of key nutrient 
receptors such as ‘taste’ receptors (T1R2, T1R3 and T2R) and short chain fatty acid 
receptors (40, 41, 43, 120) would help understand the changes in plasma PYY 
witnessed. Nutrient stimulation of human L cell cultures from inflamed CD samples 
would be the most appropriate way to unravel any difference in L cell PYY secretion 
between inflamed and normal ileal tissue.  
Earlier reports have suggested that ghrelin is upregulated in male IBD patients with 
ileal disease, irrespective of disease activity. These changes were also correlated with 
lower leptin levels [264]. Ghrelin showed a tendency to be increased (3-fold) in CD 
samples irrespective of the disease phenotypes.  
The direction of response can be taken as broadly indicative of disease activity as 
70.5% (12/17) of CD patients studied showed a positive response as opposed to 15.4% 
(2/13) in the control group. After treatment, only 16.7% (1/6) still had a positive 
postprandial response. The possible role of ghrelin as an anti-inflammatory hormone is 
an attractive concept given its strong correlation to the CDAI and stool frequency, and 
the paradoxical rise in ghrelin may present a marker of disease activity.  
The anti-inflammatory activities of ghrelin are complex. It decreases IL-1β, IL-6, and 
TNFα production from activated human peripheral blood mononuclear cells, T-cells 
and leptin-mediated proinflammatory cytokine protein and gene expression in these 
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cells [265]. This crosslinking between leptin and ghrelin is further developed by reports 
suggesting that ghrelin is downregulated through exogenous administration of leptin 
and IL-1 [266]. Indeed, leptin and ghrelin seem to have opposing functions both in their 
satiety and appetite regulation and in their regulation of the inflammatory response. 
Other reports have suggested an increase in plasma acetylated ghrelin expression in 
active IBD; both in UC and CD with levels returning to normal once the disease is in 
remission. A significant negative correlation is noted between ghrelin and BMI in 
inactive IBD, and IGF-1, triceps fold thickness, mid-arm circumference and percentage 
fat mass in active IBD. In the same disease state a significant positive correlation is 
found with CRP, fibrinogen and TNFα while a multilogistic regression analysis identified 
TNFα as the only significantly associated variable with ghrelin in active IBD [267, 268].  
In humans, ghrelin is encoded on chromosome 3 [269]. It is initially translated into a 
precursor, preproghrelin and subsequently cleaved to form acylated ghrelin, a 28 
amino acid peptide. Post-translational n-octanoylation of its serine-3 by Ghrelin O-
Acyltransferase, a polytopic membrane-bound enzyme, is essential to form the active 
isoform [270]. Any changes in plasma ghrelin levels witnessed in IBD could be 
secondary to a change in the expression or activity of this enzyme. No data on this are 
yet available.  
Is ghrelin paradoxically secreted from the small bowel in intestinal inflammation or is 
the enhanced secretion controlled at a distance? In intestinal inflammation, ghrelin may 
assume a secondary role, that of an anti-inflammatory peptide. We speculate that this 
plays a protective role when the antigen load of a meal is presented to the inflamed 
gut.  
As yet there are only very scarce and indirect data on the effects that routine IBD 
treatment may have on EEC function. Do EEC have a role in the enhanced appetite 
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that steroid treatment brings to patients? Corticosteroids have been shown to 
downregulate CCK activity but it is only speculation if this physiological effect has 
anything to do with corticosteroid induced weight gain [271, 272]. 
Expression levels in GIP were similar between CD and control samples. GIP is 
secreted from K cells in the proximal gut where there is unlikely to be active disease. 
As noted above when comparing PYY in small and large bowel disease, this argues 
against circuitry effecting EEC changes at sites distant to the inflammation as seen in 
murine models of colitis. This negative finding is also important since it shows that EEC 
upregulation in intestinal inflammation is not a non-specific effect on all gut hormones 
However, the situation is clearly all the more complex when taken together with the 
enhanced and abnormal ghrelin levels, secreted from the adjacent but non-inflamed 
stomach. The mechanistic basis for this discrepancy is entirely unclear. 
However, elevated plasma GIP levels had been described in an earlier report [273]. In 
addition, due to its incretin role, increased GIP signalling might offer a potential 
explanation to the observed hyperinsulinaemia and enhanced β cell function observed 
in IBD. This has been noted to be protective in IBD [274-276]. Though, no specific 
elevation in plasma GIP was noted in the current study, attenuation in enzyme activity 
of the degrading enzyme DP4 in IBD might lead to increased bioavailable GIP, hence 
promoting its incretin effect and offer a physiological explanation to the observed 
hyperinsulinaemia in IBD.  
Integrated plasma leptin levels showed no difference between disease group and 
controls. This in disagreement with earlier reports where elevated leptin levels have 
been noticed in chemical models of intestinal inflammation in mice with levels 
correlating with the degree of inflammation and the development of anorexia [260]. 
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In this study no significant change in plasma leptin has been noted between the two 
studied groups. Leptin showed no correlation to disease presence or state as 
measured by histological assessment, CDAI or CRP but only to BMI and weight loss – 
which are proxy measures of body fat content. The role of leptin in inflammation 
seems to be associated with prolonged anorexia, a common finding in patients with 
IBD [277]. An overexpression of leptin mRNA in white adipose tissue [278] was 
reported in IBD patients compared to controls, indicating that leptin might participate 
in the inflammatory process by enhancing mesenteric TNFα expression [261] and that 
leptin from WAT rather than T cells is the more pathophysiologically important. 
Treatment of CD patients with Infliximab significantly increased leptinaemia, implying 
that TNFα exerts a major inhibitory action on leptin production in these patients 
[252]. To this effect, recruitment of CD patients treated with biologics was kept to a 
minimum.  
7.2.1.1 Summary 
 
The data in this thesis has shown an increase in EEC markers and transcription factors 
at the tissue and plasma levels in intestinal inflammation by multiple techniques. In 
inactive disease, EEC peptide expression returned to normal levels thus linking the 
inflammatory pathway to an exaggerated post-prandial response. These data and the 
correlation between the EEC peptide response and clinically relevant symptoms do 
support the concept of a causal link to appetite dysregulation in CD by an exaggerated 
EEC response in intestinal inflammation. Inevitably, further research is now required. 
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7.2.2 DP4 expression in intestinal inflammation 
 
DP4 gene expression in CD displayed a significant (4.5-fold) upregulation. However, 
my subsequent work on protein expression at the tissue and plasma level showed that 
DP4 protein expression in CD is significantly reduced.   
I then attempted to model this further, using a Caco-2 cell monolayer model of the 
intestinal epithelium, and using a cytokine key to CD inflammation.  This preliminary 
work on DP4 in Caco-2 cells did not replicate the reduced protein levels observed in 
CD but showed an upregulation of DP4 protein expression upon rhTNFα exposure. 
As shown in the table 54, the disparity between mRNA and protein DP4 expression 
has been previously described. 
 mRNA Protein 
DP4 expression in Caco-2 cells after rotavirus infection 
[279]. 
⇔ ⇓ 
IL-12 induced DP4 upregulation in activated lymphocytes 
[280]. 
⇔ ⇑ 
IL-1 induced DP4 expression in gingival fibroblasts [281]. ⇑ ⇑ 
rhTNFα induced DP4 expression in caco-2 cells ⇑  ⇑  
DP4 expression in CD  ⇑  ⇓  
Table 54. mRNA and DP4 expression in various cell types. A disparity between mRNA and 
protein expression has been reported before in Caco-2 cells after rotavirus infection and in IL-
12 induced upregulation of activated lymphocytes.  
 
DP4 transcription depends on multiple factors including, upstream stimulatory factor 
[282], hepatocyte nuclear factor [283], cdx-2 and cmy-c [284]. The latter transcription 
factor plays a repressor role and its expression has been shown to be increased in IBD 
[285]. Hepatocyte nuclear factor-1α and IL-6 have been shown to act in tandem in 
increasing the expression of the human angiotensin gene [286]. As IL-6 expression is 
increased in CD [287] and independently expressed by Caco-2 cells [288], this could 
be a possible explanation for the witnessed increase in DP4 mRNA expression. These 
complex transcription factor pathways could certainly interplay to explain the disparity 
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reported in this thesis. Functional protein is more important than mRNA transcript: 
the reasons for the mismatch are unclear but a high level of enzyme degradation and 
turnover may be responsible. It would be very helpful to undertake enzymatic activity 
assays in the next phase of this work. 
A correlation between enzyme activity and protein expression has previously been 
shown in RA and SLE. This is a very likely explanation to what is being unravelled in 
IBD.  
In addition, there are enormous differences between the acute exposure of TNFα to a 
minimalist model like the Caco-2 cell line and the chronic complex immunological 
disease that is human chronic idiopathic IBD. CD is driven by a chronic state of 
inflammation at the mucosal/submucosal level complicated by a chronically active and 
overarching immunological system. This clear distinction needs to be kept in mind in all 
studies utilizing a single cell line to ‘model’ a complex disease state.  
7.2.2.1 Summary 
 
As in the inflammatory states described above, in IBD there is a decrease in DP4 
expression. Protein DP4 expression is significantly decreased in CD at the tissue and 
plasma level. In the absence of other factors, a decrease in DP4 expression would lead 
to an increase in bioavailable GIP, GLP-1 and GLP-2 and a decrease in bioactive PYY. 
This would lead to an enhanced glucose control, improved mucosal integrity and 
altered appetite regulation in this group of patients. Harnessing the activity and 
expression of this peptide in intestinal inflammation would be of good clinical use as it 
would potentially lead to improved appetite in this patients and a healthier gut mucosal 
integrity.  
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7.2.3 Protective effects of GLP-2 on tight junction expression after cytokine 
exposure 
 
The positive effects of GLP-2 on intestinal epithelial proliferation have been previously 
shown [289]. Data from preliminary work on the minimalistic model of intestinal 
inflammation described in Chapter 6 show a protective effect of GLP-2 on tight 
junction protein expression. 
GLP-2 exposure had a positive effect by increasing TEER after cytokine exposure. This 
was possibly effected through its actions on the expression of the tight junction 
proteins Zo-1 and occludin. Protein expression significantly increased at day 17 of 
incubation in cells grown in a GLP-2 containing medium. This increase correlated with 
a parallel peak in TEER. Most importantly the drastic and expected drop in TEER 
secondary to cytokine exposure was much highly attenuated in the GLP-2 exposed 
monolayers. 
Zo-1, occludin and claudin-1 expression in these cells did not decrease in response to 
rhTNFα as was witnessed in the naïve cells. This preliminary work highlights an 
exciting role for GLP-2. It seems that GLP-2 has a protective role in maintaining a 
stable gut epithelial permeability after cytokine exposure. This may find a role in 
treatment and would be greatly beneficial in medical conditions like IBD where 
recurrent mucosal inflammation is common. 
The effects of GLP-2 on intestinal permeability have been replicated in a CD-1 mouse 
model. Mice were treated subcutaneously with GLP-2 or h[Gly2]GLP-2 (a synthetic 
protease resistant analogue) twice daily and then sacrificed at day 10. Jejunal mucosa 
permeability was then studied using an Ussing chamber. Both paracellular ion and 
EDTA permeability and transcellular HRP permeability were decreased in the GLP-2 
treated mice. Functional changes were seen 48 hours prior to the expected 
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morphological changes due to GLP-2 thus excluding an increase in mucosal thickness 
as the cause of the decreased permeability [290]. 
Does GLP-2 play a positive role in intestinal inflammation solely through its effect on 
intestinal permeability or does it have an anti-inflammatory role? 
This intestinal growth hormone has been studied as a therapeutic target in mouse 
models of intestinal inflammation. Colitic HLA-B27 mice treated with intravenous GLP-
2 showed a reduction in diarrhoea, 90% reduction in gross inflammation and a 40% 
reduction in microscopic disease. GLP-2 effectively decreased the expression of 
inflammatory mediators such as TNFα and IFNγ. Both the oral and intravenous routes 
were as effective in treating inflammatory disease [291, 292].  
In DSS and TNBS colitis models, GLP-2 has been shown to ameliorate inflammation 
through a reduction in IL-1, TNFα and IFNγ by the activation of VIP enteric neurons. 
Collectively, both in healthy tissue and disease, GLP-2 has been shown to increase 
crypt cell hyperplasia, decrease crypt cell apoptosis, increase enterocyte and villous 
length, mucosal weight and bowel weight and length [293-295]. 
Colitic IL-10 -/- mice treated with GLP-2 showed a similar reduction in IL-1, TNFα and 
IFNγ. FACS analysis of lamina propria cells demonstrated a decrease in the CD4-T cell 
population following GLP-2 treatment in colitic mice and an increase in CD11b/F4/80 
macrophages. In colitis animals, intracellular cytokine analysis demonstrated that GLP-2 
decreased lamina propria macrophage TNF-α production but increased IGF-1 
production, whereas TGF-ß was unchanged [296].  
GLP-2 has independent anti-inflammatory properties. It downregulates the Th1 
inflammatory process, via the activation of VIP enteric neurons in an IL-10 independent 
fashion [296-299].   
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Preliminary work in moderate to severe Crohn’s disease has been encouraging [300]. 
Early response rates of 44% showed a small improvement to the response rate of 32% 
in the placebo arm of this study. 50% remission rate was achieved in open-label 
treatment phase. A high drop out rate due to inconsistent compliance and poor 
patient recruitment were at fault in this early pilot study. 
It is tempting to speculate about the process in which GLP-2 protects the cellular 
monolayer permeability to cytokine exposure. Do the negative effects on IL-1, TNFα 
and IFNγ expression observed in mouse models play a role in stabilising the expression 
of the tight junction proteins? Are its roles as an anti-inflammatory peptide, and 
inhibiting cytokine-induced tight junction expression disruption independent or 
interlinked? Once again, further study is required. 
7.3 Limitations of the studies in this thesis 
 
7.3.1 Human studies 
 
The major issue with the patients recruited is the difficulty with standardisation. 
Patients inevitably had different degrees and patterns of intestinal inflammation, and 
may have different underlying genotypes or triggers. Additionally, they were treated 
with different therapies: it is neither ethically nor practically possible to overcome this.  
Although every effort was made to standardise recruitment, this proved to be difficult 
in a single-centre study without affecting the power of the research study. Patient 
recruitment with a history of biological therapy and surgical treatment was kept to an 
absolute minimum. Apart from the obvious potential effects of resections of EEC-rich 
intestinal segments on the post-prandial response to food intake, other factors such as 
vagal damage at the time of the resection may greatly affect the gut hormone response. 
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Endoluminal ulceration due to CD will certainly affect the distribution of the EEC as do 
mucosal oedema and fibrosis. To account for this, EEC were quantified per villus/crypt 
unit as previously shown [93], but this is an imperfect solution. Another way to solve 
this problem would have been to collect tissue by surgical means. This would have 
given me access to both inflamed tissue and periadjacent normal intestinal mucosa. 
Studying the EEC response in normal mucosa adjacent to areas of inflammation while 
comparing this to anatomically distant normal tissue would have given another 
dimension to this study.   
Disease activity was assessed by independent endoscopic, radiological, histological and 
biochemical assessments. CDAI was used as a standard patient questionnaire to 
numerically quantify and follow up disease activity [301]. This validated clinical score is 
fraught with problems. Stool frequency is numerically the strongest disease predictor 
in this activity score. While this may be effective in patients with colonic disease, stool 
frequency is a very insensitive biomarker of disease activity in SB or stricturing disease. 
There are several items whose numerical score directly relate to the degree of stool 
frequency, including number of liquid bowel movements, number of diphenoxylate 
tablets consumed, feeling of wellbeing, body weight, and hematocrit. Non-
diphenoxylate anti-diarrhoeal tablets are not taken into account and the numerical 
analogue scores for abdominal pain and wellbeing are very subjective and clearly do 
not take into account patients with psychogenic or functional bowel disease. 
Several stem cell differentiation transcription factors (Math-1, Neuro D, Phox2b, 
Nkx2.2, Foxa 1, Foxa 2, Isl-1, Gfi1, GATA-4, Pax-6 and Insm-1) have been studied but 
due to their low expression no sensible data could be gleaned out of these studies. A 
potential way forward would have been to collect single endocrine cells through laser 
capture microdissection. After bioanalysis and amplification of the recovered RNA, 
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qPCR could be attempted with the cDNA transcripts. However with genes with a low 
copy number of transcripts this strategy may prove equally ineffective. 
A specific DP4 inhibitor was not been added to my plasma samples prior to storage, 
with only a generic protease inhibitor (aprotonin) being used. Such a measure might 
have affected the ratio of bio-available to non-bioavailable EEC peptides in our plasma 
samples, but would not affect the key question as to whether there were differences 
between patients and healthy controls. To minimise this, samples have been 
immediately put on ice once obtained and stored at -20˚C. Where bioactive peptides 
have been studied, total peptide levels have been quantified too. EEC peptide 
expression has been studied using multiple modalities.  
7.3.2 Studies on Caco-2 cells 
 
There are two major limitations to this set of studies. Due to time constraints, and an 
inexplicable loss of response to rhTNFα in the very last part of my study, tight junction 
protein quantification after cytokine exposure was carried out independently only two 
times (rather than the usual three). TEER has been used as a proxy measure of 
monolayer permeability. Although TEER is a good indirect measure of ion permeability, 
it is not an indicator of macromolecular permeability. Although it would be very 
surprising to see a discrepancy between the two, this is still a possibility. A formal 
permeability test using FITC-Dextran (4kDa) is planned to further explore this.  
7.4 Future work  
Clearly more research needs to be done in order to translate this work into a fuller 
understanding of the regulation of appetite in IBD. In this final section, some key future 
experimental plans are outlined.  
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7.4.1 EEC peptides 
 
Similar future studies would need to particularly target patient heterogeneity. In an 
ideal situation patient recruitment should be improved by involving multiple clinical 
sites. Histological proof of disease activity should be available in all patients recruited 
and representative sections should be graded by a number of independent 
histopathologists. EEC expression could be then more closely correlated to the 
inflammatory activity with normal samples from the same patients acting as internal 
controls. The effect of anti-inflammatory treatment could then be better quantified. To 
minimise intra-assay variability, histological quantification of EEC expression should be 
carried out numerous times by different individuals. Finally as done in this study, the 
same samples should be used to study different EEC peptides so as to minimise the 
effect of patient heterogeneity.  
7.4.2 Dissect the Enteroendocrine Gut-Brain signalling pathways in CD functional 
Magnetic Resonance Imaging (fMRI). 
 
A great deal of research in my host group has been mapping the CNS response to 
nutrients in healthy subjects. The primary aim of this proposed study will be to 
examine the effects of ingested nutrients on brainstem satiety centre activation in 
patients with active CD, quiescent CD and healthy controls. This will help to dissect 
the gut-enteroendocrine-brain circuitry and further highlight its role in the aetiology of 
altered appetite in intestinal inflammation. fMRI may also prove invaluable in assessing 
the response to future therapeutic interventions. 
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7.4.3 The protective effect of GLP-2 on gut mucosal permeability 
 
The present experimental work should be taken forward by further replicating and 
quantifying expression of further tight junction proteins. Caco-2 monolayer 
permeability needs to be analysed by carrying out formal permeability testing.  
The protective effect of GLP-2 on cytokine induced tight junction protein expression 
attenuation also needs to be further investigated. Using qPCR, the anti-inflammatory 
effects of GLP-2 should be further dissected by quantifying the cytokine response of 
Caco-2 cells to rhTNFα stimulation in naïve and treated cells, but these studies also 
need to be taken into more complete animal models of gut inflammation. The results 
of this preliminary work will form the basis of further experimental work in human 
subjects. 
7.5 Conclusion 
 
The potential effects of EEC peptides on appetite regulation and gut mucosal integrity 
have been studied in intestinal inflammation. A significant upregulation of relevant EEC 
peptides has been noted possibly leading to altered appetite and satiety in CD patients, 
which adds to the co-morbidity in these patients. The dynamics of EEC peptide 
physiology are further complicated by the attenuation in DP4 expression noted in 
intestinal inflammation.  
Finally, in a minimalist cellular model of intestinal inflammation, a potentially exciting 
role for GLP-2 has been discovered. Its protective effect on gut mucosal integrity after 
cytokine exposure has been dissected through my findings on its effects on tight 
junction protein expression. These findings all have a strong clinical translational 
potential. Further work will be underway to harness this to the fullest.  
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Appendix 
 
 
VISUAL ANALOGUE SCORE SHEET 
 
1 How severe is your 
abdominal (tummy) pain? 0   5   10 
  Nil     Worst possible pain 
 
 
 
2 
 
 
How severe is your nausea? 
0   5   10 
  Nil     Worst possible nausea 
 
 
 
3 
 
 
How bad is your appetite? 
0   5   10 
 
  OK     Worst possible appetite 
 
 
4 
 
How bad is your feeling of 
bloating? 
0   5   10 
 
  Nil     Worst possible bloating 
 
 
5 
 
How severe is your 
diarrhoea? 
0   5   10 
 
  Nil     Worst diarrhoea 
 
6 How bad is your vomiting 0   5            10 
 
  Nil     Worst Ever Vomiting             
 Total Score (Office Use)         ___/60 
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STOCK SOLUTIONS 
 
1. TBS (x10) 
Tris base                                        3.05g 
NaCl                                              40g 
H2O                                               to 500ml (pH to 7.6) 
 
2. Citrate buffer (pH 6) 
Citric acid                                       2.1g 
H2O                                                to 1 litre (pH to 6) 
 
3. Tris-EDTA buffer (pH 8) 
EDTA                                             0.37g 
Tris                                                1.21g 
H2O                                                to 1 litre (pH to 8) 
 
4. Protein extraction buffer 
NaCl                                              120mM 
HEPES                                            25mM (pH 7.5) 
Triton-x-100                                   1% 
EDTA                                             2mM 
NaF                                                25mM 
NaV04                                             1mM 
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5. Transfer buffer (x10) 
Tris base                                         3.05g 
Glycine                                           14.4g 
Methanol                                        150ml 
H2O                                                to 1000ml – cool to 4°C 
 
6. Transfer Buffer (x1) 
X10 transfer buffer                          100ml 
H2O                                                750ml 
Methanol                                         150ml 
 
7. Tank Buffer (x10) 
Tris base                                        12g 
Glycine                                           57.6g 
SDS (10%)                                      40ml 
H2O                                               to 400ml  
 
8. Laemmli buffer (x4) 
Tris 0.5M (pH 6.8)                           4.4ml 
Glycerol                                         4.4ml 
SDS 20%                                         2.2ml 
1% Bromophenol blue                      0.5ml 
ß-mercaptoethanol                          0.5ml 
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9. Resolving Buffer 
Tris base                                         36.6g 
H2O                                                to 200ml (pH 8.8) 
 
10. Stacking gel buffer 
Tris base                                          3g 
H2O                                                 to 50ml (pH 6.8) 
 
11. Initiator - 10% Ammonium persulphate 
Ammonium persulphate                    0.1g 
H2O                                                 to 1ml (fresh every 2-3 days) 
 
12. 0.25% Trpsin 
2.5% Trypsin (Invitrogen)                  0.5ml 
0.5M EDTA (Invitrogen)                    0.5ml 
PBS (Invitrogen)                                up to 5ml (store in aliquots at -20°C) 
 
13. Gel recipes 
Volumes are in millilitres unless stated otherwise 
 7.5% Gel 10% Gel 12% Gel 4% Stacker Gel 
Acrylamide  3.12 4.15 4.98 0.69 
Resolving buffer  3.13 3.13 3.13 n/a 
Stacking buffer  n/a n/a n/a 1.25 
10% SDS  0.125 0.125 0.125 0.05 
H2O  6.14 5.1 4.27 3 
Ammonium 
Persulphate (µl) 
63 63 63 100 
TEMED (µl) 6.3 6.3 6.3 4 
TEMED = Tetramethylethylenediamine 
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GLP-1/Phox2b Immunoflourescence 
 Step Duration 
(minutes) 
1. Dewax and rehydrate with IMS and xylene  30’ 
2. TBS wash 15’ 
3. Citrate PH 6/EDTA pH 8 – high power 2.5’ 
 Citrate PH 6/EDTA pH 8 – medium power 5’ 
 Citrate PH 6/EDTA pH 8 – medium power 5’ 
4. Cool 10’ 
5. TBS wash 15’ 
6. Permeabilize in 0.1% Triton-100 (10µl in 1ml of TBS) 60’ 
7. TBS 10’ 
 GLP-1  
8. Block in 10% normal donkey serum at RT 
1mls TBS 
3% BSA = 0.03g 
10% NDS =100µl  
60’ 
9. Incubate with 1° AB (goat anti-human) at a dilution of 1:100 
at RT in 1% serum @ 4°C 
1mls TBS 
1% NDS = 10µl 
3% BSA = 0.03g 
1% AB = 10µl 
Overnight (O/N) 
10. TBS wash 10’ 
11. Incubate with 2° AB (donkey anti-goat Cyanine 5 (Cy5) 
1:100)  
60’ 
12. TBS x2 30’ 
 Phox2b  
13. Blocking AB (1%) 
1 drop goat serum 
0.05g BSA 
5mls TBS  
60’ 
14. Primary AB 1:200 @ 4°C 
Use Block to dilute 
O/N 
15.  TBS x2 10’ 
16. Secondary AB (goat anti-rabbit fluorescein isothiocyanate 
(FITC) 1:100) 
60’ 
17. TBS 10’ 
18.  DAPI – 1mg/ml – need 10ug/ml – hence one ml of DAPI in 
100ml of TBS 
10 sec 
19. TBS 10’ 
20. MOUNT 30’ 
21. STORE at 4°C in foil   
22.  Microscopy  
NDS = normal donkey serum, AB = antibody 
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GLP-1/CgA Immunoflourescence 
 
 Step Duration 
(minutes) 
1. Dewax and rehydrate with IMS and xylene  30’ 
2. TBS wash 15’ 
3. Citrate pH 6 – high power 2.5’ 
 Citrate pH 6 – medium power 5’ 
 Citrate pH 6 – medium power 5’ 
4. Cool 10’ 
5. TBS wash 15’ 
6. Permeabilise in 0.1% Triton-100 (10 µl in 1ml of TBS) 60’ 
7. TBS 10’ 
 GLP-1  
8. Block in 10% normal donkey serum at RT 
1mls TBS 
3% BSA = 0.03g 
10% NDS =100µl 
60’ 
9. Incubate with 1° AB (goat anti-human) at a dilution of 1:100 
at RT in 1% serum @ 4°C 
1mls TBS 
1% NDS = 10µl 
3% BSA = 0.03g 
1% AB = 10µl 
O/N 
10. TBS wash 10’ 
11. Incubate with 2° AB (donkey anti-goat Cy5 1:100)  60’ 
12. TBS x2 30’ 
 CgA  
13. Blocking antibody (goat serum) 3% 
0.15g BSA 
3 drops of goat serum 
5mls TBS 
Blocking antibody (donkey serum) 3% 
0.15g BSA 
3 drops of donkey serum (150µl) 
5mls TBS 
60’ 
14. Primary polyclonal rabbit anti-human 1:2000 @ 4°C 
Use Block to dilute 
O/N 
15.  TBS x2 10’ 
16. Secondary AB (goat anti-rabbit FITC 1:100) 60’ 
17. TBS 10’ 
18.  DAPI – 1mg/ml – need 10 µg/ml – hence 1 ml of DAPI in 
100ml of TBS 
10 sec 
19. TBS 10’ 
20. MOUNT 30’ 
21. STORE at 4°C in foil   
22.  Microscopy  
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